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This first chapter is divided in three parts.  
In the first part, anatomy, physiology of the kidneys are briefly presented, followed by 
pathophysiology, symptoms and diagnosis of chronic kidney disease (CKD). 
The second part summarizes current knowledge on cystatin C in human and veterinary 
medicine, namely its history, assays, relationship with glomerular filtration rate (GFR), 
biological and clinical variations both in human and veterinary medicine. 
In the third part, the need for and different aspects of validation to understand the scientific 
aims of this thesis, described in Chapter II. 
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1. Feline chronic kidney disease 
1.1. Anatomy of the feline kidney 
The kidneys are well-protected bean-shaped paired organs located in the 
retroperitoneal space.
1
 The normal size of feline kidneys is between 3.7 and 4.0 cm.
2
 
Macroscopically on dorsal section, every kidney consists of an outermost region, the cortex, 
an inner region, the medulla and a central area, the renal pelvis, with entrance, exit and origin 
of renal artery, renal vein and ureter respectively
1
 (Figure 1, 2). The functional unit of the 
kidney is the nephron, which consists of the renal corpuscle, the renal tubules and the 
collecting duct (Figure 3). The renal corpuscle consists of the glomerulus and Bowman’s 
capsule and is located in the cortex.
3
 A feline kidney contains 175 000 nephrons.
4
 Every part 
of the nephron has its specific function, which will be explained briefly in the following 
section. 
 
Figure 1. Venous plastinate preparation of 
a feline kidney. (scale in cm) (Picture Bart 
De Pauw, museum of morphology, faculty of 
veterinary medicine, Ghent University) 
Figure 2. Longitudinal cross-section of the 
kidney. (Picture Bart De Pauw, museum of 
morphology, faculty of veterinary medicine, 
Ghent University)  
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Figure 3. The nephron. Adapted from Young B et al., 2006.
5
 
 
 
1.2 Physiology 
The kidney is responsible for maintaining homeostasis. In mammals, both kidneys 
receive approximately 25% of the cardiac output. First, blood is filtered in the glomerulus, 
which consists of a network of capillaries enclosed within Bowman’s capsule.6 Glomerular 
filtration rate (GFR) is determined by the mean net filtration pressure, permeability of the 
filtration barrier and area available for filtration.
6
 The main force favouring filtration is the 
glomerular hydrostatic pressure of cardiac origin opposed by plasma (oncotic) pressure of 
plasma proteins and urine  hydrostatic pressure within Bowman’s capsule.6,7 The glomerular 
filtration barrier consists of the capillary endothelium, the glomerular basement membrane 
and the visceral epithelium with podocytes.
6
 The permeability is determined by the size and 
the charge of the molecules within the bloodstream.
6
 In normal kidneys, high and 
intermediate molecular weight proteins and the anionic form of the molecules are retained 
Chapter I General introduction 
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within the blood stream, whereas water and solutes are freely filtered The glomerular filtrate 
is collected in Bowman’s space and flows to the tubular lumen.6  
The main function of the tubules is secretion and reabsorption of filtered substances. 
The tubules are divided into several segments, with every segment having a specific function. 
In the proximal tubule, at least 60% of most filtered substances is reabsorbed by several 
mechanisms including passive diffusion, solvent drag, primary active transport, and carrier-
mediated secondary active transport.
6
 Active tubular secretion of creatinine (Cr) occurs in the 
proximal tubule, in humans,
8
 but is minor in dogs
9,10
 and negligible in cats.
11
 The thin limb of 
the loop of Henle ‘s major function is essential for urine concentration by water 
reabsorption.
6,7
 The ascending loop of Henle and the distal tubules reabsorb salts without 
water,
7
 and can secrete or reabsorb potassium.
6
 In the collecting duct and the final segment of 
the distal tubules, solute excretion and final regulation of urine volume occur.
6,7
 The 
reabsorption in the proximal tubule occurs independently of the physiologic state. In the distal 
tubule and collecting duct on the other hand, the processes are controlled by several 
hormones, including aldosterone, angiotensin II, antidiuretic hormone, endothelin, atrial 
natriuretic peptide, parathyroid hormone, calcitriol and calcitonin. Aldosterone and 
angiotensin II are both part of the renin-angiotensin-aldosterone system (RAAS), increasing 
blood systemic and glomerular pressure, and therefore increasing GFR. The mechanism is 
explained in Figure 4. Renin is released after a decrease in renal perfusion and catalyses the 
transformation of angiotensinogen to angiotensin I, which is converted to the more active 
angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II activates sodium 
uptake in both the proximal tubule and collecting duct and stimulates the release of 
aldosterone and vasopressin. Aldosteron enhances Na
+
- and water reabsorption to correct 
volume depletion.
5
 Antidiuretic hormone (ADH, vasopressin), enhances salt reabsorption 
from the thick ascending limb and the collecting duct, and does not enhance dilution of the 
tubule fluid, but water reabsorption in the collecting ducts.
5
 Endothelin and atrial natriuretic 
hormone regulate sodium transport in the distal part of the nephron. Parathyroid hormone, 
calcitriol and calcitonin regulate calcium reabsorption in the distal nephron and connecting 
segment.
6
 The kidney itself also produces two hormones: erythropoietin and calcitriol. 
Erythropoietin is synthesized in the peritubular cells, and regulates erythrocyte production in 
response to hypoxia. Calcitriol induces active intestinal calcium absorption and acts in 
synergy with parathyroid hormone for calcium release from bone.
7
 
Chapter I General introduction 
 
21 
Figure 4. Schematic overview of the renin-angiotensin-aldosterone system. Adapted from 
Verlander J, 2007.
6
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1.3 Feline chronic kidney disease 
 
1.3.1 Definition, prevalence and cause  
Chronic kidney disease (CKD) is characterised by a permanent reduction in 
functioning nephrons. Compensatory mechanisms try to sustain kidney function, but lead to a 
progressive loss of remaining functioning nephrons.
12
 Therefore, CKD is an irreversible and 
slowly progressive disease. It is defined as kidney damage that has existed for at least 3 
months, with or without reduction in GFR for more than 3 months.
12
 The estimated 
prevalence in cats is between 1.6 and 20%,
13
 and increases with age, with over 30% in cats 
older than 15 years.
14
 Breeds more often represented are Siamese, Abyssinian, Persian, Maine 
Coon and Burmese cats.
13-16
 
Chronic kidney disease can be caused by several diseases and disorders that affect 
glomeruli, tubuli, blood supply or the interstitium. However, damage to each of these 
components affects the entire nephron.
17
 In cats, tubulo-interstitial nephritis is most 
commonly observed.
12
 Causes of CKD can be congenital or acquired, but the initiating cause 
can often not be determined at time of diagnosis.
12
 
 
1.3.2 Consequences and symptoms 
Since the kidneys are involved in homeostasis of the entire body, CKD affects many 
organs, and therefore general condition.
18
 Symptoms manifest due to retention of products 
that should normally be excreted (e.g. phosphorus, urea, Cr) or excretion of compounds that 
should normally be retained (e.g. water and protein).
18
 Polyuria and polydipsia are caused by 
a decrease in adequate urine concentrating ability due to increased solute load per surviving 
nephron and loss of responsiveness to ADH.
12
 Azotemia is defined as increased nonprotein 
nitrogenous compounds in the blood, detected as increased serum urea and serum Cr (sCr).
14
 
Uremia refers to the clinical signs related with renal failure e.g. anorexia, nausea, halithosis 
(uremic breath), diarrhea, melena and convulsions.
12,19
 Uremia is caused by disturbed 
excretion of electrolytes and water, reduced excretion of organic solutes and impaired 
hormone synthesis.
12
 Systemic hypertension is common in feline patients with CKD and may 
cause CKD or may adversely affect renal function.
20
 CKD causes hypertension by retention of 
sodium, activation of RAAS, vascular dysfunction and endothelin production.
21
 On the other 
hand, systemic hypertension might cause glomerular hypertension and proteinuria, 
Chapter I General introduction 
 
23 
retinopathy or choroidopathy, encephalopathy and left ventricle hyperthrophy.
22
 Renal 
secondary hyperparathyroidism is an increased production of parathyroid hormone with 
parathyroid cell proliferation, due to hypocalcemia, hyperphosphatemia and reduced renal 
calcitriol (vitamin D3) production.
7,20
 Clinical signs are rather uncommon in cats,
12
 but it is 
essential to monitor phosphorus since parathyroid hormone is an uremic toxin and a major 
contributor to CKD progression.
7
 Metabolic acidosis results from loss of ability to excrete 
hydrogen ions and decreased filtration of acids.
12
 It has been shown that acidosis is a 
consequence rather than a cause of CKD progression. Clinical effects include anorexia, 
nausea, vomiting, lethargy, weakness, muscle wasting, weight loss and loss of appetite 
(Figure 5).
23
 Anemia is mainly caused by erythropoietin deficiency, but iron deficiency due to 
malnutrition, myelofibrosis, erytropoietic inhibitor substances and blood loss might contribute 
also.
12
 Clinical signs include pale mucous membranes, weakness and anorexia.
12
 
Hypokalemia is caused by decreased intake, increased loss or translocation of fluid from 
extracellular to intracellular.
24
 The most common symptom in cats is polymyopathy, but mild 
cardiac arrhythmias can also occur.
12
 On histopathology, the kidneys are small, irregular and 
pitted. The asymmetry between the kidneys may reflect differences in severity of the disease 
and the effect of compensatory hypertrophy (Figure 6).
12
 
 
Figure 5. Cat with CKD (IRIS stage 4). Note the thin body condition score (1/9), muscle 
atrophy of the hindlimbs and spine (    ), and bad hair condition.  
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Figure 6. Kidneys from a cat with end stage renal failure. (Pictures Leslie Bosseler, 
department of pathology, bacteriology and poultry diseases, faculty of veterinary medicine, 
Ghent University)  
 
 
 
 
 
 
  
1.3.3 Progression and survival of feline chronic kidney disease 
 
Due to compensatory hypertrophy of the remaining nephrons, clinical signs and 
laboratory abnormalities compatible with CKD only manifest in an advanced stage of the 
disease, limiting therapeutic options to palliative or supportive care.
17,25
 The standard care for 
feline CKD is aimed at improving clinical signs and slowing down disease progression.
26
 Cats 
with CKD that were treated with a renal diet, characterized by a reduced protein, phosphorus 
and sodium content had less uremic episodes and showed a significant reduction in renal-
related death.
27
 In contrast to treatment with a renal diet, no survival benefit from treatment of 
proteinuria with benazepril, an ACE-inhibitor was demonstrated.
28
 Although recent 
International Renal Interest Society (IRIS) guidelines recommend treatment of CKD cats with 
urinary protein:creatinine ratio (UPC) ≥ 0.4 in all IRIS stages ‒ also in IRIS stage 1 ‒, the 
point at which a reduction in proteinuria improves survival is currently unknown.
29
 The 
higher Cr, urea, phosphate, UPC and lower haematocrit at time of diagnosis, the shorter the 
survival time is in cats with CKD.
26,28,30,31
 Consequently, it was demonstrated that cats 
diagnosed and treated in an earlier stage of the disease have an increased median survival 
time.
26
 It is suspected that early treatment can delay progression of kidney dysfunction and 
prevent or postpone disease complications.
17,25
 However, at this point, no renal variable can 
reliably predict the survival time in a cat with CKD.
20
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1.4 Diagnosis 
1.4.1 Routine diagnosis of feline chronic kidney disease 
1.4.1.1 Signalment, history, physical examination  
Nevertheless breed disposition has been described for underlying renal diseases, and 
most cats are geriatric, CKD can manifest in cats from all ages and breeds.
12,16
 There is also a 
large variation in the stage of illness in which cats are presented to the veterinarian.
16
 The 
most commonly observed historic findings are polyuria and polydipsia, lethargy, anorexia and 
weight loss. The abnormalities on physical examination include dehydration, mostly small 
and irregularly shaped kidneys, poor body condition score, and periodontal disease. The 
signalment, history and clinical findings can give an indication for CKD, but are nonspecific, 
making diagnosis of CKD difficult.
15,16
 In addition, in early stages of CKD, no clinical signs 
or abnormalities on physical examination are present.
15,16
 Therefore, blood and urine 
sampling are necessary to diagnose CKD.  
1.4.1.2 Azotemia  
Azotemia is routinely measured by serum urea and sCr.
25,32
 Urea is the main form of 
nitrogen elimination from protein catabolism.
32
 It is freely filtered by the glomerulus and 
reabsorbed by the tubules. Creatinine concentration in blood is determined by  production of 
Cr by the muscles  and renal excretion,
25
 but also on the volume of distribution, demonstrated 
in dogs.
9
 Creatinine is produced by degradation of creatine and creatine-phosphate, mainly 
present in skeletal muscles.
7
 Therefore, production is proportional to muscle mass and might 
change due to muscle wasting.
25
 Creatinine is almost completely excreted by relatively 
constant glomerular filtration without tubular reabsorption or secretion in cats.
11,32
 Since Cr 
production is rather constant, GFR can be estimated based on sCr concentration. In contrast to 
sCr, urea production is not constant and is more heavily influenced by extra-renal factors than 
sCr, making urea not as useful as indicator of GFR.
7,32
 A major limitation of both urea and 
sCr is the low sensitivity to detect kidney dysfunction. The relationship between GFR and 
urea and Cr is inverse curvilinear, which means that changes in Cr and urea are only small in 
early stages of CKD. It is assumed that approximately 75% of the nephrons must be non-
functional until sCr or urea increase above the upper limit of the reference interval (RI) 
(Figure 7).
7,12
 Measurement of urea is useful for monitoring the effect of dietary protein 
restriction.
33
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Urea is mostly measured with an enzymatic assay.
7,32
 For sCr, routine analyses in cats 
and dogs are  mostly based on the nonspecific Jaffe reaction.
34
 Jaffe does not represent an 
analytical method, but refers to a chemical reaction i.e. the red colour formation when Cr 
reacts with picric acid in an alkaline medium.
35
 Pseudo-creatinine chromogens i.e. proteins, 
ketones and glucose, overestimate true sCr.
36,37
 Some manufacturers have adjusted the Cr 
calibration i.e. the modified Jaffe, to minimize the pseudo-Cr contribution, but this strategy 
assumes that the pseudo-Cr chromogen interference is a constant among samples, which is an 
oversimplification.
36
 The enzymatic method deals more effectively with the interferences,
38
 
but a small overestimation is possible compared with the former golden standard method, 
high performance liquid chromatography (HPLC).
39
 In cats, the enzymatic method favours 
the (modified) Jaffe method, which overestimates low sCr and underestimates high sCr.
39
 
However, the results of that study have to be interpreted cautiously, because, to the authors’ 
knowledge, no comparison of feline sCr measured with the (modified) Jaffe or the enzymatic 
method, with the new proposed golden standard in humans, the gas-chromatography-isotope 
dilution mass spectrophotometry (IDMS) reference method, has been performed.
36
 In 
addition, the recent introduction of the global Cr standard material SRM 967 has influenced 
sCr values in humans, but there are no guidelines yet how to adapt sCr calibration for the 
different assays according to the IDMS standard.
35
 No information in cats is currently 
available. Despite its limitations, sCr is the most efficient indirect GFR marker in mammals.
7
 
Another limitation of sCr are the inappropriate RIs. In the reference groups, it is possible that 
animals with unrecognized CKD are included.
25
 According to the guidelines of the American 
Society of Veterinary Clinical Pathology (ASVCP), a RI should be determined in a healthy 
population, taking into account clinical, biological and geographical factors. Biological 
variability, including the breed effect and interference should be considered to determine the 
need for separate RIs.
40
 In addition, RIs differ between laboratories, making interpretation of 
results difficult.
41
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Figure 7. Percentage of remaining renal functional capacity. Adapted from 
http://www.iris-kidney.com
42
 (Accessed 20/10/2015). 
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1.4.1.3 Urine specific gravity  
Urine specific gravity (USG) is the weight of urine compared with an equal volume of 
distilled water. It is an accurate reflection of urine osmolality and of the solute concentration 
of the urine solution. It is a reference standard to evaluate urine concentration.
32
 Urine 
specific gravity is estimated by measurement of the refractive index with a refractometer. 
Most refractometers are calibrated for human urine, and may overestimate feline urine 
concentration.
19,43
 However, errors do not change clinical decisions and are more pronounced 
for concentrated urine samples, which make the human devices useable.
43,44
 Both digital and 
optical hand-held refractometers correlate well with feline urine osmolality, but it is 
recommended to always use the same assay, since USG measurements with the digital 
refractometer are consistently higher.
44
 Urine specific gravity is lower in old cats and after 
water intake.
45
 Feline urine may be highly concentrated or diluted, depending on the 
hydration status of the cat, and the USG RI is between 1.001 and 1.065 or even 1.080.
19,46
 
Based on comparison of urine solute concentration with glomerular filtrate, iso-, hypo- and 
hypersthenuria can be defined. Isosthenuria (USG 1.007–1.015) is defined as urine with the 
same, hyposthenuria (USG < 1.007) as urine with lower and hypersthenuria (USG >1.015) as 
urine with higher concentration as unaltered glomerular filtrate respectively.
32
 Some cats with 
CKD can retain adequate urine concentrating ability in the early phase of the disease, but 
most cats with CKD have USG < 1.035.
14-16,34
 Urine specific gravity is the major laboratory 
parameter for differentiating azotemia. In case of CKD, persistent renal azotemia is present, 
i.e. renal azotemia present in a fasted and well-hydrated pet over several weeks.
12,42
 The three 
types of azotemia with determinants are presented in Table 1. 
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Table 1. Three types of azotemia with the major criteria to differentiate them. Adapted 
from Stockham SL and Scott MA, 2008; Elliott and Barber, 1998.
16
 
Type of azotemia USG Urine Volume Cause 
Prerenal ≥ 1.035 Decreased ↓ GFR due to dehydration, 
blood loss, shock or           
↓ cardiac output 
Renal < 1.035 Mostly increased Renal disease 
Postrenal Variable Decreased Urinary tract obstruction, 
uro-abdomen.    
 
1.4.1.4 Proteinuria and systolic blood pressure 
Systemic hypertension may cause progression of kidney disease. Glomerular 
hypertension might develop, and consequently glomerular injury and proteinuria, since cats 
with CKD cannot compensate for increased glomerular pressure.
12
 Hypertension is defined as 
systolic blood pressure (SBP) > 160 mmHg, and needs to be measured according to the 
American College of Veterinary Internal Medicine (ACVIM) consensus guidelines using a 
Doppler ultrasonographic technique.
22
 Efforts should be taken to avoid white coat 
hypertension.
47
 Hypertension is not predictive of survival, but is associated with proteinuria, 
which has been shown to be a major contributor of renal disease progression and 
mortality.
20,30,48
 It is currently unclear if proteinuria itself contributes to progression, or that it 
is only  a marker for renal deterioration.
49
 Urine of a healthy cat also contains a small quantity 
of protein, but the term “proteinuria” as diagnosis means detection of an excessive amount of 
proteins in the urine.
50
 Proteinuria can be classified according to the likely source of 
proteinuria.
50
 It is important to eliminate pre- and postrenal proteinuria and non-renal 
proteinuria, by following sequential steps.
50
 Only persistent renal proteinuria, i.e. proteinuria 
demonstrated in three or more urine samples over at least a two-week period, is indicative for 
CKD.
42,50
 It is a consequence of increased permeability of the glomerular barrier and impaired 
reabsorption of the proximal tubules.
51
 The severity can be determined by measuring the 24h 
protein excretion, or UPC, which has been shown to be highly correlated with the 24h protein 
excretion.
52
 In cats, proteinuria is defined as UPC ≥ 0.4 or microalbuminuria in three or more 
samples collected two or more weeks apart that cannot be attributed to a pre-or post-renal 
cause.
50
  Most cats with CKD only have mild proteinuria (UPC < 1.0), and it has been shown 
that an increasing UPC, including UPC values within the reference range are associated with 
an increased mortality both in azotemic and non-azotemic cats.
30,50,53
  
Chapter I General introduction 
30 
The most commonly used proteinuria screening test is the colorimetric Dipstick test, 
but the outcome is influenced by pH, sediment and concentration of albumin and urine, which 
may lead to false positive or negative results.
54
 Measurement of UPC is always recommended 
for CKD screening, to evaluate severity of renal lesions. Changes in UPC should always be 
interpreted together with sCr concentrations, as a decrease in functioning nephrons may cause 
a decrease in UPC. Improving renal function is reflected in decreasing UPC with stable sCr, 
whereas decreasing UPC and increasing sCr are suggestive for CKD progression.
54
 
Both cats and dogs with CKD are categorized into stages from IRIS to obtain uniform 
guidelines for diagnosis, treatment and prognosis.
12
 Pets are staged over several weeks when 
they are fasted and well hydrated.
12
 Stages 1–4 are based on sCr concentration, and substages 
are based on UPC and SBP (Figure 8). 
1.4.1.5 Medical imaging 
Medical imaging, particularly ultrasonography, may help to identify kidney disease 
and potentially an underlying cause of renal disease.
12
 Major ultrasonographic changes 
include decrease in renal size, increased cortical echogenity, decreased corticomedullary 
distinction and poorly discernible internal architecture.
55,56
 However, normal renal 
ultrasonography does not eliminate the possibility of renal disease.
32
 Further, some 
abnormalities such as increased cortical echogenity have been described in clinically normal 
cats,
57
 and ultrasonographic findings do not correlate with the degree of renal dysfunction.
56
 
Therefore, ultrasound is an insensitive and unspecific method for diagnosis of CKD, but 
essential to find an underlying cause. 
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Figure 8. IRIS staging of feline CKD. Adapted from www.iriskidney.com (accessed 
19/02/2015);
42
 Elliott  and Watson, 2014.
58
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Borderline hypertension 150‒159 
Hypertension 160‒179 
Severe hypertension ≥ 180 
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1.4.2 Reference method for kidney function evaluation: GFR 
Determination of GFR is the best method to evaluate kidney function.
7
 GFR is 
estimated by the renal clearance of a substance. Renal clearance is the volume of plasma that 
is cleared of the substance during a given interval of time.
25,59
 The renal clearance of a 
substance equals GFR if the marker is not protein bound, is solely excreted by filtration of the 
kidneys, is not secreted or reabsorbed by the tubules, is not toxic and does not alter GFR 
itself.
59
 Urinary clearance requires bladder catheterisation, collection of timed urine samples 
and continuous infusion, which makes this an unpractical method for clinical settings.
60
 
Plasma clearance methods are more commonly used in cats, with several markers: 
radiolabelled markers, exogenous Cr and iohexol and inulin. The plasma clearance method 
involves a bolus dose of the filtration marker with several timed blood samples.
39,61-64
 The 
calculated GFR depends on the used pharmacokinetic model, and the number and timing of 
blood samples.
59
 In practice, these methods are advised for cats with questionable renal 
function, but with normal renal parameters.
12
 Nevertheless, these methods are very time-
consuming, for an accurate GFR estimate and therefore not routinely used in practice (Figure 
9,10).  
 
Figure 9. Intravenous injection of 
exogenous Cr and iohexol. 
 
 
 
Figure 10. Jugular venepuncture in a 
combined exogenous Cr-iohexol clearance 
test. 
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Therefore, several attempts were made to develop more user- and cat-friendly 
methods, such as limited sampling methods.
65-70
 However, most of these methods were 
developed in healthy cats. Currently, only two studies have evaluated the limited sampling 
strategies in a large group of cats with different GFR.
65,69
 A limitation of the markers to 
perform clearance tests is that they require expensive and labour-intensive assays. Iohexol is 
determined with HPLC, an expensive test. Plasma Cr can be measured more easily, but 
injectable exogenous Cr is not commercially available. In humans, several equations for GFR-
estimation are available based on sCr concentration and demographic variables. The CKD-
Epidemiology Collaboration (CKD-EPI) equation has replaced the Modification of Diet in 
Renal Disease (MDRD) Study Equation in 2009, and is most  commonly used.
71
 In cats, 
regression models were developed based on the routine renal variables sCr, serum urea, USG, 
UPC and SBP, but the low coefficients of determination indicated that these formulas are not 
able to predict GFR accurately.
69
  
 
1.5 Need for new biomarkers for early diagnosis of feline chronic kidney disease 
The main objective in management of CKD is an early therapeutic intervention to 
slow down disease progression. Cats with CKD often hide symptoms, impeding early 
diagnosis.
29
 Therefore, cats are most often diagnosed in late stages of the disease, making 
intervention less effective.
29
 It has been shown that survival time for cats diagnosed and 
treated in an early stage is significantly longer than in a more advanced stage.
26
 Therefore, it 
is suspected that early diagnosis will prolong life expectancy and improve quality of life. In 
humans, screening patient groups at risk for CKD, eg. diabetes or hypertension, is one of the 
major health tools for the early detection of CKD.
72
 It has been shown in humans that early 
diagnosis prevents important disease complications.
72
 However, we have to keep in mind that 
human CKD is a syndrome, caused by various renal diseases, most of them glomerular 
diseases. This is in contrast to cats, in which tubulointerstitial nephritis is the most common 
diagnosis.
29
 This difference might be important for screening of cat-groups at risk and for the 
selection of screening tests. In contrast to humans, diabetic kidney disease seems to be less 
important in cats.
72
 Screening of elderly cats, hyperthyroid cats and breeds predisposed for 
kidney disease such as Persian and Abyssinian are recommended.
72
 In humans, estimated 
GFR formulas facilitate earlier diagnosis, but those are not yet available for cats. Direct 
measurement of GFR is considered the best overall index for evaluating kidney function.
7
 
However, for an accurate GFR-estimation, this procedure is labour-intensive and time-
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consuming, making it an inappropriate method for routine use in daily practice.
34
 For that 
reason, the indirect markers of GFR, sCr and urea, are most commonly measured, but they are 
insensitive and unspecific. It is assumed that these increase only when approximately 75% of 
kidney function is lost.
20
 Especially cats in IRIS stage 1 and early stage 2 are challenging to 
identify, since their Cr concentration is mostly within the laboratory RI, and other 
abnormalities i.e. USG <  1.035, renal proteinuria, abnormal diagnostic imaging findings, 
abnormal kidney biopsy findings, are not always present or not detected by veterinary 
practioners.
42
 Therefore, there is a need for new methods to rapidly and easily detect early 
feline CKD. In an early stage of the disease, secondary changes are only small, making 
identification of the underlying cause more plausible. If the underlying cause is treatable, 
stabilisation or maybe improvement of the kidney function can be achieved, but in most cases, 
the changes are permanent. In more advanced stages, changes are irreversible, impeding 
identification of the underlying cause, hindering treatment and deteriorating prognosis.
73
 
Limited sampling strategies to estimate GFR have been investigated, but are not yet ready for 
use in practice. To give an accurate GFR estimate, these methods still require different 
samples, and remain unpleasant and time-consuming. Measurement of a renal marker that 
only requires one blood or urine sample to evaluate kidney function with high sensitivity, is 
one of the major objectives in feline nephrology.  
Prior to the present thesis, several attempts were made to diagnose CKD in cats early. 
Several urinary biomarkers may allow localization of the kidney damage. Albumin is a 
marker for glomerular damage,
51
 but is not specific for CKD and does not show advantage 
over UPC.
49,74
 Besides glomerular markers, cats with CKD  show a significantly higher 
urinary concentration of several tubular markers, such as cauxin, retinol binding protein 
(RBP), N-acetyl-β-D-glucosaminidase (NAG) compared to healthy cats.75-77 Also the 
inflammatory cytokines, transforming growth factor-β1 (TGF-β1) and interleukin-8 (IL-8) 
were significantly higher in cats with CKD compared to healthy cats.
78,79
  However, it is 
currently unknown if these markers allow detection of early feline CKD. Therefore, further 
research towards early detection of feline kidney damage was warranted. 
 A possible and promising marker is Cystatin C (CysC). Cystatin C is a low molecular 
weight (LMW) 13 kilodalton (kDa) protein and proteinase inhibitor involved in the 
intracellular protein catabolism that is produced at a constant rate, because it is encoded by a 
housekeeping gene.
80
 Studies in rats have shown that there is no plasma protein binding, 
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which allows glomerular filtration without restriction.
81,82
 Cystatin C is reabsorbed in the 
proximal tubules by megalin-mediated endocytosis and is completely catabolized.
83
 It is 
generally accepted that no tubular secretion of CysC occurs.
82,84
 CysC has many properties in 
humans that are ideal for endogenous GFR marker applications such as: constant production 
and plasma concentration in the absence of GFR variation, low intra-individual variability, no 
plasma protein binding, no tubular secretion or reabsorption and no extra-renal clearance.
84
 
Cystatin C is considered superior to sCr in detecting renal dysfunction in humans.
85
 If sCysC 
has the same advantages in cats as in humans and dogs, this marker can improve early 
diagnosis of feline CKD, timely treatment, and prolong life expectancy. Furthermore, urinary 
CysC (uCysC) concentrations are extremely low in healthy individuals compared with 
individuals with renal tubular damage.
86,87
 Therefore, uCysC can be used as a marker for 
proximal tubular damage. This marker sparked our interest to investigate in cats. However, 
we have to take into account the between-species difference. A homology of 70% in amino 
acid sequence between human and feline CysC has been reported.
88,89
 It is currently unknown 
if this difference has consequences for the physiological role of feline CysC and for its 
evaluation. 
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2. Cystatin C: a new renal marker and it potential use in small animal 
medicine 
Adapted from: Ghys L, Paepe D, Smets P, Lefebvre H, Delanghe J, Daminet S. Cystatin C: a 
new renal marker and its potential use in small animal medicine. Journal of Veterinary 
Internal Medicine 2014;28:1152-1164.  
2.1 History 
In the early 1960s, a new protein was discovered in normal human cerebrospinal 
fluid
90
 and the urine of patients with proteinuria.
91
 The highest concentration of this protein 
was measured in cerebrospinal fluid, followed by plasma, saliva and urine,
92
 which suggested 
production in the central nervous system, and catabolism by the kidney.
93-95
 The single 
polypeptide chain contained 120 amino acids, and the molecular mass was 13.260 kDa.
93
 
Abrahamson et al. observed expression in every examined tissue, including kidney, liver, 
pancreas, intestine, stomach, lung, placenta, seminal vesicles and salivary gland.
80
 Due to 
similar activity as cystatin A and B, this new protein was named cystatin C.
96
 These cystatins 
inhibit the activity of cysteine proteinases, and therefore protect host tissue against destructive 
proteolysis.
97
  
 
Cystatin C in serum was investigated as a potential marker for GFR, because a better 
correlation was observed between the reciprocal of CysC and GFR, compared with the serum 
concentrations of other measured LMW proteins such as beta-2 microglobulin, retinol-
binding protein and factor D.
98,99
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2.2 Assays 
2.2.1 Human medicine 
In 1994, a fully automated particle-enhanced turbidimetric immuno-assay (PETIA)
a
 
for CysC was developed and validated in serum
100
 and urine.
101
 A few years later, a particle-
enhanced nephelometric immuno-assay (PENIA)
b
 was validated in serum
102
 and urine.
103
 
Concentrations of CysC measured in serum using PENIA showed good correlation with those 
obtained with the PETIA.
102,104,105
 However, this correlation was not observed above 
concentrations of 2 mg/L, with the PETIA yielding lower concentrations.
106
  
 
 
Figure 11. The human particle-enhanced 
nephelometer (PENIA). 
 
Both turbidimetry and nephelometry are based on the dispersion of light, caused by 
immune complexes formed by CysC and latex particles coated with polyclonal antibodies. In 
the turbidimetric assay, the particles are polystyrene particles that are 38 nm in diameter,
100
 
and in the nephelometric assay, the particles are chloromethylstyrene particles that are 80 nm  
in diameter.
107
 Both assays use polyclonal rabbit anti-human CysC antibodies. The major 
difference between these 2 methods is that PENIA
b
 can only be used with a specialized auto-
mated immunonephelometer (Figure 11), whereas PETIA
a
 can be used with several analyzers, 
including the Cobas Fara analyzer
c
,
108
 Hitachi analyzer
d
,
109
 Cobas 6000 analyzer
e
 
110
 and 
Abbott Architect ci8200
f
.
111
 
 
 Newer devices are available, but are limited for veterinary use due to high cost. No 
interferences of triglycerides (≤ 8.5 mmol/L), bilirubin (≤ 150 µmol/L), hemoglobin (≤ 1.2 
g/L) or rheumatoid factors (< 3230 kIU/L) were observed for PETIA
a
.
100
 PENIA
b
 showed 
even less interference.
107
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Similar to Cr, standardization regarding CysC has been accomplished and certified 
reference material (ERM-DA471/IFCC), is available both for both PENIA
b
 and PETIA
g
 
analyzers and enzyme-amplified single radial immunodiffusion.
112-115
  
2.2.2 Small animal medicine 
Currently, veterinary assays for measurement of CysC are not available. Therefore, 
results in animals obtained using the assays designed for humans, do not reflect exact CysC 
concentrations. An amino acid sequence homology of approximately 70% between human 
and feline CysC has been reported.
88,89
 In dogs, homology between 46% and 79% has been 
reported;
116
 but others have reported a maximum and minimum amino acid sequence 
homology of 63% and 22% respectively.
89
 Cystatin C was first demonstrated in canine 
amyloid plaques.
117
 This finding was of major importance, because the authors demonstrated 
cross reactivity between the rabbit anti-human CysC antibody from human PETIA
a
 and 
canine CysC present in cerebrospinal fluid. Based on those findings and the studies in 
humans, Jensen et al.
118
 performed the first validation study using PETIA
a
 to measure sCysC 
in dogs (Table 2). Several other authors also have measured sCysC with PETIA
a
 in healthy 
dogs and in dogs with kidney disease.
119-123
 Cross reactivity between sCysC and the 
polyclonal rabbit anti- human CysC antibody by western blotting was only shown in 1 
report,
120
 and analytical validation parameters were sufficient for PETIA
a
.
118,120,123
 PETIA
a
 
also was validated for measurement of canine urinary CysC.
124
 Miyagawa et al.
125
 also 
measured canine sCysC with a non-commercially available enzyme-linked immunosorbent 
assay (ELISA) using the same antibody from PETIA,
a
  but this technique is not suitable for 
everyday practice. Jonkisz et al.
126
 observed significantly different results for serum CysC as 
measured by PENIA
b
 among dogs of all IRIS stages, which was not observed with PETIA
a
. 
Based on those findings, the authors suggested that PENIA
b
 is more precise. In our opinion, 
parallel validation of both PENIA
b
 and PETIA,
a
 and correlation with GFR measurements are 
necessary to determine which assay is most appropriate for veterinary use. 
 
Nakata et al.
88
 developed recombinant feline CysC in Escherichia coli and 3 
monoclonal antibodies against this protein. These antibodies were also able to recognize 
native feline CysC. These authors aimed to design a sensitive and specific sandwich ELISA to 
detect feline CysC, but this assay is not yet available. Prior to this thesis, no adequate 
validation of PETIA
a
 and PENIA
b
 was performed to evaluate feline CysC. This requires 
further investigation. 
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Table 2. Validation parameters of human CysC assays in canine veterinary medicine.  
 
Authors Assay-analyser Samples Inter-assay 
CV 
(%) 
Jensen et al.
118
 PETIA 
(Cobas Fara II, Hoffman-
La Roche, Switzerland) 
Low sCysC (< 1.1 mg/L) 
Medium sCysC (1–2 mg/L) 
High  sCysC (> 2 mg/L) 
9.6 
5.9 
1.7 
Almy et al.
120
  PETIA 
(Hitachi 912, Roche, IN, 
USA) 
Low sCysC 
Medium sCysC 
High sCysC 
4.7 
4.7 
2.9 
Wehner et al.
123
 PETIA 
(Hitachi 911, Roche, 
Germany) 
High sCr 
Normal sCr 
2.9 
3.6 
 
CysC, cystatin C; CV, coefficient of variation; PETIA; particle enhanced turbidimetric assay; 
sCr, serum creatinine. 
 
2.3 Cys C and GFR 
2.3.1 Human medicine 
Several studies in humans have shown that the reciprocal of sCysC correlates more 
closely with GFR as measured by exogenous clearance tests, than the reciprocal of sCr (Table 
3). Additionally, no significant correlation was observed between the reciprocal of sCr and 
GFR in patients with normal GFR, whereas the correlation with the reciprocal CysC 
concentration extended to the entire GFR range and remained significant.
100
 However, the 
correlation between GFR and the reciprocal of sCysC is weak in healthy individuals.
127
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Table 3. Correlation data for comparisons between the reciprocal of sCysC or sCr and 
exogenous marker clearance in humans.  
 
Author GFR-marker Correlation coefficient (r) 
  sCysC Cr 
Grubb et al.
98
 
51
Cr-EDTA 0.77 0.75 
Simonsen et al.
99
 
51
Cr-EDTA
 
0.75 0.73 
Kyhse-Andersen
100
 Iohexol  0.87 0.73 
Newman et al.
107
 
51
Cr-EDTA 0.81 0.50 
Bökenkamp et al.
128
 Inulin 0.88 0.72 
Randers et al.
129
 
99m
Tc-DTPA 0.87 0.81 
Risch et al.
130
 [
125
I] iodothalamate 0.83 0.67 
Stickle et al.
131
 Inulin 0.77 (4−12 years) 
0.87 (12−19 years) 
0.84 (4−12 years) 
0.89 (12−19 years) 
Nitta et al.
132
 Inulin 0.84 0.72 
 
sCysC, serum cystatin C; sCr, serum creatinine; GFR, glomerular friltration rate; Cr, 
creatinine; 
51
Cr-EDTA, 51-chromium-labeled ethylenediamine tetra-acetic acid;  
99m
Tc-
DTPA, 99-metastabile-technetium-labeled diethylenetriamine penta-acetic acid. 
 
The sensitivity and specificity of the 2 variables were compared by receiver operating 
curve (ROC) analysis, and sCys C had a higher sensitivity and negative predictive value in 
detecting a decreased Cr clearance as compared with sCr.
107
 Serum CysC concentration began 
to increase when the GFR decreased, whereas sCr did not change.
107,133
  
 
 In human medicine, equation formulas were developed in patients with CKD and are 
commonly used to estimate GFR based on sCr
71,134-139
 or sCysC.
140-143
 Equation formulas 
based on sCysC provided a more accurate and precise GFR estimate than those obtained with 
the sCr concentration
140
 and did not underestimate the measured GFR.
142
 However, an 
equation including both plasma Cr and sCysC provided better results than all the other 
equations, especially in patients with early stage renal impairment.
144,145
  
 
In humans, sCysC has a larger intra-individual variation and smaller inter-individual 
variation compared with sCr, which leads to a higher critical difference for the comparison of 
sequential serum concentrations for CysC.
146
 These findings lead to the assumption that 
sCysC is better as a screening test for decreased GFR, and that sCr is better for monitoring 
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changes in established renal disease.
147
 Serum CysC showed no advantages over sCr in 
patients with advanced  chronic renal insufficiency.
147,148
 Additionally, in the general healthy 
population, GFR equations based on CysC were not superior compared with those based on 
Cr.
149
 Authors have attributed the large bias of GFR equations to the fact that the equations 
were developed in populations with CKD and low GFR, because non-renal factors may differ 
between patients with CKD and healthy individuals.
149
 Non-renal elimination and lack of 
CysC measurement standardization may contribute to the observed differences.
147
 Therefore, 
in human medicine, sCysC is used as an additional marker for GFR evaluation, without 
replacing sCr.  
 
2.3.2 Small animal medicine 
Cystatin C has been evaluated as an endogenous indirect marker for GFR in 
dogs.
120,123,125
 Dogs with CKD had significantly higher CysC concentrations compared with 
healthy dogs
120,121,125
 and dogs with various non-renal diseases (immune-mediated, endocrine, 
dermatologic, cardiologic, neoplastic)
118,119,122,123,150
 (Table 4). There was overlap in sCysC 
concentrations between dogs with non-renal disease and healthy dogs
118,125,150
  and between 
healthy dogs and dogs with CKD.
119,122,125
 These results indicate that, currently,  sCysC is not 
a good marker for kidney damage. However, no GFR measurement was performed. Thus, 
early kidney impairment in healthy dogs or dogs with non-renal diseases cannot be excluded. 
   
Furthermore, very limited information is available for dogs with clinical signs of CKD 
but without azotemia. In 1 study, plasma CysC was increased in only 1 of 7 dogs that met 
those criteria.
119
 No clearance test was performed in that dog, and thus it is unclear whether or 
not GFR was decreased.
119
 In a remnant kidney model in young adult Beagle dogs, correlation 
with GFR was better for the reciprocal of CysC (r = 0.79) than sCr (r = 0.54) in the first week 
after the procedure, when the GFR was lowest (0.50 ± 0.15 mL/min/kg). At 10 weeks after 
the procedure, when GFR was higher (1.00 ± 0.27 mL/min/kg) but still below the RI 
(3.50‒4.50 mL/min/kg),120 equal correlation was observed for sCysC and sCr.120 The authors 
hypothesized that the equal correlation of sCysC and sCr with increasing GFR was due to a 
difference in inter- and intra-individual variation. The inter- and intra-individual variation for 
sCysC and sCr was investigated in the dog by calculating the index of individuality (IoI) 
determined by the analytical, inter-individual and intra-individual coefficient of variation.
151
 
For parameters with a low IoI, the repeat test results will be similar to the first result and will 
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not provide new information.
152
 If parameters have a high IoI, the ratio of true positives/false 
positives will increase.
152
 In humans, this explains the higher sensitivity of sCysC (high IoI) 
in detecting renal impairment, but in dogs, sCysC and sCr showed comparable IoI.
151
 
However, the authors attributed the difference in IoI of sCysC and sCr between humans and 
dogs to different storage times, different food, different physical activity index and different 
breeds, which requires further investigation.
151
 
 
A higher sensitivity of sCysC (76%) than sCr (65%) and comparable specificity (87% 
for sCysC and 91% for sCr) for detecting decreased GFR (< 3.0 mL/min/kg), as measured by 
an exogenous Cr clearance test, was observed in dogs by Wehner et al.
123
 In this study, dogs 
with normal GFR (≥ 3 mL/kg/min; n = 23), slightly decreased GFR (2.00‒2.99 mL/min/kg; n 
= 22) and markedly decreased GFR (< 1.99 mL/min/kg; n = 15) were included. Cystatin C 
and sCr had comparable positive predictive values, but sCysC had higher negative predictive 
value (69%) compared with Cr (62%) for detecting early CKD.
123
 There was a slightly better 
negative correlation  between sCysC (r = -0.630) and exogenous Cr clearance compared with 
sCr (r = -0.572).
123
 There was also a better correlation between sCysC (r = -0.704) and 
plasma iohexol clearance compared with sCr (r = -0.598). In that study, 88 dogs with CKD 
and 43 healthy control dogs were included.
125
 
 
In cats, Cys C was evaluated in 2 reports, and contradictory results were observed. 
Martin et al.
153
 concluded that plasma CysC was not a valuable marker for the detection of 
renal impairment, because only 14 of the 75 cats that had clinical signs of CKD and azotemia 
had CysC concentrations above the upper reference limit of 4.11 mg/L, which was determined 
by the authors. However, group allocation in this study did not take into account IRIS 
guidelines, and the RI was not calculated according to the ASVCP guidelines.
40
 Until now, 
GFR has only been measured in 1 report on feline CysC; Poświatowska-Kaszczyszyn154 
found a significantly better correlation between GFR and sCysC (r = -0.51) than between 
GFR and sCr (r = -0.46), which is comparable to findings in humans
98-100,107,129-132,155,156
 and 
dogs.
120,123,125
 An interesting and common finding in the 2 studies is the overlap in sCysC 
concentrations between healthy cats and cats with CKD. In addition, sCysC also overlapped 
between the different IRIS stages in the study of Poświatowska-Kaszczyszyn.154 In Martin et 
al,
153
 no GFR measurement was performed: thus early kidney impairment in the healthy cats 
cannot be excluded. In the study of Poświatowska-Kaszczyszyn,154 GFR was calculated, and 
GFR was also found to overlap between healthy cats and cats with CKD, potentially 
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explaining the overlap of sCysC for both groups. However, this study lacked information on 
USG and used the 1-compartment model for GFR calculation. It is generally accepted that 1-
compartment models may overestimate true GFR,
59
 which recently was confirmed by Finch et 
al.
62
 Thus, correlation between sCysC and GFR should be further investigated, and a 
reference interval should be calculated according to the ASVCP guidelines. 
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Table 4. Overview of studies evaluating the use of sCysC in small animal medicine. 
Serum CysC (mg/L) was expressed as the mean ± SD, median sCysC or (range). 
 
Species Authors Status Age (years) n sCysC 
Dog Jensen et 
al.18
118
 
Healthy 
Non renal 
disease 
CKD 
1-9 
0.5-13 
 
0.5-9 
17 
12 
 
8 
1.06 
1.62 
 
5.01 
Dog Almy et al.
120
 Healthy 
CKD 
Adult 
Adult 
25 
25 
1.08 ± 0.16 
4.37 ± 1.79 
Dog Braun et al.
119
 Healthy 
CKD 
 (sCr > 133 
µmol/L) 
Signs of CKD, 
no azotemia 
Azotemia, no 
signs of CKD 
0.16-16.5 
 
179 
 
27 
 
7 
 
13 
0.60  ± 0.31 
 
(0-8.6) 
 
(0.2-1.2) 
 
(0-1.2) 
Dog Wehner et al.
123
 Healthy 
(sCr (55.31–
108.5 µmol/L)) 
Reduced ECPC  
( < 3 
mL/min/kg) 
0.25-13 
 
 
0.5-15 
99 
 
 
15 
(0.68-1.6) 
 
 
> 1.6 
Dog Gonul et al.
121
 Healthy 
CKD 
1-9 
2-13.5 
10 
20 
1.2 ± 0.42 
2.96 ± 1.09 
Dog Miyagawa et 
al.
125
 
Healthy dogs 
CKD 
Neoplasia 
Congestive heart 
disease 
 76 
88 
5 
5 
0.85 ± 0.15 
1.23 ± 0.21 
0.93 ± 0.13 
0.80 ± 0.12 
Cat Martin et al.
153
 Healthy 
Signs of CKD 
and azotemia 
Signs of CKD, 
no azotemia 
Azotemia, no 
signs of CKD 
NS 99 
75 
 
35 
 
24 
1.60 
2.64 
 
1.595 
 
1.74 
 
Cat Poświatowska-
Kaszczyszyn
154
   
Healthy 
CKD 
- IRIS 1 
- IRIS I2 
- IRIS II3 
- IRIS I4 
NS 24 
46 
16 
16 
6 
8 
0.7 ± 0.2 
1.3 ± 0.6 
1.1± 0.3 
1.0 ± 0.5 
1.4 ± 0.3 
1.25 ± 0.6 
ECPC, exogenous creatine plasma clearance; NS, not specified. 
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2.4 Urinary CysC 
2.4.1 Human medicine 
Cystatin C is freely filtered through the glomerulus, reabsorbed and catabolized in the 
tubules, as has been shown in rats.
82,157
 With normal renal function, CysC can be found in 
small quantities in the urine.
92
 With proximal tubular damage, uCysC increases.
86,87
 Urinary 
CysC was higher in human patients with renal tubular damage compared with patients with 
proteinuria without tubular damage and a healthy control group.
87,158
 Urinary CysC might be 
more sensitive than other LMW proteins, such α1-microglobulin and β2-microglobulin, 
because uCysC showed the highest correlation coefficient with sCr.
159
 However, it is 
mandatory to measure total proteinuria, because massive proteinuria has been shown to 
inhibit tubular reabsorption of CysC in experimentally-induced nephropathies
160
 and in 
children with idiopathic nephropathy,
161
 causing higher uCysC concentrations and therefore 
underestimating tubular function. 
 
2.4.2 Small animal medicine 
 
To the authors’ knowledge, only 1 report has validated PETIAa for measuring canine 
uCysC in healthy dogs, dogs with renal impairment and dogs with non-renal disease.
124
 The 
assay was linear and precise and the uCysC/uCr ratio was significantly higher in dogs with 
renal disease compared with healthy dogs and dogs with non-renal disease. Although the 
results for uCysC seem promising in dogs, additional studies are required. First, uCysC has 
not yet been investigated in cats. Second, nor in cats and dogs, uCysC was investigated as a 
marker of early renal damage. Third, canine and feline CysC are not yet available, and 
therefore, the accuracy of the method could not be evaluated. Fourth, follow-up to evaluate 
uCysC/uCr as a prognostic marker was not performed. Additionally, the effect of proteinuria 
on uCysC concentration was not investigated. 
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2.5 Biological  factors influencing sCysC 
2.5.1 Human medicine 
2.5.1.1 Age and gender 
Because the estimation of renal function by sCr requires adjustment for height and 
body composition, sCysC was studied as an alternative marker for GFR in children and the 
elderly. Serum CysC showed diagnostic superiority over sCr as a marker for decreased GFR 
in the pediatric population,
156
 and the CysC-based GFR equation was better than the Schwartz 
formula,
162-164
 except in individuals > 60 years old.
165
 The superiority of CysC and more 
common use of an enzymatic assay instead of the Jaffe method to measure Cr resulted in a 
new Schwartz formula.
166
 Interestingly, several studies have shown that sCysC is high during 
the first days of life, rapid declined during the first 4 months, and then stays constant beyond 
the first year of life.
167,168
 In contrast sCr falls to a nadir at 4 months, gradually increases to 
adult concentrations by 15–17 years of age.169 The decrease of both parameters during the 
first year can be explained by developing renal function, which causes an increase of GFR. 
The increase of sCr beyond the first year of life is mainly due to increasing muscle mass and 
body weight,
169
 in contrast with sCysC, which is not correlated with muscle mass.
127,170
 In an 
adult population, increasing age, sex, greater weight, greater height, cigarette smoking and 
higher C-reactive protein (CRP) concentrations were independently associated with higher 
sCysC concentration before
171
 and adjusting for age, sex and weight of individuals for whom 
GFR was estimated by a urinary Cr clearance test.
172
 The latter indicates that these factors 
may influence sCysC independent of their effects on renal function. However, others have 
observed no difference between healthy male and female individuals.
173,174
 
 
Serum CysC concentrations were significantly higher in individuals > 80 years 
compared with individuals between 65 and 80 years of age, which correspond to the inverse 
change of the predicted Cr clearance.
175
 However, no benefit was found for sCysC compared 
with sCr in detecting early renal impairment.
176
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2.5.1.2 Inter-individual variation 
A larger intra-individual variation has been reported for CysC compared with sCr in 
healthy individuals and in individuals with impaired kidney function,
130,177,178
 and a smaller 
inter-individual variation has been found.
146
 Therefore, some authors propose using sCr as the 
marker of choice for detecting temporal changes in renal function.
146
 A possible explanation 
for the greater intra-individual variation for CysC is the better ability of CysC to reflect small 
changes in GFR.
130
  
2.5.1.3 Food 
Serum CysC was unaffected after intake of a cooked meal, whereas the sCr 
concentration was significantly higher after eating.
179
  
2.5.1.4 Storage  
Cystatin C generally is considered a stable protein.
84
 Cystatin C was stable in serum 
for 6 months at -80 °C, and for 7 days at temperatures ranging from 20 °C to -20 °C.
105
 Others 
have reported stability up to 1 month at 2‒8 °C180 but only 1 day at ambient temperature 
(19‒23 °C) and 2 days at 4 °C.101 No significant differences in sCysC concentrations were 
observed when comparing concentrations of selected proteins in samples stored at -25 °C for 
2 years and 25 years, with samples stored for 1 month.
181
 
 
Urinary CysC was stable  at urine pH  ≥ 5, at  both -20 °C and 4 °C for 7 days and at 
20 °C for 48h.
103
  
 
2.5.2 Small animal medicine 
 
Serum Cr concentration in dogs is influenced by breed, age, diet and exercise, which 
may result in errors in diagnosing CKD.
7
 Because sCysC appeared to be a sensitive GFR 
marker, some authors have investigated the effect of physiological factors on sCysC. Plasma 
CysC was shown to be lower in adult dogs compared with younger and older dogs and lower 
in dogs with body weight < 15 kg compared to heavier dogs.
119
 In the latter study, 179 dogs 
were included: 89 young dogs (< 1 year), 39 adult dogs (1–8 years) and 51 old dogs (8‒16.2 
years). An overlap in plasma CysC concentration was observed (0.12–1.10 mg/L in the adult 
dogs, 0–1.73 mg/L in the young dogs and 0‒1.60 mg/L in the old dogs). Moreover, it was 
unclear whether all of the dogs were healthy, because complete blood count (CBC), serum 
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biochemistry or urinalysis were not performed. Other studies did not find a correlation 
between sCysC  and age or weight.
123,151
 No circadian rhythm or sex difference were 
observed.
119,123
 In Wehner et al., 99 healthy dogs were included, with an equal gender 
distribution (52 female, 47 male dogs) and a wide range in age and body weight (3 months‒13 
years; 5–42 kg).123 In contrast, the study of Pagitz was limited by including only 24 healthy 
dogs (16 female and 8 male) with an age range of 10‒97 months.151 Because contradicting 
results were reported regarding the effect of age and bodyweight on sCysC in dogs, additional 
studies in a larger number of healthy dogs, preferably in which GFR is measured, are 
required.  
 
In contrast to plasma Cr concentration, which increases in dogs during the first 12 h 
after a meal, plasma CysC concentration showed a dramatic decrease during the first hour 
after a meal. This decrease lasted for 9 h, and then returned to baseline after 12 h.
119
 Based on 
these results, dogs should be fasted for at least 12 h before taking blood samples to measure 
CysC concentration. Creatinine originates primarly from the amino acids glycine, arginine 
and methionine, but also from the gastrointestinal tract, which can explain the increase after a 
meal.
182
 Because plasma CysC concentration is mainly determined by GFR, and it has been 
shown that a meal causes a significant increase in GFR,
183
 the increased clearance of CysC 
could explain the decreased concentration, but this has not yet been confirmed. 
 
To the authors’ knowledge, no studies about the biological variation of sCysC in cats 
have been performed.  
2.6 Clinical factors influencing sCysC 
2.6.1 Human medicine 
2.6.1.1 CysC in  patients with diabetes mellitus 
Diabetic nephropathy is a common complication in human diabetes patients and is 
characterized by persistent albuminuria and an associated decrease in GFR.
184
 Several studies 
have reported that sCysC is a better GFR marker than sCr for the early detection of incipient 
diabetic nephropathy.
185,186
 Moreover, the correlation between GFR measured with 
51
Cr-
EDTA and sCysC (r = 0.84) was significantly stronger compared using estimated GFR (r = 
0.70).
186
 However, others have reported that sCysC is equal to sCr as a GFR marker in micro- 
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and macro-proteinuric diabetes patients.
187
 This difference can be explained by the different 
methods used to measure sCr, differing GFR reference methods and varying diabetes 
populations studied.  
2.6.1.2 CysC and AKI 
Acute kidney injury (AKI) is associated with high mortality. Therefore, early detection 
is critical to prevent further progression.
188
 Serum CysC concentration could detect 
development of AKI 1 or 2 days earlier than sCr concentration in intensive care patients with 
≥ 2 predisposing factors of AKI.188 A limitation of this study was that GFR was not measured. 
Interestingly, the uCysC concentration also may predict renal replacement requirement in 
patients initially diagnosed with non-oliguric acute tubular necrosis.
189
 In similar studies, 
CysC was as effective as
190
 or less sensitive than
191
 sCr in the detection of AKI. However, 
similar to sCr, CysC could not discriminate between CKD and AKI.
192
 In conclusion, several 
authors
193,194
 have suggested that the use of CysC to detect AKI must be evaluated in larger 
studies and with different types of AKI and that the prognostic value also must be determined.  
2.6.1.3 CysC and thyroid function 
In patients with hyperthyroidism, renal blood flow is stimulated, which causes 
increased GFR.
195
 Serum Cr concentration decreases, which masks patients with concurrent 
CKD.
196
 Contrasting effects have been observed in patients with hypothyroidism.
197,198
 As 
sCysC was introduced as a new marker of kidney function, the impact of thyroid dysfunction 
on sCysC also was investigated. With therapy, sCysC concentration increased in patients with 
hypothyroidism, and decreased in patients with hyperthyroidism.
199-201
 However, others did 
not observe higher or lower sCysC concentrations in patients with untreated hyper- or hypo-
thyroidism respectively.
202
 When considering sCysC concentrations in patients with 
hyperthyroidism, GFR is overestimated and, in patients with hypothyroidism, GFR is 
underestimated.
203
 Den Hollander suggested that there is an increased or decreased production 
of CysC in hyper- and hypothyroidism respectively, due to the influence of the thyroid state 
on general metabolism.
204
 Serum concentrations of CysC and TGF-β1 were significantly 
higher in patients with hyperthyroidism and a positive correlation between sCysC, thyroid 
hormones and TGF-β1 was observed.205 After treatment, sCysC and TGF-β1 decreased. In 
vitro findings have suggested an increase in TGF-β1 concentration in hyperthyroidism and a 
stimulatory effect of thyroid hormones and TGF-β1 on CysC production.205 
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2.6.1.4 CysC and cardiovascular risk 
Chronic kidney disease is a known risk factor for ischemic heart disease. In contrast 
with sCr, CysC was associated with an increased risk of  heart failure.
206
 Serum CysC tends to 
be a stronger predictor of mortality than sCr in elderly individuals with heart failure,
207
 as 
well as in the entire elderly population.
208
 Because CysC is a proteinase inhibitor that plays an 
important role in tissue remodelling, the higher CysC concentration also could represent a 
compensatory mechanism in vascular injury.
209
  
2.6.1.5 CysC and cancer 
Because renal disease has a high prevalence in the elderly, concurrent neoplasia may 
be present. Decreased regulation by cystatins is responsible for increased cysteine protease 
activity in tumor cells.
210-212
 Cystatin C has two anti-tumor effects. First, it is a major inhibitor 
of the cathepsins, enzymes that cause degradation of basal membranes by tumor cells. 
Therefore, CysC suppresses the metastastic process.
84
 Second, CysC also inhibits TGF-β and 
its TGF-β signaling pathway.213,214 The specific role of CysC in oncogenesis has not yet been 
elucidated. However, individuals with untreated carcinomas
215
 and leukemia
216
 had 
significantly higher sCysC concentrations compared with patients after therapy. However, 
two other studies
155,217
 did not find a difference in sCysC concentrations between patients 
with malignancy and a healthy control group.  
2.6.1.6 CysC and inflammation 
In vitro, CysC regulates certain aspects of immune function,
218
 because IL-10 controls 
CysC synthesis in response to inflammation.
219
 Several reports have shown a good correlation 
between sCysC and other inflammatory markers,
172,220,221
 but these studies were performed in 
populations with either cardiovascular
221
 or renal impairment,
220
 which can cause bias. 
Dexamethasone caused a dose-dependent increase of CysC secretion in vitro,
222
 in vivo, 
sCysC is influenced by prednisolone administration.
223,224
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2.6.2 Small animal medicine 
One study in dogs showed no influence of inflammation on sCysC.
123
 However, only a 
limited number of dogs was examined; therefore additional research is needed to examine the 
impact of this condition on sCysC. Because glucocorticoids are commonly administered to 
small animals, future studies are needed to evaluate whether corticosteroids falsely increase 
sCysC. Serum CysC concentration and GFR should be measured in healthy dogs and cats 
before, during and after glucocorticoid administration. 
 
In a study comprising 10 volume-depleted dogs, and one dog with AKI, a weaker 
correlation between sCysC and GFR than sCr and GFR was observed.
120
 These results 
indicate that CysC is not a good GFR marker for decreased GFR due to pre-renal causes. 
However, caution is warranted. Only a few dogs were sampled, which could have influenced 
the regression analysis. Furosemide administration used to achieve volume depletion also 
could have affected CysC kinetics.
120
 In the same study, the sCysC concentrations of the dog 
with AKI fell within the RI established for healthy dogs,
120
 in contrast to observations in 
human patients.
133
 This suggests that in dogs with AKI, sCysC is not a sensitive indicator of 
decreased GFR. However, in critically ill dogs, sCysC concentrations were significantly 
higher in dogs in shock compared with healthy dogs,
225
 but this result was not observed in 
multiple-trauma dogs, which is in contrast to reports in human.
226
 To date, no large-scale 
study in dogs with AKI has been performed to evaluate sCysC.  
 
One of the diseases leading to AKI in dogs is babesiosis, and the diagnosis of this 
serious complication is difficult. Photochemistry assays can cause false-positive results in 
babesiosis due to free haemoglobin or bilirubin.
227
 In one study, no increased sCysC or sCr 
concentration was observed. Studies investigating correlations between GFR and sCr and 
sCysC should be performed to identify the most appropriate marker for screening for renal 
damage in dogs with babesiosis.
227
 In our opinion, additional studies in dogs with AKI or pre-
renal azotemia are needed. 
 
Cystatin C also was of particular interest in dogs with visceral leishmaniasis, a disease 
that results in CKD due to immune complex dispositions and glomerular injury.
228
 In humans, 
sCysC concentrations were positively correlated with circulating immune complexes and the 
production of granulocyte-macrophage colony stimulating factor (GM-CSF), 2 factors leading 
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to glomerular dysfunction in leishmaniasis.
229
 In dogs with visceral leishmaniasis, mean 
sCysC concentration was significantly higher than in the control groups, and sCr 
concentration was lower than in the control group, although not significantly. However, the 
mean sCysC concentration fell within the RI proposed by two other authors.
119,150
 GFR should 
be determined and renal biopsies should be performed to determine if the increased sCysC 
concentration in dogs with leishmaniasis is due to immune-complex deposition or an extra-
renal factor. 
 
In human medicine, contradictory reports have been published regarding the effect of 
different tumors on sCysC concentration. Therefore, studies in small animals to evaluating the 
effect of neoplasia on sCysC are essential. Cystatin C is an anti-tumor marker, because it is a 
protease inhibitor, and therefore it inhibits damage from the tumor cells and the metastatic 
process. Serum Cr concentration is not a good GFR marker in patients with neoplasia due to 
the decreased muscle mass, and sCysC potentially may be a valuable alternative. 
 
Cystatin C has not yet been investigated in cats with non-renal disease, except for 
hyperthyroidism. Serum CysC was evaluated in cats with hyperthyroidism using PETIA
a
. No 
correlation was observed between GFR measured by exogenous inulin clearance and 1/sCysC 
concentration, although a significant correlation between GFR and 1/sCr was observed.
230
 
Additionally, no significant decrease in sCysC concentration was observed after treatment 
with 
131
I.
230
 Although preliminary, the study of Jepson et al.
230
 suggests a potentially similar 
influence of thyroid function in cats as in humans, with  hyper- and hypothyroidism causing  
increased or decreased sCysC concentrations, respectively. Additional studies to clarify the 
impact of thyroid function on CysC are warranted. 
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3. Validation of biomarkers 
Before CysC can be used in small animal practice, this marker needs to be validated. 
Validation is defined as the evaluation of the quality of a measurement, in order to identify 
the presence of an analyte, and to evaluate the status of the test subject.
231
 It is fundamental to 
investigate if the measured concentration of the marker reliably reflects the status of the 
animal.
232
 Hence, validation is composed of analytical, biological and clinical aspects. 
 
3.1 Analytical validation 
In practice, validation is performed by evaluating the analytical performance followed 
by observing how the test behaves in patients.
232
 First, the analytical validation is determined. 
It determines the fitness of an assay, that has been developed and standardized for an intended 
purpose.
233
 As described above, no veterinary CysC assays are available. Therefore, in this 
PhD thesis, it will be tested if the human assays can reliably measure feline CysC. This can be 
evaluated by determining the imprecision, inaccuracy and analytical sensitivity.
232
 The 
imprecision is the level of difference between results of replicates of a sample within and 
between runs of the same test method in a given laboratory.
233
 The within- and between-run 
imprecision is calculated from the results of replicate measurements on the same specimen on 
the same day and on several consecutive days respectively.
232
 Samples with low, middle and 
high concentrations should be included. The imprecision is reported as coefficient of variation 
(CV), and should not exceed 15%.
234
 The inaccuracy can be defined as the difference 
between the mean value of a series of measurements and the true value. Inaccuracy can be 
evaluated by spiking recovery, linearity check, control material or comparison of analytical 
methods. If the analyte is available, spiking recovery can be performed, by adding a known 
amount of the analyte in both patient samples and diluent. If the recovery of the spike with 
samples equals recovery of the spike with diluent, the sample matrix is valid.
232,235
 Another 
method used when the analyte is not available, is linearity check. The analyte concentration is 
measured before and after dilution with the appropriate diluent. A correlation coefficient of 1 
indicates a 100% recovery.
232
 Figure 12 illustrates imprecision and inaccuracy. The analytical 
sensitivity is determined by the limit of detection (LOD), the smallest amount of the analyte 
in the sample that can be detected. In practice, a sample with low or no analyte concentration 
is measured several times and the estimated detection limit is calculated based on the mean 
value and standard deviation.
232,235
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 Figure 12. Inaccuracy and imprecision. The 
true value is in the centre. Imprecision 
represents the closeness of the repeated 
measures, whereas inaccuracy is the difference 
between the true value and the mean of the 
repeated measures. Adapted from Jensen AL, 
2000.
232
  
 
3.2 Biological validation 
A second step in analyte validation is to know test results in healthy animals i.e. the 
biological validation.
232
 The analyte concentration can be affected by both non-host and 
inherent host-factors.
231
 Non-host factors are technical factors such as contamination or 
detoriation of the sample, which are essential to be studied, in order to determine appropriate 
handling of samples.
231
 Host-factors can be subdivided in the inherent factors age, sex, breed, 
nutritional status; and the acquired factors, caused by disease.
231
 To know if a measured value 
of the analyte is abnormal, it is necessary to know an estimated value from a healthy 
population of comparable individuals, the reference population.
40
 A RI is determined in a 
minimum of 120 reference individuals by a nonparametric method with 90% confidence 
intervals.
40
 It is essential to know the influence of inherent and pre-analytical factors to 
determine if separate RIs are necessary.
40
 Inclusion and exclusion criteria, based on narrowly 
or extensive defined procedures to define health, should be established.
40
  
 
3.3 Clinical validation 
A third step is to compare test results in healthy animals with various groups of 
diseased animals i.e. the clinical validation.
232
 The ability to discriminate between patients 
with and without the disease is a major determinant of the clinical utility.
40
 To test this, three 
criteria should be kept in mind: the appropriate animals should be selected i.e. animals for 
which the disease is a differential diagnosis; the animals should be classified as with or 
without the disease, independently from the evaluated laboratory test; the test should be 
performed in batch i.e. at the same point in time for all animals.
232
 The result indicates if the 
Inaccuracy 
Imprecision 
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analyte is significantly different between healthy and diseased animals. Next step is to 
establish a decision threshold, which is selected for characterizing a test results as positive or 
negative.
40
 This can be derived from the result of a gold standard method,
231
 or from 
prospective studies with thorough deliberation and planning.
40
 Based on this limit, test results 
can be classified into positives and negatives and the sensitivity and specificity of a test can 
be calculated. The sensitivity is defined as the proportion of patients with the disease that test 
positive and specificity is defined as the proportion of patients without the disease that test 
negative.
232
 The higher the sensitivity and specificity, the better the test. Depending on the 
chosen cut-off value, dividing test results in negative or positive, sensitivity and specificity 
change. This can be displayed in a graph i.e. ROC, with sensitivity on x-axis and (1-
specificity) on the y-axis.
232
 Based on this curve, the overall diagnostic accuracy of the test 
can be determined visually and mathematically. The better the test discriminates between 
healthy and disease, the closer the ROC curve is situated in the upper left-hand corner of the 
graph.
232
   
After the validation process, all factors are known that have to be taken into account to 
criticize the marker. 
 
Figure 13. ROC curve. The sensitivity is plotted as a function of (1-specificity) over the 
range of selected cut-off values. Tests with a poor performance tend toward the diagonal line, 
tests with a good performance tend upward and leftward. The highest sensitivity and 
specificity is the top-leftmost point. In this example, the cut-off value that gives this point is  
15.5. Adapted from Jensen AL, 2000.
232
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4. Conclusion 
 
Since routine renal markers, sCr and urea, are insensitive markers of renal function, 
there is a need for markers that can reliably and easily detect early kidney dysfunction in cats. 
 
Cystatin C has the potential to become a valuable biomarker in small animal medicine, 
but adequate analytical, biological and clinical validation is needed first. 
 
A few studies using canine serum have been performed, but studies in cats are scarce. 
This thesis aimed to validate CysC in cats at analytical, biological and clinical level. First, 
there is a need to perform a thorough analytical validation of the nephelometric and 
turbidimetric assays for determining CysC in feline serum and urine. These studies will 
identify which assay is most suitable for feline CysC measurement. To evaluate whether 
sCysC is a better GFR marker than sCr, it is necessary to evaluate the biological factors that 
may influence sCysC and to establish a RI. In addition, the correlations of GFR with sCysC 
and sCr must be compared. To use sCysC as GFR marker in practice, conditions that might 
influence CysC also must be investigated. Finally, further investigations of uCysC should be 
performed to assess its value for the detection of tubular dysfunction. 
 
 
End Notes 
 
a
 PETIA Cystatin C assay, Dako, Glostrup, Denmark 
b 
PENIA Cystatin C assay, Siemens, Marburg, Germany 
c 
Cobas Fara analyser, Roche Diagnostics, Basel, Switzerland 
d  
Hitachi analyser, Roche Diagnostics, Indianapolis, IN 
e 
Cobas 6000 analyser, Roche Diagnostics, Basel, Switzerland 
f
 Abbott Architect ci8200 analyser, Abbott Laboratories, Abbott Park, IL 
g
 PETIA Cystatin C assay, Gentian AS, Moss, Norway 
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Chronic kidney disease (CKD) has a high prevalence in cats. It is a progressive and 
irreversible disease. Early detection and consequent treatment are essential and may increase 
median survival time by preventing further renal damage.  
The best overall index for evaluating kidney function, is measurement of glomerular filtration 
rate (GFR), but this procedure is time-consuming and labour-intensive and is not an 
appropriate method for routine use. The indirect markers, serum creatinine (sCr) and serum 
urea, both lack sensitivity and specificity. They only increase when up to 75% of the 
functional renal mass is lost, and they are influenced by non-renal factors. 
There is a need for renal markers that can detect feline CKD early and easily. A possible 
marker is cystatin C (CysC). Studies in humans and dogs revealed promising results, but data 
in cats are scarce. 
The scientific aims of this thesis were: 
1. Evaluate precision, accuracy and analytical sensitivity of a commercial available 
human particle enhanced nephelometric assay (PENIA) and particle enhanced 
turbidimetric assay (PETIA) for feline CysC determination in both serum and urine. 
2. Determine optimal storage conditions for sCysC and urinary CysC (uCysC) and 
evaluate the effect of feeding on feline sCysC. 
3. Determine the effect of age, breed and sex on feline serum CysC (sCysC) and 
establish a reference interval. 
4. Evaluate sCysC and uCysC in cats with hyperthyroidism and cats with feline 
immunodeficiency virus (FIV)-infection. 
5. Evaluate CysC as a marker for CKD in cats. 
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Summary  
 
In people and dogs, Cystatin C (CysC) seems superior to serum creatinine (sCr) to 
estimate the glomerular filtration rate (GFR). A particle-enhanced nephelometric 
immunoassay (PENIA) and turbidimeter (PETIA) are available to measure CysC in humans, 
but there are no reports in cats. The objective of this study was the validation of the human 
CysC PENIA and PETIA with feline serum and urine, and to perform a pilot study comparing 
serum and urine CysC between healthy cats and cats with chronic kidney disease (CKD). 
Protein purification was performed to produce feline recombinant CysC. 
 
The feline CysC gene (CST3) was isolated from white blood cells and the plasmid 
with CST3 was cloned into 3 different expression vectors: Escherichia coli, Pichia pastoris 
and HEK293T mammalian cells. Western blot analysis was used to assess cross-reactivity 
between feline CysC and the polyclonal rabbit anti-human CysC antibody from PENIA and 
PETIA. Imprecision and linearity were determined for feline serum and urine CysC. Serum 
and urine CysC were measured in 10 healthy and 10 CKD cats. 
 
Feline recombinant CysC could not be produced. Cross-reactivity between the 
polyclonal rabbit anti-human CysC antibody from both PENIA and PETIA and feline CysC 
was demonstrated. Intra-assay coefficients of variation for serum and urine were 1.3% and 
0.4% for PENIA and 0.8% and 0.4% for PETIA and the inter-assay coefficients of variation 
12.5% and 4.1% for PENIA and 9.5% and 15.9% for PETIA. Measured with PENIA, cats 
with CKD had a significantly higher serum CysC concentration (1.24 (0.63–2.99) vs 0.79 
(0.43–1.05) mg/L; P = 0.02) and urine CysC/urinary Creatinine (uCr) ratio (565.6 (0–1311) 
vs < 0.049/uCr mg/mol; P = 0.005) compared with healthy cats.  
 
The human nephelometric assay showed satisfactory validation results for feline 
CysC, in contrast with PETIA. Cats with CKD had a significantly higher sCysC concentration 
and uCysC/uCr ratio compared with healthy cats. Additional studies are necessary to evaluate 
CysC as an early marker of renal damage in cats.  
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Introduction 
 
Chronic kidney disease (CKD) is a common disease in cats and has an estimated 
prevalence between 1.6% and 20% in the general cat population,
1
 and of 30% in cats older 
than 15 years.
2
 Early detection and treatment of CKD are very important to slow down 
progression of renal disease and improve the long-term prognosis, including the quality of 
life.
3
 
Evaluation of the glomerular filtration rate (GFR) – the volume of ultrafiltrate 
produced per minute of time – is considered the gold standard to evaluate kidney function.4 
Direct measurement of GFR in animals is based on the clearance of markers that are freely 
filtered through the glomerulus, and that undergo minimal tubular absorption or secretion.
5
 
Because accurate determination of GFR is labor-intensive and time-consuming, it is not 
routinely used in veterinary practice. The routine indirect diagnostic markers for GFR, serum 
urea and serum creatinine (sCr), are only increased when > 75% of the functional renal mass 
is lost.
4
 This implies that CKD is currently diagnosed in a relatively late stage. Moreover, 
serum urea and sCr are influenced by food intake, medication and muscle mass.
4
 
Consequently, there is an urgent need for indirect markers that can reliably and easily detect 
early kidney dysfunction in cats. 
 
Cystatin C (CysC) is a 13 kDa protein, first described in cerebrospinal fluid of healthy 
humans.
6
 It is part of a family of proteinase inhibitor proteins, which play a major role in the 
intracellular catabolization of peptides and proteins.
7
 It is produced by all nucleated cells at a 
constant rate, since it is encoded by a housekeeping gene.
8
 Most of the properties that are 
required for an ideal endogenous GFR marker apply for CysC, as shown in the rat.
9
 Besides a 
constant production and constant plasma concentration in the absence of GFR-variation, it 
shows a low intra-individual variability, exhibits no plasma protein binding, no tubular 
secretion or absorption and no extra-renal clearance.
10
 In addition, as CysC is completely 
catabolized in the tubulus, only small amounts can be found in the urine of healthy people.
11
 
In people
12,13
 and dogs
14
 with tubular dysfunction, urinary CysC (uCysC) concentration is 
significantly higher compared to that in healthy individuals. This suggests that uCysC can 
also be used as a tubular marker in people and dogs. 
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Several studies in people confirm the superiority of serum CysC (sCysC) to sCr in the 
detection of renal impairment.
15,16
 Additionally, in dogs, sCysC has a higher sensitivity and 
negative predictive value compared with sCr for detecting renal impairment.
17-19
 Serum CysC 
has also been investigated in human patients with risk of acute kidney injury (AKI), one of 
the major complications of CKD. Serum CysC was able to detect development of AKI one or 
two days earlier than sCr,
20
 but the significantly higher mean sCysC only lasted for 24h.
21
  
 
Three methods for measurement of CysC are available in humans: an enzyme-linked 
immunosorbent assay (ELISA), a particle-enhanced turbidimetric immunoassay (PETIA) and 
a particle-enhanced nephelometric immunoassay (PENIA).
22-24
 Currently, no commercial 
veterinary CysC assays are available. Therefore, the human assays need to be validated for the 
different species of interest. As the immunoassays are based on an antibody-antigen reaction, 
demonstration of cross reactivity between the feline CysC antigen and the anti-human CysC 
antibody used in the nephelometric and turbidimetric assay had to be established by Western 
blotting. The nephelometric and turbidmetric assay are based on dispersion of light by 
immunocomplexes present in the sample. When reagent is added to serum, CysC will bind 
antibodies coated with chloromethylstyrene particles (PENIA) or polystyrene particles 
(PETIA). These aggregates cause dispersion of light and an electric signal. Concentration is 
determined with a standard curve, based on pure human CysC. This makes that the measured 
feline CysC concentration is not an exact concentration but relative. Therefore, a feline CysC 
standard should be produced. Production of feline recombinant CysC has been described 
earlier.
25
  
 
The first aim of this study was the production of feline recombinant CysC. The second 
aim was the validation of the human PENIA and PETIA for determination of CysC in serum 
and urine of cats. After evaluation of the validation parameters, the most satisfactory assay to 
measure feline CysC was selected. In addition, a pilot study was performed to evaluate if the 
CysC concentration determined in feline serum and urine significantly differed between 
healthy cats and CKD cats.  
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Materials and methods 
 
Study design 
For the production of feline recombinant CysC, the feline CysC gene (CST3) was 
cloned into a plasmid. Consequently, CysC was cloned into an expression vector with a fusion 
protein, followed by protein purification. For the validation, blood and urine samples were 
collected from 10 healthy cats and 10 cats with CKD. In all cats, complete blood cell count 
(CBC), serum biochemistry profile and complete urinalysis were performed. Blood and urine 
samples of three healthy cats and four CKD cats were selected for Western blot analysis for 
PENIA and two CKD cats (one proteinuric and one non-proteinuric) and one healthy cat for 
PETIA. Blood and urine samples of six healthy cats and six cats with CKD were used for 
assay validation. Serum and urine samples of all 20 cats were analysed with the best assay to 
measure their CysC concentration. This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. The protocol was approved by the Local Ethical and Deontological 
Committee of the Faculty of Veterinary Medicine, Ghent University (EC2011_197). All 
owners whose animal participated in the study signed an informed consent. 
 
Animals and samples 
Adult healthy and CKD cats were included, regardless of breed and sex. Cats were 
considered healthy when there was no disease history and no abnormalities were detected on 
physical examination, CBC, serum biochemistry profile and urinalysis. Criteria for normal 
urinalysis were: urine specific gravity (USG) > 1.035, inactive urinary sediment, urinary 
protein to creatinine ratio (UPC) < 0.4 and negative bacteriological urine culture.
2  
Cats with 
sCr > 141.2 µmol/L and USG < 1.035 were excluded. 
Diagnosis of CKD was made prior to inclusion. Cats were diagnosed with CKD based 
on the presence of clinical signs compatible with CKD and laboratory (i.e. renal azotemia and 
USG < 1.035) findings.
 
Cats were classified into four stages according to the International 
Renal Interest Society (IRIS) guidelines.
2
 Cats with evidence of severe concurrent systemic 
diseases based on their history, physical examination, CBC, serum biochemistry profile and 
urinalysis were excluded. Likewise, cats receiving medication within one month prior to 
inclusion, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, 
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antibiotics, β-blocking agents, and angiotensin-converting enzyme (ACE), were also 
excluded.  
 
Analytical Methods 
 
Sample collection 
Five mL of blood were collected by jugular venipuncture using a 23 G needle. After 
centrifugation (5 minutes at 2431 x g), one mL of serum was analysed on the same day. The 
CBC
a 
and serum biochemistry profile
b
 were performed in all cats. The assay for creatinine 
was a kinetic Jaffe reaction.
26
 A modified totally enzymatic procedure, first described by 
Talke and Schubert
27
 was used to measure serum urea. In cats older than 6 years, serum total 
thyroxine was also measured. The remaining serum was divided into aliquots of 250 µL and 
stored at -72 °C until analysis. In one healthy cat, 4 mL of blood were taken on EDTA for 
CST3 cloning. 
Ten mL of urine were taken by cystocentesis with a 22 G needle. The USG was 
determined using a manual refractometer. Urinalysis consisted of a urinary dipstick test,
c
 
measurement of UPC,
d
 microscopic sediment analysis and bacterial culture.
e
 All analyses 
were performed at a constant room temperature of approximately 20 °C. Urine was 
centrifuged (3 minutes at 447 x g) in a tube, and the urinary sediment was analysed within 30 
min. The sediment was prepared by decanting the supernatant, to leave an equal amount of 
urine and sediment in the conical bottom of the tube. A drop of resuspended sediment in urine 
was placed on a glass slide and covered with a coverslip. Crystals and casts were evaluated 
per low-power field (10x objective) and cells were evaluated per high-power field (40x 
objective).
28
 The supernatant and remaining serum were divided into aliquots of 250–300 µL, 
and stored at -72 °C until analysis (minimum 4 weeks, maximum 76 weeks). 
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Cloning of CST3 and protein purification 
RNA was isolated from the white blood cells with Total RNA Isolation Reagens 
(TRIR).
f
 The quality and quantity of RNA was evaluated by agarose gel electrophoresis and a 
spectrophotometer.
g
 One µg RNA was transformed into cDNA
h 
with oligo-dTs and 
hexameres. The complete coding sequence of feline CST3 was amplified with polymerase 
chain reaction (PCR)
i
 with cDNA as template and primers based on the feline CST3 sequence 
from the sequence database (Acc.No. NM_001184972). The obtained RT-PCR product of 589 
base pairs (bp) was visualized with agarose gel electrophoresis and eluted with a commercial 
kit.
j
 The elution product was ligated into the pCR-II vector and transformed in DH5a 
competent cells.
k 
Six clones were cultivated in 5 mL buffer (with ampicillin as antibiotic), 
followed by extraction of the plasmid DNA into 50 µL (Birnboim method) with a production 
of ± 4 µg/µL measured with the spectrophotometer.
g 
Clone verification was performed with 
EcoRI restriction digest analysis on 1µg plasmid DNA. The insert in the pCR II vector was 
cut, and the size was analysed by agarose gel electrophoresis. The clones with correct insert 
dimensions were selected, and the insert was sequenced with a commercial kit
l 
and the DNA 
was analysed.
m
 Finally, the sequences were analysed with BioEdit.
n
  
The plasmid with the feline CysC gene was cloned into expression vectors for 
Escherichia coli, Pichia pastoris and HEK293T mammalian cells with and without fusion 
proteins (maltose binding protein (MBP) glutathione S-transferase (GST) or human serum 
albumin (HSA)). The fusion proteins enhance solubility and expression of feline CST3. 
Between CysC and the fusion protein at the N-terminus, DEVD or DELD was inserted, a 
recognition site for murine caspase-3, to remove the fusion protein during purification. At the 
N-terminus of the construct (just before the fusion protein), a His-6 Tag was inserted, 
necessary for the purification. For Escherichia coli, two constructs were cloned to test 
expression: pLHM36CystatinC (MHHHHHH-MBP-DEVD-CystatinC and pLHG36CystatinC 
(MHHHHHH-GST-DEVD-CystatinC). For Pichia pastoris the constructs were: 
pAoXZalfaH-DEVD-CystatinC and pAOXZalfaH-HSA-DEVD-CystatinC. The construct for 
the human cells was pCAGGSsH-C-CystatinC (AHHHHHH-MBP-DELD-CystatinC). DEVD 
or DELD are the recognition sites for murine caspase-3, which cuts CysC immediately after 
DEVD or DELD. The first amino acid after DEVD or DELD is the first amino acid of CysC. 
The expressed fusion protein with CysC was purified by Ni-affinity chromatography, 
followed by murine caspase-3, to remove CysC from the fusion protein. Feline CysC was 
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finally purified by gel filtration chromatography. A schematic overview of expression in 
E.Coli is shown in Figure 1. 
 
Figure 1. Overview of cloning of CST3 (feline CysC gene) in E.Coli. The plasmid with 
CysC and the PLHM36 plasmid were cloned into Escherichia coli with MBP-GST maltose 
binding protein or glutathione S-transferase, fusion proteins, enhancing solubility and 
expression level; His-6 tag, essential for protein purification; DEVD, recognition site for 
murine caspase-3, cutting the protein right before CysC. 
 
 
CysC 
Escherichia coli 
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Western blot analysis 
Sample volumes of 15 µL serum and 15 µL urine were loaded onto a 12% SDS-PAGE 
gel,
o
 together with a standard
p
 and a human CysC standard.
q,r
 After gel electrophoresis, the 
separated proteins were blotted onto a nitrocellulose membrane
s
 with a transfer buffer
s
 
containing 10% methanol. The residual binding sites were blocked for 1 hour at room 
temperature with Tris buffered saline containing 1% Tween-20 (TBS-T)
s
 and 5% milk 
powder. The membrane was then incubated overnight at 2−8°C with a polyclonal anti-human 
rabbit CysC antibody
t
 at a dilution 1/2000. After washing with TBS-T containing 5% milk 
powder, the blots were incubated for 1 hour at room temperature with donkey anti-rabbit IgG 
Horseradish Peroxidase-linked whole antibody
o
 at a dilution 1/3000. Proteins were visualized 
with a chemiluminiscent substrate
u
 and after exposure to a film.
o 
 
Validation of the PENIA and PETIA 
Serum and uCysC were analysed with PENIA
v 
using the nephelometer
w
 and PETIA
x
 
using the Cobas analyser.
y 
PENIA and PETIA measure proteins in biological samples after 
reaction with a specific antiserum or reagent, resulting in complex formation in suspension. A 
light signal, emitted by an infrared diode (wavelength 840 nm), passes through the 
suspension, and a portion is scattered forward by the complexes, where it is focused onto a 
photodiode by an optical lens system. The particles are used if the antigen-antibody reaction 
does not permit sufficient formation of complexes to scatter the light. The voltage signal, 
which is directly proportional to scattered light intensity, is converted to digital units (“bits”) 
and compared to the corresponding values for the standard curve.  
1. Assay sensitivity 
The assay sensitivity was calculated based on the mean and corresponding standard 
deviation (SD) of the assay diluent (blank sample) analysis to determine the lowest 
concentration of sCysC and uCysC that can be measured.
29
 According to an earlier report,
29
 
the limit of detection (LOD) was then calculated as two times the SD above the mean blank 
sample value which was obtained from 20 replicate measurements.  
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2. Imprecision 
Serum and urine samples of six healthy cats and six CKD cats were analysed in 
duplicate on the same day and on three consecutive days. The intra-assay coefficient of 
variation (CV) was determined by dividing the SD of the parallel measurements on the same 
day by their mean and then multiplied by 100.
29
 The inter-assay CV was determined likewise 
from the measurement on three consecutive days.
 29 
3. Linearity 
The method accuracy was assessed by evaluation of the linearity under dilution.
29
 One 
serum and one urine sample with high CysC concentration were serially diluted four times. 
The observed serum and urinary CysC concentrations were plotted against the expected 
concentrations, and linear regression analysis was performed to calculate the corresponding 
correlation coefficient. 
 
Measurement of sCysC and uCysC in healthy cats and cats with CKD 
 After validation of the nephelometric and turbidimetric assay for feline CysC, serum 
and urine sample volumes of 250 µL were analysed with the assay with the best validation 
parameters. During the analysis, room temperature was constant at approximately 22 °C. 
Urinary CysC was expressed as a ratio to the urinary creatinine (uCr) concentration, to 
compensate for differences in urine flow rates.
30 
 
Statistical analysis 
Analyses were performed with a commercial software tool
z
. Descriptive statistics, 
Kolmogorov-Smirnov and Shapiro-Wilk tests were used to check the data for normal 
distribution. For parameters that approached a normal distribution
31
 (age, USG, sCr, serum 
urea, sCysC and uCysC/uCr ratio), the Student’s t-test was used to test for significant 
differences between the healthy cats and cats with CKD. For non-normally distributed 
parameters (body weight, UPC and uCr), the Mann-Whitney U test was used. The level of 
significance was assigned at P < 0.05.  
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Results  
 
Study population 
In total, 20 client-owned cats were recruited (age range: 1.8–19 years). Breeds 
included one Ragdoll, one Oriental Shorthair and 18 Domestic Shorthair cats. Eight cats were 
male neutered and 12 female neutered. 
 
Ten cats were considered healthy, and 10 cats with CKD were included. Among the 
latter, two cats had IRIS stage 2 CKD, one of which had proteinuria (UPC > 0.40), three cats 
had IRIS stage 3 CKD, one cat had no proteinuria and one had borderline proteinuria (UPC 
0.2–0.4) and one had severe non-renal proteinuria (UPC = 2.07), with a positive urine culture 
(Escherichia coli). Five cats had IRIS stage 4 CKD, with one cat borderline proteinuric, and 
the other four proteinuric (UPC > 0.40). One cat of the IRIS stage 3 group had hematuria (> 
200 RBC/high-power field) and a positive urine culture (Escherichia coli).  
Age, body weight, USG, UPC, serum urea, sCr, and uCr were compared between the 
healthy cats and cats with CKD (Table 1). Urine specific gravity was significantly lower in 
cats with CKD (P < 0.001), whereas UPC (P = 0.002), serum urea (P = 0.008), sCr (P = 
0.001), and uCr (P < 0.001) were significantly higher in CKD cats compared with values in 
healthy cats. No statistical differences were observed for age and body weight.  
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Table 1. Overview of the clinicopathological findings in 10 healthy and 10 CKD cats. 
Variables that approach normal distribution are expressed as mean ± standard deviation (SD). 
Non-normally distributed parameters are expressed as median (interquartile range). 
 
Variable Healthy cats (n =10) Cats with CKD (n =10) 
Age (years) 6.95 ± 5.22 9.8 ± 4. 9 
Body weight (kg) 4.50 (1.59) 3.6 (2.1) 
USG 1.049 ± 0.011 1.013 ± 0.003 
UPC 0.15 (0.06) 0.6 (1.1) 
Serum urea (mmol/L) 9.39 ± 2.48 43.5 ± 29.5 
sCr (µmol/L) 103.71 ± 12.92 540.8 ± 251.9 
uCr (µmol/L) 21879.00 (12486.70) 3270.9 (1193.4) 
CKD, chronic kidney disease; SD, standard deviation; USG, urine specific gravity; UPC, 
urine protein:creatinine ratio; sCr, serum creatinine; uCr, urinary creatinine. 
 
Cloning of CST3 and protein purification 
Three of the six clones possessed a sequence coding for CST3, 100% identical to what 
has been described earlier.
25 
After expression in Escherichia coli, no protein band could be 
detected at the expected molecular weight of CysC, 13 kDa. Also electrophoresis results from 
Pichia pastoris and the HEK293T mammalian cells could not demonstrate CysC (Fig 2). 
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Figure 2. Gel electrophoresis results of the protein purification expression vector 
Escherichia coli (A), Pichia pastoris (B) and HEK293T mammalian cells (C). 
Recombinant CysC protein could not be demonstrated. 
 
 
 
Western blot analysis 
On Western blot analysis with antibodies from PENIA, a band was visible in urine at 
the expected CysC MM of approximately 13 kDa in the CKD cats with proteinuria, but not in 
the healthy cats nor in the cat with CKD without proteinuria (Figure 3B). A less prominent 
band was also visible at the molecular weight of approximately 52 kDa, which was not seen 
in the human CysC standard. In serum blots, however, there were no bands visible at the 
molecular weight of approximately 13 kDa, only light bands at approximately 52 kDa, both in 
the healthy and CKD cats (Figure 3A). On Western blot analysis with feline samples and  
antibodies from PETIA, on the other hand, a small band was visible in serum in one CKD cat 
at the expected MM of 13 kDa, but as for PENIA, small bands were also visible at 
approximately 26 and 52 kDa. This could also be observed at the standard (Fig 3C). For urine, 
a small band was more clearly visible at the expected MM of 13 kDa and was more 
pronounced in the proteinuric CKD cat. There was no difference in intensity of the bands 
between the healthy cat and the non proteinuric cat (Fig 3D). 
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Figure 3. Western Blot analysis with chemiluminiscent detection of the polyclonal rabbit 
anti-human cystatin C antibody from the PENIA in feline serum (A) and urine (B); Western 
blot analysis with chemiluminiscent detection of the polyclonal rabbit anti-human cystatin C 
antibody from the PETIA in feline serum (C) and urine (D).  
 
 
 
Numbers indicate the molecular mass (kDa); STD, human purified Cystatin C; M, 
colorimetric marker; H, healthy cat; CKD/NP, non-proteinuric cat with chronic kidney 
disease; CKD/P, cat with chronic kidney disease and proteinuria. 
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Validation of the PENIA and PETIA 
The inter-and intra-assay CVs for CysC analyses in serum with PETIA and PENIA 
were comparable. For PETIA the inter-assay CV appeared even better. For urine on the other 
hand, the inter-assay CV was higher for PETIA than for PENIA. In addition, the LOD was 
high for PETIA. (Table 2). Regression analysis after serial dilution of a serum sample and 
urine sample showed a linear relationship between the observed and the expected uCysC and 
sCysC concentration for PENIA (Table 2; Figure 4A; Figure 4B), but the relation was less 
linear for PETIA (Table 2; Figure 4C, 4D). 
 
Table 2. Validation parameters of the turbidimetric immunoassay compared with the 
nephelometric assay (both n = 6). The validation parameters for the PENIA appeared better 
than PETIA. 
 
 
Validation parameter PETIA PENIA 
  Sensitivity 
 Limit of detection (mg/L) 
 
0.39 mg/L 
 
0.049 mg/L 
Serum  Precision 
 Intra-assay coefficient of variation (%) 
 Inter-assay coefficient of variation (%) 
 
0.8 
9.5 
 
1.3 
12.5 
Urine  Precision 
 Intra-assay coefficient of variation (%) 
 Inter-assay coefficient of variation (%) 
 
0.4 
15.9 
 
0.4 
4.1 
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Figure 4. Sequential dilution of  serum and urine  of a cat with chronic kidney disease (CKD) 
analysed with PENIA (A, B) and PETIA (C, D) to evaluate linearity.  
 
 
  
 
Cys C, Cystatin C; r, correlation coefficient. 
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Pilot study on sCysC and uCysC in healthy cats and cats with CKD 
Based on the validation observations, but also due to practical reasons, PENIA was 
used for comparison of sCysC and uCysC/uCr ratio between 10 healthy cats and 10 cats with 
CKD (Table 3). The accuracy of the determined concentrations is unknown, as a purified 
feline CysC standard was not available at the time of measurement. Serum CysC (P = 0.02) 
and uCysC/uCr (P = 0.005) were significantly higher in CKD cats compared with the values 
in healthy cats. Urinary cysC was < LOD in all healthy cats, and in one CKD cat. The cat with 
a urinary tract infection (UTI) showed a high uCysC/uCr ratio (1282.3 mg/mol) compared to 
the mean uCysC/uCr ratio (612.63 mg/mol), but it was comparable to another CKD cat 
without UTI (1271.9 mg/mol). 
 
Table 3. Relative sCysC and uCysC/uCr concentrations in 10 healthy and 10 CKD cats.  
As the parameters approach normal distribution, they are expressed as mean ± SD.  
 
Parameter Healthy cats (n = 10) Cats with CKD (n =10) 
sCysC (mg/L) 0.74 ± 0.20 1.42 ± 0.68 
uCysC/uCr (mg/mol) < LOD 645.1  ± 539.4 
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Discussion 
 
This study had several important findings. We were not able to produce recombinant 
feline CysC with Escherichia coli, Pichia pastoris or mammalian cells as vector. We 
demonstrated that the human nephelometric and turbidimetric assay can be used to measure 
feline CysC, both in serum and urine. However, validation parameters of PENIA appeared to 
be better. Therefore, PENIA was used for analysis of sCysC and uCysC in both CKD and 
healthy cats. Both were significantly higher in CKD than in healthy cats. 
 
Despite an earlier report,
25
 we were not able to produce feline recombinant CysC with 
Escherichia coli as vector. Also with the other vectors, Pichia pastoris and the mammalian 
cells, feline recombinant CysC could not be produced. An early transcription or translation 
stop could explain our findings. Based on our experiments, a feline CysC standard could not 
be produced and therefore the human CysC standard needs to be used. This means that the 
obtained CysC concentrations are only relative values and we cannot evaluate which 
proportion of feline CysC is detected with the human assays. 
 
On Western blotting, a protein band of approximately 13 kDa was observed in urine 
with PENIA antibodies, and both in serum and urine with PETIA antibodies. On all blots, a 
weaker band of approximately 26 and 52 kDa was also visible in serum and urine. According 
to an earlier report,
19
 a similar molecular weight band was also seen in Western blots of 
pooled serum samples from people, dogs, and cats, developed with a polyclonal rabbit 
antihuman CysC antibody.
19
 Nevertheless, there are some remarks. Firstly, on the PENIA 
blot, a major band at 13 kDa was observed in urine, but not in serum. On the PETIA blot, a 
small band could only be observed in serum from the non-proteinuric cat. This cat was in 
IRIS stage 3, and the proteinuric cat in IRIS stage 4. One would expect the signal to be 
stronger in the IRIS stage 4 CKD cat. For both PENIA and PETIA, signals were stronger in 
urine than in serum. A possible explanation is the higher CysC concentration in urine 
compared with that in serum. However, also in serum samples with high CysC concentrations, 
the 13 kDa band was absent. Alternatively, a difference in molecular structure between the 
urinary and serum form of feline CysC could explain the stronger signal in urine. Cystatin C 
inhibits cysteine peptidase through a substrate-competing mechanism.
32
 Studies in rats and 
people have indeed shown that only the free and thus low molecular weight form of CysC 
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passes through the glomerulus, and that only the free form can be detected in urine.
9,11
 A 
homology of 70% between feline and human CysC has been reported.
25,33
 The epitope 
sequence to which the polyclonal rabbit anti-human CysC antibodies bind is not provided by 
the manufacturers of PENIA and PETIA, so a further evaluation of the difference of cross-
reactivity between the antibodies against feline sCysC and uCysC is not possible. This could 
also explain the weak but positive signal on the serum blot with PETIA antibodies in contrast 
with PENIA. 
 
PENIA showed a good precision and good linearity for feline sCysC and uCysC. For 
feline sCysC, the inter-assay CV of 12.5% was considered acceptable.
34
 For PETIA on the 
other hand, the inter-assay CV for uCysC was higher than 15%, which is still acceptable, but 
far less ideal than PENIA.
34
 Also LOD was high compared to PENIA, impeding CysC 
measurement in urine, in which low concentrations are expected. A less linear relationship 
than for PENIA between the observed and expected sCysC and uCysC could be observed 
after serial dilution of a serum and urine sample. Although two previous studies have 
evaluated feline CysC in plasma by a human turbidimetric assay,
35
 and in serum by a human 
nephelometric assay,
36
 no validation data were documented. Validation data provided by the 
manufacturer of the nephelometric assay for human serum are an intra-assay CV range of 1.5–
3.1%, and an inter-assay CV range of 1.5–3.5%, and for the PETIA an intra-assay CV of 
0.6%–2.7% and an inter-assay CV of 1.9%–3.8%. Several studies have reported an intra-
assay CV for the PENIA ranging from 2.0 to 7.1% and an interassay CV ranging from 2.6 to 
7.9% for human urine.
12,13,37
 For the PETIA, validation reports are available for dogs, with 
intra-assay CVs ranging from 0.9% to 2.4% and inter-assay CVs ranging from 1.7% to 9.6% 
for serum. 
18,19,38
 For urine, only one validation report for PETIA is available with mean intra-
assay and inter-assay CV of 6.4% and 2.9% respectively.
14
 Matrix interferences cannot be 
excluded, but are not provided by manufacturers of both PENIA and PETIA. Based on our 
findings and a similar study in dogs,
39
 we recommend using PENIA for CysC evaluation in 
cats. 
 
 The PETIA had a high LOD and was somewhat less accurate. Based on these 
observations, but also due to practical reasons, we analysed serum and urine samples of 10 
healthy and 10 CKD cats with PENIA, to compare sCysC and uCysC. We detected a highly 
significant difference in sCysC concentration between healthy cats and cats with CKD. 
However, some overlap in the concentrations of both groups was noticed. As we did not 
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perform a GFR measurement in these cats, we cannot exclude that some of the healthy cats 
had early renal disease. The one CKD cat with UTI in our study also did not have a higher 
uCysC/uCr in comparison with other CKD cats. In people
37
 and dogs,
12
 hemoglobin did not 
interfere with the measurement of uCysC. However, to the authors’ knowledge, there are no 
reports about the measurement of uCysC in patients with lower UTI. 
 
Our results are in accordance with an earlier study.
36
 In contrast, plasma CysC in CKD 
cats did not exceed a relatively broad reference interval determined with a turbidimetric assay 
reported earlier for a group of healthy cats.
35
 As GFR was not determined,
35
 early, but 
undiagnosed, kidney impairment cannot be ruled out in apparently healthy animals. Other 
explanations for the differences include the different types of assays used for CysC 
determination. 
 
Based on our results, the results of an earlier study, and studies in dogs and people, we 
suggest that sCysC may be a promising marker for GFR estimation in cats. As the 
nephelometric assay is commercially available and requires only 250 µL of serum, it can be 
automated, which is a major advantage. Further studies are needed to evaluate if sCysC has a 
similar superiority over sCr in detecting early kidney damage in cats, as reported in people 
and dogs. 
 
Urinary CysC levels were below the limit of detection in the healthy cat group, and 
CKD cats had significantly higher uCysC/uCr than the healthy cats. Cystatin C is a small 
protein that is completely reabsorbed and catabolized in the proximal tubules. Detectable 
urinary concentrations thus reflect tubulointerstitial damage.
40
 Other markers for tubular 
damage, such as N-acetyl-b-D-glucosaminidase (NAG) and retinol-binding protein (RBP), 
have previously been measured in feline urine.
41,42
 For RBP, our research group validated and 
applied a human ELISA kit in cats.
42,43
 There are important advantages of uCysC as renal 
marker over uRBP and uNAG. Firstly, the nephelometer technology (uCysC) is less time-
consuming than an ELISA (uRBP) or a nonautomated colorimetric technique (uNAG). 
Secondly, uNAG seemed to overlap between healthy cats and cats with CKD, and the assay 
showed a very high inter-assay CV.
41
 
 
A limitation of this study was the small number of patients included. Additional 
studies with more patients, GFR measurement, and the assessment of diagnostic sensitivity 
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and specificity are required for further evaluation of CysC as a marker in feline renal 
medicine.  
 
Conclusion 
 
In conclusion, this study is the first report on the validation of a nephelometric and 
turbidimetric assay to measure CysC in serum and urine of healthy cats and cats with CKD. 
Based on the validation results, we recommend to use PENIA for uCysC measurement in cats. 
Serum CysC can be analysed both with PENIA and PETIA. A significant difference in sCysC 
and uCysC between CKD and healthy cats could be observed. However, additional studies are 
required.  
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Summary 
 
Serum cystatin C (sCysC) is a possible marker for early detection of chronic kidney 
disease (CKD) in cats. Further biological and clinical validation are required. The objective of 
this study was fourfold. The first two aims were to investigate if food intake and/or circadian 
rhythm affect feline sCysC. The third aim was to study the stability of sCysC at different 
storage conditions and the effect of an extra freeze-thaw cycle. The fourth aim was to 
investigate if plasma CysC (pCysC) differed from sCysC. A crossover study with 10 healthy 
laboratory cats fed the same commercial dry food was performed to study the influence of 
feeding and diurnal variation. Four CKD and three healthy cats were included for the storage 
study and 17 CKD and 10 healthy cats for comparison of pCysC with sCysC. 
 
A significant daily sCysC variation was seen. Pre- and postprandial sCysC and sCr 
concentrations did not change significantly. Serum CysC significantly increased during 
storage at room temperature. After freezing, sCysC significantly decreased after five and 12 
months at both -20 °C and -72 °C. Plasma CysC was significantly lower than sCysC.  
 
These findings suggest that it is not mandatory to fast cats before evaluation of sCysC 
and sCr. Samples were stable during routinely used storage conditions. Freezing is not 
recommended for longer than five months, based on our findings. However, additional studies 
are required to value the clinical relevance of decreased sCysC observed after prolonged 
storage. Plasma and serum CysC cannot be compared directly.  
 
Keywords: Cat; Chronic kidney disease; Meal; Plasma, Serum; Temperature 
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Introduction 
 
Chronic kidney disease (CKD) is one of the most common feline diseases of geriatric 
cats. Early diagnosis and subsequent treatment of CKD aids in improving quality of life and 
longevity.
1,2
 Since clearance tests to evaluate glomerular filtration rate (GFR) are impractical 
to perform,
3
 the indirect GFR markers, serum creatinine (sCr) and urea, are measured 
routinely. These both lack sensitivity and specificity for early diagnosis of feline CKD.
3
 
Therefore, indirect markers that can reliably and easily evaluate kidney function in cats are 
required. 
 
Cystatin C (CysC) is a low molecular mass (MM) protein (13 kDa). Studies in rats 
have demonstrated that CysC fulfils the required properties for an endogenous GFR marker.
4
 
Our research group has validated the human particle enhanced nephelometric immunoassay 
(PENIA) (BN Prospec, Siemens) for determination of feline CysC in serum and urine.
5
 In a 
pilot study serum CysC (sCysC) was significantly higher in cats with CKD compared to 
healthy cats. These findings make it an interesting renal marker. However, further 
investigation is warranted to evaluate the diagnostic value of sCysC as a renal biomarker in 
cats. 
 
One of the shortcomings of sCr is the effect of food intake. Dietary meat intake 
increased sCr both in dogs
6
 and cats.
7
 However, sCysC is not influenced by food intake in 
humans,
8,9
 in contrast with dogs.
10
 In addition, a circadian variation of sCr has been observed 
for both humans
11
 and dogs,
12,13
 although the magnitude of these variations was minor and 
probably not clinically relevant.
3,11
 For sCysC, a circadian variation has been observed in 
dogs,
14
 but not in humans.
11
 To the authors’ knowledge, studies in cats evaluating the effect of 
feeding and circadian rhythm on sCysC and comparison with sCr are not yet available. 
 
For use in practice, it is important to know the appropriate storage conditions for 
samples before measurement of CysC. To the authors' knowledge, the stability of feline CysC 
during storage has not yet been studied. In humans
15
 and dogs,
14
 sCysC seemed to remain 
stable after storage for six and 12 months respectively at -80 °C. 
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Cystatin C is mostly measured in serum. Some studies in dogs
10
 and cats
16
 have 
measured CysC in plasma instead of serum. To the authors’ knowledge, no studies compared 
sCysC with plasma CysC (pCysC). However, this information would be useful in clinical 
practice. 
 
The purpose of this study was fourfold. The first two aims were to investigate the 
effect of feeding and diurnal variation on feline sCysC compared with sCr. Thirdly, the 
stability of feline sCysC was investigated  during storage at room temperature (RT) for one 
day, at 4 °C for one day and one week, and at -20 °C and -72 °C for five months and one year. 
The effect of an extra freeze-thaw cycle on samples stored at -20 °C and -72 °C was also 
investigated. Finally, concentrations of CysC measured in plasma and serum were compared. 
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Materials and methods 
 
Study population 
To determine the effect of feeding and daily variation on sCysC and sCr, healthy 
laboratory domestic short- or longhair (DSH/DLH) cats were included. For the storage study 
and comparison of sCysC and pCysC, client-owned CKD and healthy cats were included. 
Inclusion criteria for the healthy cats were: no disease history and no clinically relevant 
abnormalities detected upon physical examination, complete blood cell count (CBC), serum 
biochemistry profile (including total thyroxine concentration) and urinalysis. Cats with body 
condition score (BCS) < 4 or ≥ 6 on a 9-point scale17 were excluded for the food study. For 
the other study under- and overweight cats (BCS 3–7) could be included. Cats with urine 
specific gravity (USG) < 1.035 could only be included if concurrent azotemia was absent, i.e. 
sCr < 161.8 µmol/L (see Chapter IV §4.2). Cats were excluded if they received medication 
that could influence kidney function such as non-steroidal anti-inflammatory drugs 
(NSAIDs), angiotensin converting enzyme (ACE)-inhibitors or angiotensin receptor blockers 
(ARB), from the month before the study-onset onwards.  
 
The diagnosis of CKD was based on the presence of compatible clinical signs, 
persistent renal azotemia and USG < 1.035. Only CKD cats with International Renal Interest 
Society (IRIS) stage 2 or higher were considered for this study. Exclusion criteria for cats 
with CKD were evidence of concurrent systemic disease based on the history, physical 
examination, CBC, serum biochemistry profile and urinalysis. Treatment with ACE- 
inhibitors or ARB was stopped one week before the onset of the study. Treatment with a renal 
diet could be continued. Both CKD and healthy cats were excluded if they had received 
NSAID’s, corticosteroids, antibiotics or β-blocking agents within one month prior to 
inclusion. 
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Study design 
The effect of feeding versus fasting and diurnal variation was tested in a crossover 
study that lasted 43 days. Samples were taken on day 34 and day 43. All cats received a 
standard maintenance diet (Hill’s Science Plan feline Adult Optimal Care Chicken Dry) for 
the duration of the study. All cats were fed an amount of energy required to maintain ideal 
body weight. The estimated amount of food was calculated as the sum of the metabolic 
weight and the energy factor for active cats as indicated in the guidelines of the European Pet 
Food Industry Federation (Fediaf) and adapted to maintain a steady body weight. Cats were 
randomly divided in two groups: group A and B. Pre-prandial samples were taken from all 
cats after fasting overnight for at least 16 h. During the experimental procedure, water was 
offered ad libitum to all cats. Group A was fed after the first blood sample was drawn, while 
group B remained fasted for 10 h. One week later, group B cats were fed after the first blood 
sample was drawn and group A was fasted. Cats that were fed, had access to food for one 
hour. The amount of food eaten was recorded. The other blood samples were taken 30 min, 1 
h, 2 h, 3 h, 4 h, 6 h, 10 h and 12 h after the meal was taken away in both group A and B, 
according to a similar study in dogs.
10
 
 
For the storage study and comparison of sCysC and pCysC, both CKD and healthy 
cats were fasted the night before the sampling, but water was accessible. The protocol of the 
studies was approved by the Local Ethical and Deontological Committee of the Faculty of 
Veterinary Medicine, Ghent University (EC2011_197; Date of approval January 30, 2012). 
All owners whose animal participated in the study gave written informed consent. 
 
Procedures 
A standard physical examination, including thyroid gland palpation as previously 
described,
18
 was performed in all cats prior to inclusion. For the laboratory cats, this was 
repeated on day 33 of the crossover study. Additionally, systolic blood pressure (SBP) was 
measured using the Doppler ultrasonic technique according to the ACVIM consensus 
guidelines.
19
 Cats were considered hypertensive if SBP exceeded 160 mmHg.
19,20
 To perform 
complete blood examination, two mL of blood were taken by jugular venipuncture using a 23 
G needle. After centrifugation (5 min at 1931x g), serum was analyzed the same day. The 
CBC
a
 and serum biochemistry
b
  were performed in all cats. Urine (5 mL) was collected by 
ultrasound guided cystocentesis with a 22 G needle. Urine specific gravity was determined 
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using a manual refractometer. Further urinalysis consisted of a urinary dipstick test
c
, 
measurement of the urinary protein: creatinine ratio (UPC)
d
, sediment analysis and bacterial 
culture
e
. Urine was centrifuged (3 min at 355 x g) and the urinary sediment was analyzed 
within 30 min as previously described.
21
  
 
During the feeding study, additional blood samples were taken with a 25 G needle. On 
the day the samples were taken, the amount of food that was eaten was recorded. Blood was 
centrifuged (5 min at 1931x g) and serum was divided in aliquots of 300 µL and stored at -72 
°C until batched analysis. Samples of the feeding study were analysed within four days after 
sampling. Group A and B were compared in the crossover design. 
 
For the storage study, 4 mL of blood were taken additionally and centrifuged for 5 min 
at 1931x g. Serum was divided in eight aliquots of 300 µL and stored at room temperature 
(RT) (20 °C), at 4 °C, at -20 °C and at -72 °C. Within 3 h, CysC was measured in one aliquot 
of serum stored at RT (T0 sample). Twenty-four hours after sampling, one aliquot of serum 
stored at 20 °C (T24hRT) and 4 °C (T24h4 °C) was analysed. Furthermore, sCysC was 
determined after one week of storage at 4 °C (T1w4 °C), after five and 12 months at -20 °C 
(T5m-20 °C and T12m-20 °C) and after five and 12 months at -72 °C (T5m-72 °C and T12m-72 
°C). After measurement of sCysC in  T12m-20 °C  and T12m-72 °C, the aliquots were refrozen 
at -20 °C and reanalysed the next day, to assess the effect of an extra freeze-thaw cycle. At the 
several time points, serum samples were analysed in batch, and the same reagent with the 
same lot number was used. 
 
To compare sCysC with pCysC, 2 mL of blood were taken additionally in an EDTA- 
and serum tube that were centrifuged (5 min at 1931 x g). Plasma and serum aliquots of 300 
µL were stored at -72 °C until batched analysis. 
 
Serum feline CysC was determined using PENIA
f
, previously validated for feline 
CysC by our group.
5
 Serum Cr was analyzed in the food study with an enzymatic assay
g
, 
previously validated for cats by our group.
22
 Serum Cr was analyzed in the other studies with 
a modified Jaffe assay, validated by a veterinary commercial laboratory, with a RI of 
(64.5‒161.8 µmol/L) (see Chapter IV §4.2).  
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Statistical methods 
Statistical analyses were performed using statistical software
h
. The level of 
significance was set at 0.05. All data were analysed with a general linear model. If a 
significant time effect was observed, a Tukey’s test was used as post-hoc test. Interactions 
between the status (food versus fasted) and time points were tested for the feeding study. If 
the interactions were not significant, the time to time comparison was performed globally. If 
the interactions were significant, the time effect was analysed separately (fasted or meal). 
Bland-Altman plots were designed to compare sCysC with pCysC. 
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Results 
 
Study population and procedures 
 Ten healthy laboratory DSH/DLH cats were included to study diurnal variation and 
the effect of feeding on sCysC and sCr. Mean ± standard deviation (SD) age of the complete 
group was 9.9 ± 2.2 years. Group A and B both consisted of five cats: four female neutered 
and one male neutered cat. The two groups in the feeding study did not significantly differ in 
age, bodyweight, SBP, heart rate, sCr, urea, USG and UPC. The breed and the number of 
females and males were identical in each group. The descriptive statistics of group A and B 
are presented in Table 1. Between  day 1 and day 33, the day before blood sampling, 8/10 cats 
had lost weight i.e. median (range) 0.1 (0–0.6) kg. The bodyweight of the other two cats 
remained stable. During the blood sampling, only 4/10 ate the total amount of food required 
to maintain ideal body weight i.e. median (range) 75 (49–100)%. 
 
To investigate the effect of storage temperature and duration, four cats with CKD and 
three healthy cats were included. One CKD cat was a British shorthair cat, all other cats were 
DSH/DLH cats. The CKD group consisted of four male neutered cats and the healthy cats of 
one male neutered and two female neutered cats. In the CKD group, three cats were in IRIS 
stage 2 and one cat was in IRIS stage 4. One cat was treated with ACE-inhibitors, but the 
therapy was stopped one week before sampling.  
 
Plasma CysC and sCysC were measured in 10 cats with CKD and in 17 healthy cats. 
Six CKD cats were DSH/DLH. The others were a Burmese cat, a Ragdoll, a Siamese and a 
British shorthair cat. All healthy cats were DSH/DLH. The CKD group consisted of one 
female, two female neutered and seven male neutered cats. Seven of the 10 CKD cats were in 
IRIS stage 2, two in IRIS stage 3 and one in IRIS stage 4. In one of the CKD cats, ACE-
inhibitor therapy was stopped one week before inclusion. The other CKD cats did not receive 
renin-angiotensin-aldosterone system (RAAS) modulating therapy.  
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Table 1. Descriptive statistics (mean ± SD) of healthy laboratory cats of group A (meal-
fasted) and group B (fasted-meal) at T0. No statistical differences were observed. P-values 
have been added in brackets. 
Variable Group A (n = 5) Group B (n = 5) 
Age (years) 
(P = 1.0) 
9.9 ± 2.3 10.0 ± 2.4 
Bodyweight (kg) 
(P = 0.4) 
3.8 ± 0.6 4.3 ±1.1 
Heart rate (bpm) 
(P = 0.9) 
166 ± 32 168 ± 19 
SBP (mmHg) 
(P = 0.7) 
154 ± 23 148 ± 24 
sCr (µmol/L) 
(RI 64.5–161.8) 
(P = 0.6) 
114.6 ± 11.4 120.0 ± 17.2 
sCysC (mg/L) 
(P = 0.4) 
0.83 ± 0.19 0.78 ± 0.12 
Serum urea (mmol/L) 
(RI 6.2–12.7) 
(P = 0.08) 
6.7 ± 0.9 7.9 ± 1.0 
USG 
(P = 0.8) 
1.037 ± 0.018 1.034 ± 0.015 
UPC 
(P = 0.2) 
0.18 ± 0.04 0.35 ± 0.23 
 
SD, standard deviation; SBP, systolic blood pressure; bpm, beats per minute; sCr, serum 
creatinine; RI, reference interval; sCysC, serum cystatin C; USG, urine specific gravity; UPC, 
urinary protein:creatinine ratio. 
 
Effect of feeding 
There was no significant difference in mean sCysC and sCr concentration between 
fasted cats and cats that had been fed. Figure 1 and 2 present mean ± 1.96 x standard error of 
the mean of sCysC and sCr of the fed and unfed cats. There was no interaction between time 
and status (meal or fasted) for sCysC, therefore the time to time comparison of sCysC could 
be done globally. Serum CysC was significantly different between T0, 30 min (P = 0.009) 
and 4h (P < 0.001); between 30 min and 2 h (P < 0.001), 3 h (P = 0.002), 4 h (P < 0.001), 6 h 
(P < 0.001), 9 h (P < 0.001) and 12 h (P < 0.001); between 1 h and 2 h (P = 0.01), 4 h (P < 
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0.001), 6 h (P = 0.03), 9 h  (P = 0.01) and 12 h (P < 0.001); and between 3 h and 4 h (P = 
0.001). For sCr, there was a significant (P < 0.001) interaction between time and status. 
Therefore, time effect was analysed separately for each status. No time effect was observed in 
either status.  
 
Figure 1. Mean serum CysC (sCysC) concentration with 95% CI (mean ± 1.96 x SEM) 
in 10 heathy cats fasted and after a meal. Although the figure suggests a significant 
difference, no effect of feeding on sCysC could be observed. The maximum and minimum 
sCysC concentrations were observed 36 and 246 min after the first sample respectively. 
 
Figure 2. Mean serum creatinine (sCr) concentration with 95% CI (mean ± 1.96 x SEM) 
in 10 healthy cats fasted and after a meal. As for sCysC, no significant difference between 
fed and unfed cats can be observed. 
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Effect of storage 
To determine optimal storage conditions, serum samples of all seven cats were 
analysed. The mean ± SD concentrations, the mean ± SD difference with T0 samples and the 
mean percentage increase and decrease are presented in Table 2 and Table 3. Serum CysC 
significantly differed from baseline values at room temperature (P = 0.03). After freezing, 
sCysC decreased and significantly differed from baseline values after five (P = 0.001) and 12 
months (P < 0.001) at -20 °C, and after five (P = 0.002) and 12 months (P < 0.001) at -72 °C. 
The sCysC concentration was significantly higher in samples stored at -20 °C (P = 0.003) and 
-72 °C (P = 0.04) after an extra freeze-thaw cycle.  
 
Table 2. Mean ± SD concentration and mean % increase or decrease of sCysC at 
different storage conditions. * indicates if the concentration is significantly different from 
T0 sample. 
 
 T0 T24h 
RT 
T24h 
4°C 
T1w 
4 °C 
T5m 
-20°C 
T5m 
-72 °C 
T12m 
-20 °C 
T12m 
-72 °C 
sCysC (mg/L) 1.2 
± 
0.5 
1.3 
±    
0.5* 
1.3 
± 
0.5 
1.3 
± 
0.5 
1.1 
± 
0.5* 
1.1 
± 
0.5* 
1.0 
± 
0.5* 
1.0 
± 
0.4* 
Mean difference 
(mg/L)  
0.02 
± 
0.02 
0.02 
± 
0.02 
0.03 
± 
0.03 
0.1 
± 
0.07 
0.1 
± 
0.07 
0.3 
± 
0.07 
0.3 
± 
0.08 
Mean % 
increase/decrease 
 1.9% 1.7% 0.6% -10% -10% -21% -21% 
 
SD, standard deviation; sCysC, serum cystatin C; RT, room temperature. 
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Table 3. Mean ± SD concentration and mean % increase or decrease of sCysC and 
uCysC before and after freezing-thawing. * indicates if the sCysC and uCysC 
concentrations post freeze/thaw cycle significantly differ from before freeze/thaw cycle. 
 
  Before 
freeze/thaw 
cycle 
After 
freeze/thaw 
cycle 
Mean ± SD 
difference 
Mean % 
increase/ 
decrease 
sCysC 
(mg/L) 
-20 °C 1.0 ± 0.5 1.1 ± 0.5* 0.08 ± 0.04 8.3% 
-72 °C 1.0 ± 0.4 1.0 ± 0.5* 0.07 ± 0.07 6.7% 
 SD, standard deviation; sCysC, serum cystatin C. 
Effect of anticoagulant 
The medium effect (plasma or serum) was independent of the status effect (healthy or 
CKD). A highly significant effect of the medium on CysC was observed. Plasma CysC was 
significantly lower (P < 0.001) than sCysC in both healthy cats and cats with CKD. The 
Bland-Altman Plot shows wide limits of agreement (Figure 3), indicating that sCysC and 
pCysC were not equivalent. A trend could not be observed.  
 
 
Figure 3. Bland-Altman Plot of plasma 
cystatin C (pCysC) and serum cystatin 
C (sCysC). SD, standard deviation. 
“Mean” is the mean CysC concentration 
in serum and plasma of the different 
samples respectively. “Difference” is the 
difference in CysC concentration 
between serum and plasma. 
 
Chapter IV Biological validation  
 
118 
Discussion 
  
Firstly, we demonstrated that feeding with commercial dry food does not influence 
sCysC and sCr in cats. We also observed that there was a significant daily variation of sCysC 
in contrast with sCr. Secondly, our study showed that feline sCysC decreases over time after 
freezing. Thirdly, we observed that pCysC is significantly lower than sCysC in cats. 
 
To the authors’ knowledge, this is the first study evaluating the effect of fasting versus 
feeding on sCysC in cats. Similar to human medicine
8,9
 no effect of feeding on sCysC could 
be demonstrated. However, food can cause chylomicronaemia.
23
 In humans, it has been 
shown that chylomicrons can cause interference with the PENIA,
24
 but whether the same 
occurs in cats is not known. In dogs, feeding a commercial diet caused a dramatic decrease in 
pCysC concentration, which started the first hour after the meal and lasted for 9 h. After 12 h, 
pCysC returned to baseline values
10
 Other authors described no effect of feeding on canine 
sCysC.
25
 Braun and colleagues linked the decrease in pCysC to an increase in GFR, but the 
dietary effect on GFR has only been demonstrated in healthy dogs after consumption of raw
26
 
or cooked meat,
27
 but not after a commercial diet. Studies evaluating GFR in healthy cats 
after consumption of a commercial diet or raw or cooked meat are not available.  
 
Feeding did not affect sCr in the present study, which suggests that fasting prior to 
measurement of feline sCysC and sCr is not absolutely mandatory. In contrast to the present 
study, a postprandial increase
7
 and decrease
28
 in feline sCr have been described. Sagawa et al. 
postulated an increase in sCr in relation to the creatine content of the diet. Both in the present 
study and the study of Reynolds and colleagues, cats were given a commercial dry cat food 
with poultry meat meal as meat source. For dogs, commercial dry dog foods may cause an 
increase,
29
 decrease
27
 or no change in sCr.
30
 The protein content of the diets of the present 
study and the study of Reynolds and colleagues corresponds with the normal protein 
requirement.
31
 Reynolds and colleagues attributed a lower postprandial sCr concentration to 
increased GFR. However, unaltered sCr concentrations with increased mean GFR have been 
observed in cats, but these cats were fed a high protein diet.
32
 To the authors’ knowledge, no 
results are available in cats fed a normal protein diet. Therefore, it appears unlikely that 
feeding a diet with normal protein content causes an increased GFR leading to decreased sCr. 
Other explanations for different findings in the studies might be inter-individual differences 
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between cats and the amount of food provided. We observed large inter-individual differences 
in postprandial change in sCr concentration, which was also seen in dogs.
29
  
 
We observed a significant time to time variation for sCysC, but not for sCr. Serum 
CysC significantly differed between the first samples, T30 and T60 respectively, and the 
evening samples. However, the changes in sCysC were only small. In addition, we also 
observed large discrepancies between individuals. Therefore, the diurnal variation in sCysC is 
probably not clinically relevant. Limited information is available about circadian variability of 
sCysC and sCr. In humans, higher sCysC concentrations were observed in the afternoon.
11
 
Reynolds and colleagues observed 18% higher sCr concentrations in the afternoon than in the 
morning in fed cats. In dogs on the other hand, lower sCr concentrations in the evening are 
seen in both fasted dogs and dogs receiving a meal once daily.
33
 Additional studies with more 
cats and sampling over a longer period are required to investigate diurnal variations in blood 
parameters in cats. 
 
This study showed that feline sCysC was significantly different after storage at RT for 
24 h and after longer storage at -20 °C and -72 °C, compared to T0. However, the difference 
after storage at RT was small and probably not clinically relevant. In addition, very mild 
increases in sCysC were observed during the routinely used storage conditions, i.e. room 
temperature and 4 °C. Nevertheless, storage after five and 12 months caused a significant 
decrease in sCysC of up to 21%. To the authors’ knowledge, no other studies have evaluated 
storage of  feline sCysC. In dogs, sCysC appeared to be stable  even after one year storage at  
-80 °C.
14
 However, in the latter study, a serum pool was used, which makes comparison with 
the present study difficult. Freezing and thawing of the samples also caused a significant 
increase of the feline sCysC concentration. These findings are in contrast with human 
studies.
34
 
 
We calculated the mean percentage increase and decrease of the samples at the 
different storage conditions (Table 2 and 3). The feline sCysC range of analytical variation is 
17.4% (mean interassay coefficient of variation + 2x SD).
5,35
 The decrease in sCysC after five 
months storage at -20 °C and -72 °C and the difference after freezing and thawing may be 
caused by between-day variation of the assay. During the feeding study, samples were stored 
for four days at -72°C before sCysC analysis. Since sCysC appeared to be stable for five 
months at -72 °C, we do not think that storage of the samples at -72 °C for four days could 
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have influenced the results. Longer storage at both -20 °C and -72 °C caused a further 
decrease of the sCysC concentrations, which cannot be solely attributed to assay variation. A 
limitation of our study is the small sample group. It is difficult to value the clinical relevance 
of our the observed decrease in sCysC following longer storage, since only two studies have 
evaluated sCysC in cats.
5,36
 We also do not know if the variation at higher concentrations is 
different from low concentrations. Therefore, additional studies are warranted. However, until 
more data are available, storage of samples to evaluate sCysC is not recommended for longer 
than five months.  
 
Plasma CysC was significantly lower than sCysC, both in cats with CKD and healthy 
cats. This indicates that the anticoagulant might influence sCysC concentration. However, we 
did not investigate the effect of freezing on pCysC compared to sCysC, which could have 
influenced our results.  
 
This study is limited by the small sample size to investigate the different storage 
conditions of sCysC. Therefore, additional studies with more samples and different storage 
conditions are required. In addition, no GFR measurement was performed, thus early CKD in 
the healthy cats cannot be excluded. 
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Conclusion 
 
For the first time, the effect of feeding, storage and anticoagulant on feline CysC was 
determined. Interestingly, feeding did not affect sCysC concentration, which makes it a 
potential useful marker for use in practice. However, variability in sCysC between cats was 
large. Based on our findings, samples can be stored at RT if sCysC is analysed within 24 h, 
and at 4 °C for 1 week. If samples have to be stored for a longer period, we advise storage at -
20 °C and -72 °C for up to 5 months. However, additional studies are required, to value the 
clinical relevance of our observations. Since we did not investigate the effect of freezing on 
pCysC, we cannot exclude a different effect of freezing on pCysC compared to sCysC. Until 
this has been elucidated, we do not advise to compare plasma with serum samples for CysC 
determination and monitoring. 
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Summary 
 
Chronic kidney disease (CKD) is common in cats, but the routine renal markers, 
serum creatinine (sCr) and urea are not sensitive or specific enough to detect early CKD. 
Serum Cystatin C (sCysC) has advantages over sCr, both in humans and dogs and sCysC 
concentration is significantly higher in cats with CKD than in healthy cats. The objective of 
this study was to determine the effect of age, sex and breed on feline sCysC and to establish a 
reference interval for feline sCysC. In total, 130 healthy cats aged 1–16 years were included. 
Serum CysC was determined with a validated particle-enhanced nephelometric immunoassay. 
Serum Cr, urea, urine specific gravity (USG), urinary protein:creatinine ratio (UPC) and 
systolic blood pressure (SBP) were also measured. 
 
No significant differences in sCysC concentration were observed among young, 
middle-aged and geriatric cats; among female intact, female neutered, male intact and male 
neutered cats; and among purebred and domestic short- or longhaired cats. The 95% reference 
interval for feline sCysC was determined to be 0.58–1.95 mg/L. Serum creatinine was 
significantly higher in geriatric cats than in young cats. Serum urea in geriatric cats was 
significantly higher than in middle-aged (P = 0.004) and young (P < 0.001) cats. SBP in 
geriatric cats was significantly higher than in both middle-aged (P = 0.004) and young cats (P 
= 0.04). Male neutered and female neutered cats showed significantly higher serum urea 
concentrations than female intact cats (P = 0.003 and P = 0.006, respectively). Male intact 
cats had a significantly higher UPC than female intact (P = 0.02) and female neutered (P = 
0.02) cats. There were no significant differences among sex groups for USG. 
 
However, it is of concern that sCysC in the majority of cats with CKD in previous 
studies falls within the RI calculated in this study. Further studies are warranted to evaluate 
the diagnostic value of sCysC as a renal marker in cats. 
 
Keywords: Cat; Chronic kidney disease; Serum cystatin C; Creatinine; Biological variation; 
Healthy cat   
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Introduction 
 
Chronic kidney disease (CKD) is one of the most common feline diseases, with a 
prevalence of up to 40% in the geriatric cat population.
1
 The condition is progressive and the 
primary cause is mostly unknown,
2
 but the ultimate goal in management is early diagnosis 
and treatment to prevent disease progression.
3-5 
 
 Kidney function can be evaluated by direct tests or indirect markers. Direct tests 
require measurement of the glomerular filtration rate (GFR), based on clearance of markers 
that are freely filtered through the glomerulus without tubular reabsorption or secretion.
6
 
These tests are considered to be the reference standard method for the evaluation of kidney 
function, but are labour-intensive and time-consuming, and therefore are not routinely used. 
Indirect markers, such as serum creatinine (sCr) and urea, lack both sensitivity and 
specificity.
6
 Serum Cr in dogs is influenced by diet, hydration status, physical exercise, 
housing and drugs.
6
 Due to these limitations, there is an urgent need for indirect markers that 
can reliably and easily detect kidney dysfunction. 
 
Cystatin C (CysC) is a low molecular mass (MM), 13 kDa protein.
7
 It is a proteinase 
inhibitor, produced by all nucleated cells and is responsible for the intracellular catabolism of 
peptides and proteins.
8,9
 Cystatin C has most of the properties of an endogenous marker of 
GFR
10
 and several studies in humans
11,12
 and dogs
13-15
 confirm the superiority of serum CysC 
(sCysC) to sCr for the detection of renal impairment. Three human assays are available for the 
measurement of CysC: an enzyme linked immunosorbent assay (ELISA), a particle enhanced 
turbidimetric assay (PETIA) and a particle enhanced nephelometric assay (PENIA).
16-18
 We 
have recently validated the PENIA for feline CysC determination in serum and urine. We also 
demonstrated that sCysC and urinary CysC (uCysC) were significantly higher in cats with 
CKD than in healthy cats.
19
  
 
To use sCysC as a renal marker in practice, it is necessary to establish a reference 
interval (RI). According to the American Society for Veterinary Clinical Pathology (ASVCP) 
guidelines, the reference population should represent the animal population for which the RI 
will be used,
20
 and several breeds, ages and both sexes should be included to characterize 
biological variation and to determine if separate RIs are needed. To the authors’ knowledge, 
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no large-scale studies evaluating sCysC in healthy cats of different ages, sexes and breeds are 
currently available. However, in dogs there are conflicting accounts of the effect of age and 
body weight on sCysC.
14,15
 The objective of this study was to determine the effect of age, 
breed and gender on feline sCysC and to establish a RI for feline sCysC. 
 
Materials and methods 
 
Study population 
Healthy cats ≥ 1 year of age were recruited. To evaluate the effect of age, cats were 
divided in three groups: young (1–3 years), middle-aged (3–10 years) and old cats (> 10 
years). We aimed to include an equal number of cats in every group. Domestic shorthair 
(DSH), domestic longhair (DLH) and purebred cats were included with a maximum of 20 cats 
per breed for purebreds. Cats were considered healthy when there was no history of illness 
and if no significant abnormalities were detected on physical examination, complete blood 
cell count (CBC), serum biochemistry profile, including total thyroxin measurement in cats > 
6 years, and urinalysis. Cats with both sCr  > 141.2 µmol/L and urine specific gravity < 1.035 
were excluded. Cats were also excluded if they received non-steroidal anti-inflammatory 
drugs (NSAIDs), glucocorticoids, antibiotics, β-blockers, angiotensin receptor blockers 
(ARB) or angiotensin converting enzyme (ACE)-inhibitors within one month before 
inclusion.  
 
This study was carried out in strict accordance with the recommendations in the 
Guide for the care and Use of Laboratory Animals of the National Institutes of Health. The 
protocol was approved by the local and national ethical committees (EC2011_97) and the 
Deontological Committee of the Belgian Federal Agency for the Safety of the Food Chain 
(Approval Number EC2011_97). All owners were informed about the study and gave their 
written informed consent.  
 
Procedures 
A standard physical examination was performed on all cats, including systolic blood 
pressure (SBP) measurement using Doppler ultrasonic technique and a standardised procedure 
according to the ACVIM consensus guidelines.
21
 Cats were considered hypertensive if SBP > 
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160 mmHg.
21,22
 Thyroid gland palpation was performed in cats > 6 years, as previously 
described.
23,24
 All cats were fasted at least 16 h prior to sampling. 
 
Five millilitres of blood were collected by jugular venipuncture using a 23 G needle. 
Blood samples were then stored at room temperature to allow them to clot prior to 
centrifugation. After centrifugation (5 min at 2431x g), 1 mL of serum was analysed on the 
day of collection. CBC
a 
 and serum biochemistry profile
b  
were performed in all cats. Serum 
Cr was determined using a modified Jaffe assay (RI 44.2‒141.2 µmol/L). Serum urea was 
determined by an enzymatic assay (RI 6.16‒10.82 mmol/L). 
 
Ten millilitres of urine were collected by cystocentesis using a 22 G needle. Urine 
specific gravity was determined using a manual refractometer. Urinalysis consisted of a 
urinary dipstick test,
c
 urinary protein:creatinine ratio
d
 and urine bacterial culture.
e
 Urine was 
centrifuged (3 minutes at 447 x g) and the sediment was analysed within 30 min as previously 
described.
25 
 
Serum CysC was determined with the particle enhanced nephelometric immunoassay 
(PENIA),
f
 previously validated for feline CysC determination by our group.
19
 
 
Statistical methods 
Analyses were performed with SAS.
g 
Serum Cr, urea, sCysC, SBP, USG and UPC 
levels were compared between purebred and DSH and DLH cats, between young, middle-
aged and old cats, and between male, male neutered, female and female neutered cats using a 
linear fixed effects model with the covariates as categorical fixed effects. Normal probability 
plots were used as a diagnostic tool and normal distribution was confirmed. A global 
significance level of 5% was used and Tukey’s technique was used to adjust for multiple 
pairwise comparisons. The 95% RI was determined for all measured parameters with a 
nonparametric method with the 2.5
th
 and 97.5
th
 fractiles serving as the lower and upper 
reference limit respectively. Results are shown in the text as mean ± standard deviation. 
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Results 
 
Study population 
One hundred and thirty cats were included: 74 DSH or DLH cats and 56 purebred cats, 
including British shorthair (n = 19), Ragdoll (n = 14), Persian (n = 8), Sphynx (n = 6), 
Oriental shorthair (n = 5), Siamese (n = 3) and Birman (n = 1). The study population consisted 
of 85 female cats (40 intact, 45 neutered) and 45 male cats (11 intact, 34 neutered). The mean 
age of the population was 5.7 years with 48 young, 49 middle-aged and 33 geriatric cats. The 
mean body weight was 4.1 ± 1.1 kg. 
 
Procedures 
In the study population (n = 130), mean sCysC was 1.2 ± 0.4 mg/L; mean sCr was 
106.2 ± 19.3 μmol/L; mean serum urea was 8.6 ± 1.7 mmol/L; mean USG was 1.038 ± 0.013  
and mean UPC was 0.19 ± 0.12. USG was < 1.035 in 25/130 cats. None of these 25 cats had  
clinical signs of CKD and all had sCr < 141.2 μmol/L. At the time of inclusion, abdominal  
ultrasonography was performed in two cats and GFR was calculated in three cats based on an  
exogenous creatinine clearance test. There were no indications of early CKD. Attempts were 
made to contact the owners of these 25 cats > 2 years after inclusion in the study. Five owners 
could not be reached. None of the other cats had developed signs of CKD. Two cats died of 
neoplastic disease, two had run away, three were pregnant and one intact male cat lived 
abroad. USG and sCr were re-evaluated in 12 cats; all had USG > 1.035 and sCr < 141.2 
μmol/L. The descriptive statistics for sCr, urea, sCysC, USG, UPC and SBP of the complete 
study population are presented in table 1.  
 
Systolic blood pressure (SBP) could be measured according to ACVIM Consensus  
Guidelines
21
 in 104/130 cats. Mean SBP was 135 ± 19 mmHg. Eight cats were hypertensive 
(range, 160–182 mmHg). The mean age of the hypertensive cats was 6 years and 11 months 
(range, 2.0–12 years). Systolic blood pressure could be measured in 33/48 young cats, 39/49 
middle-aged cats and 32/33 geriatric cats. Two of the young cats, one of the middle-aged cats 
and five of the geriatric cats were hypertensive.  
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Descriptive statistics for sCr, urea, sCysC, USG, UPC and SBP are presented in Table 
1. No significant differences in sCysC concentration were observed among young, middle- 
aged and geriatric cats, among female intact, female neutered, male intact and male neutered  
cats, or among purebred and DSH or DLH cats. Domestic shorthair and DLH cats had 
significantly higher serum urea concentrations (P < 0.001) compared with purebred  cats. The 
geriatric group had significantly higher mean sCr concentration than young cats (P = 0.03) 
and significantly higher serum urea than middle-aged (P = 0.004) and young (P < 0.001) cats. 
Geriatric cats also had significantly higher SBP than both middle-aged (P = 0.004) and  young 
cats (P = 0.04). Male neutered and female neutered cats showed significantly higher serum 
urea values than female intact cats (P = 0.003 and P = 0.006, respectively). Male intact cats  
had a significantly higher UPC than female intact (P = 0.02) and female neutered (P = 0.02) 
cats. There were no significant differences among sex, age and breed groups for USG.  
 
The RI for sCysC was 0.58–1.95 mg/L (n = 130). The median and 95% RIs for sCr, 
urea, and sCysC were determined in all 130 cats (Table 2) and also in a subset of cats with  
USG ≥ 1.035 (n = 105). The RI for sCysC was 0.58–1.95 mg/L (n = 130) and 0.58–1.97 mg/L 
(n = 105); sCr was 64.5–161.8 μmol/L (n = 130) and 64.5–167.0 μmol/L (n = 105); and serum 
urea was 6.2–12.7 mmol/L (n = 130) and 6.2 –14.5 mmol/L (n = 105). Fig. 1 shows  boxplots 
and 95% RIs for sCysC, sCr and serum urea (n = 130). 
  
  
Table 1. Descriptive statistics for all cats expressed as means (standard deviation). Means sharing the same letter (or no letter) do not differ 
significantly from each other.  
 
  
Variable  Age Sex Breed 
 Y (n = 48) M (n = 49) G (n = 33) FI (n = 40) FN (n = 45) MI (n = 10) MN (n = 35) P (n = 56) D (n =74) 
sCr 
(μmol/L) 
(44.2–141.2) 
98.6  
(23.1)
a
 
110.2 
(28.4)
a, b
 
109.2 
(20.2)
b
 
98.1  
(21.9) 
106.6 
(24.2) 
107.3 
 (25.1) 
112.2  
(27.9) 
101.1 
(25.5) 
109.2 
(24.2) 
Serum urea 
(mmol/L) 
8.0 
(1.1)
a
 
8.4 
(1.4)
a
 
9.7  
(2.3)
b
 
7.9  
(1.2)
a
 
8.9 
(1.8)
b
 
8.0 
(1.5)
a,b
 
9.1 
(1.8)
b
 
7.7  
(1.2)
a
 
9.3  
(1.8)
b
 
sCysC 
(mg/L) 
1.2 
(0.4) 
1.1 
(0.4) 
1.1 
 (0.3) 
1.2  
(0.4) 
1.1 
(0.3) 
1.2 
(0.5) 
1.2  
(0.4) 
1.2  
(0.4) 
1.1  
(0.3) 
SBP 
(mmHg) 
133.2  
(18.8)
a
 
129.3 
(16.8)
a
 
144.7 
(19.4)
b
 
133.8  
(22.2) 
137.8 
(17.93) 
137.8 
 (17.5) 
133.2  
(19.3) 
136.2 
(17.0) 
135.0 
(20.3) 
USG 
1.025 
(0.015) 
1.047 
(0.012) 
1.043 
(0.011) 
1.020 
(0.017) 
1.045 
(0.012) 
1.049 
(0.012) 
1.043  
(0.012) 
1.046 
(0.015) 
1.031 
(0.012) 
UPC 
0.2  
(0.13) 
0.17  
(0.07) 
0.2  
(0.16) 
0.17 
(0.11)
a
 
0.18 
(0.14)
a,b
 
0.27 
(0.14)
c
 
0.20 
(0.09)
a, c
 
0.19 
(0.13) 
0.19 
(0.13) 
   
Y, young; M; middle-aged; G, geriatric; FI, female intact; FN, female neutered, MI, male intact; MN, male neutered; P, purebred; D, domestic 
short-or longhaired cats; sCr, serum creatinine; sCysC, serum Cystatin C; SBP, systolic blood pressure; USG, urine specific gravity; UPC, 
urinary  protein:creatinine ratio. 
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Table 2. Median (95% reference intervals) for the routine variables measured in 130 
healthy cats. 
 
Variable RI in all cats  
sCr (μmol/L)  101.3 (64.5–161.8)  
Serum urea (mmol/L)  8.2 (6.2–12.7)  
sCysC (mg/L)  1.12 (0.58–1.95)  
 
RI, reference interval; sCr, serum creatinine; sCysC, serum Cystatin C 
 
 
 
 
Figure 1. Boxplot and 95% reference interval for serum cystatin C (sCysC) (A); serum 
creatinine (sCr) (B); serum urea (C). 
 
     A 
 
 
    B 
 
 
      C 
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Discussion 
 
 This is the first article to determine RIs for feline sCysC measured using PENIA 
according to the ASVCP Guidelines
20
 and is one the largest study of the effects of age, breed 
and sex on feline sCysC in healthy cats.  We did not observe a significant difference in sCysC 
concentration among young, middle-aged and geriatric cats; male intact, male neutered, 
female intact and female neutered cats; or among DSH, DLH and purebred cats. Additionally, 
no effect of age, sex and bodyweight was demonstrated in a previous study.
26
 Our findings 
support the need for further clinical investigation of feline sCysC. 
 
Surprisingly, our observations were in contrast with human and some canine reports. 
In humans, it has been shown that sCysC is higher in males and older people.
27,28
 and 
differences among races have been described.
27
 In dogs, lower sCysC concentrations were 
observed in younger animals and in those weighing < 15 kg,
14
 but these findings have been 
contradicted by other studies.
15,29
 Moreover, significant differences between male and female 
dogs were not observed.
15
 Since we did not observe any effects of age, sex and breed on 
sCysC, partitioning of the RI is not needed for these variables. The low biological variation is 
a major advantage of sCysC over sCr.  
 
In our study, purebred cats did not have a significantly higher sCr or sCysC 
concentration than DSH or DLH cats. However, sCr concentrations are influenced by breed in 
dogs
30-32
 and by race in humans.
33
 This could be due to differences in muscle mass,
6
 and also 
to differences in GFR. The effect of race on GFR in humans
34
 and breed and bodyweight in 
dogs
35-37
 has been demonstrated. To the authors’ knowledge, the effect of breed on GFR in 
cats has not been investigated. However, one group described a potential breed effect on 
feline sCr, as Birman cats appeared to have higher sCr concentrations than the RI determined 
in specific pathogen free adult cats.
38
 A significant effect of breed on sCr was observed for 
Birman, Maine Coon, Chartreux and Persian cats, and separate RIs were proposed.
39
 The need 
for breed-specific RIs for sCr in Birmans and Siberian cats has recently been confirmed.
40
A 
preliminary retrospective study by our group, hypothesized that a breed-specific RI would be 
needed for sCr in Ragdolls,
41
 but the hypothesis was rejected in a later prospective study in 
which sCr concentrations in Ragdolls were similar to control cats.
42
 Larger studies in more 
breeds are needed to investigate possible breed differences in feline sCr concentrations.
20 
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Previous studies reported higher sCr concentrations in cats with increasing age.
43,44
 
We also demonstrated that geriatric cats had significantly higher sCr concentrations than 
young cats. This is surprising, since we expected lower sCr concentrations due to decreasing 
muscle mass in older cats.
6,44
 A significant correlation between sCr and body weight was 
observed in a population of DSH/DLH cats, but the authors attributed this to increased 
adiposity. However, no body fat content was measured.
45
 No effect of age on sCr was 
observed in that population of DSH/DLH cats.
45 
Although we found a significant difference, 
the difference in sCr  between the three age groups in our study was small and an obvious 
overlap could be observed, so the difference is probably not clinically relevant. However, we 
cannot exclude that some of the older cats had early CKD explaining the higher sCr in old 
cats. No differences among female intact, female neutered, male  intact and male neutered 
cats were observed in the present study. 
 
We also found significant differences among groups for other renal parameters. For  
urea, several significant differences were observed, namely, between middle-aged and 
geriatric cats, geriatric and young cats, purebred and DSH or DLH, female intact and female  
neutered and between female intact and male neutered cats. Urea is more likely to be 
influenced by non-renal factors than sCr.
6,46
 In humans, ethnical differences have been 
observed.
47
 Paltrinieri et al.
40 
demonstrated the need for a breed-specific RI for urea in cats. 
We are not aware of other reports about the effects of age and sex on feline serum urea. We 
also observed significantly higher UPC in male intact cats than in female intact and  female 
neutered cats. However, there was no significant difference in UPC when male intact were 
compared with male neutered cats. This finding contrasts with other studies, in which  higher 
UPC was assumed for intact male cats, due to higher urinary cauxin concentrations. Cauxin is 
a protein that regulates the production of felinine, a pheromone precursor.
48-50 
 
  Geriatric cats had a significantly higher SBP than the middle-aged and young cats. 
An age-effect on SBP has previously been described in healthy cats, 
25,51
 but other studies did 
not observe a significant association between age and SBP.
52,53
 Single measurements, such as 
those used in our study, are not sufficient for the diagnosis of hypertension.
21
 Hypertension 
should be confirmed using multiple measurements and supported with a diagnostic workup to 
establish the underlying cause,
21
 but this was beyond the scope of our study.
54,55
 Although we 
cannot rule out hypertension merely due to ‘white coat effect’, most of the hypertensive cats 
in our study were in the geriatric group and it is possible that other causes were  responsible 
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for increased SBP in this group.
54,55
 Nevertheless, longitudinal studies evaluating SBP, renal 
and thyroid function in aging cats are necessary to determine if hypertension is independently 
related to age or to co-existing diseases such as declining kidney function or hyperthyroidism. 
Interestingly, significantly higher SBP values have been reported in female cats,
52
 and in 
humans,
56
 but this sex predilection was not apparent in our study. 
 
The second major objective of this study was to determine a RI for feline sCysC 
(0.58–1.95 mg/L). Since no effect of age, gender and breed was apparent, results from the 
entire population of enrolled cats were included in the RI calculations. The ASVCP 
guidelines,
20
 state that a minimum sample size of 120 animals is necessary for RIs to be 
established. We used the recommended nonparametric method, with the 2.5th and 97.5th 
percentiles serving as lower and upper reference limits, respectively.
20
 Our RI does not 
correspond with the RI (0.34–4.11 mg/L) proposed by another group,57 but there are 
important differences between the two studies. Firstly, Martin et al.
57 
measured plasma CysC 
rather than sCysC using a turbidimetric assay, but at the time of the present study, validation 
reports or comparisons with the PENIA assay for feline sCysC were not available for this 
method. Secondly, clinical data from the cats in the Martin et al. study
57 
 were unreported so 
concurrent diseases that might have affected sCysC cannot be excluded. Finally, Martin et 
al.
57 
calculated a RI for plasma CysC based on a sample set of 99 cats, rather than the 
minimum 120 cats required by the ASVCP Guidelines.
20 
 
Previous studies have used PENIA to measure sCysC concentrations in a small number  of 
healthy cats, reporting values that fell within the RI of this study.
19,26
 However, in those studies, 
sCysC concentrations in some cats fell within RI calculated in our study (7/10 cats with 
CKD,
19
 46/46 cats with CKD).
26
 It is possible that CysC is not a reliable marker for the early 
detection of kidney dysfunction in cats. However, our study is inconclusive on this  point and 
this subject requires further investigation.  
 
There are only two published studies reporting the evaluation of feline sCysC and 
GFR.
26,58
 Serum CysC was not better correlated with GFR than with sCr in cats with 
hyperthyroidism and no change in sCysC was observed when before- and after-treatment 
values were compared.
58
 However, in healthy cats and cats with CKD, a remarkably better 
correlation with GFR was found for sCysC compared to sCr.
26
 Because GFR was not 
measured in our study, we cannot be certain that some cats of our study population did not 
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have early kidney impairment. Further research on feline sCr and sCysC is needed to 
investigate potential correlations with GFR. If the potential use of sCysC as a marker of GFR  
in clinical practice is to be explored, its ability to detect early kidney dysfunction should be 
determined by long-term monitoring of apparently healthy and also by using cats with  
medical conditions that might affect CysC production. Human studies have demonstrated that 
sCysC results in underestimation of GFR in patients with hyperthyroidism,
59
 due to a 
stimulatory effect of thyroid hormones on CysC production.
60
   
 
The sCr concentration of seven cats in our study population exceeded the upper limit 
of RI for sCr established by our laboratory (44.2–141.2 μmol/L). All cats with sCr > RI had a 
USG > 1.035. A previous study by our group reported that the RI from the external laboratory 
was not  appropriate for broad interpretation of feline sCr,
25
 since it was calculated  using sCr 
concentrations from cats aged 6 months to 1 year. Inappropriate RIs have also been reported 
for other laboratories.
61
 Because the development of laboratory-specific RIs is recom-
mended,
20
 we also calculated a RI for sCr (64.5–161.8 μmol/L). It is valuable to compare our 
results with sCr concentrations measured using the same assay method. None of the cats in 
our study had a sCr concentration over the upper reference limit (177 μmol/L) of a previously 
published RI for feline sCr,
62
 measured using a modified Jaffe reaction.  
 
Twenty-five cats in our study had USG < 1.035 and 2/25 had isosthenuric urine. 
However, none of those cats had sCr concentrations exceeding the upper RI calculated at our  
laboratory. It has been shown that USG shows daily variation
63
 and therefore, low USG does 
not necessarily reflect impaired kidney function.
64
 More than 2 years after inclusion in this 
study, the owners of 20 cats were contacted  again. None of the cats had developed clinical 
signs of CKD and all cats that were re- evaluated had USG > 1.035 and sCr < 141.2 μmol/L. 
To the authors’ knowledge, there are no published studies reporting the evaluation of USG in 
a large healthy cat population. In a prospective study of healthy Ragdoll cats, 8/62 healthy 
control cats aged 2.7 ± 1.6 years had  USG < 1.035.
42
 It has been hypothesised that the normal 
range for feline USG is 1.001–1.06565 and even up to 1.080.66  
 
Nevertheless, studies evaluating USG in a large healthy cat population of different 
ages and breeds are warranted. Additionally, our study determined that the RIs of sCysC, sCr 
and serum urea in a subset of 105 cats with USG ≥ 1.035 were minimally different from RIs 
for  these parameters from the entire study population (n = 130). However, the upper 
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reference limits for these parameters were higher in the 105-cat group, since all 25 cats with 
low USG  had low sCr and low serum urea concentrations.  
 
This study is limited by the large proportion of DSH and DLH cats enrolled vs. 
purebred cats, which might not necessarily represent the cat population examined by 
veterinarians. A second limitation is the lack of GFR measurement and limited follow-up 
information. Based on sCr concentrations and USG measurements only, we do not know if 
some cats might have had early kidney impairment. Finally, while each of the subgroups 
contained a reasonable number of cats, larger subgroups would generate more reliable data for 
comparisons of renal parameters.  
 
Conclusion 
 
To our knowledge, this study is the first report about the effect of age, breed and 
gender on feline sCysC concentration and the establishment of a RI in the more than the 
required 120 healthy cats. A promising result is that there was no biological variation 
observed for sCysC compared to sCr. Now, further studies are necessary to evaluate if sCysC 
is more sensitive and specific to detect a decreased GFR. Healthy cats and cats with CKD 
need to be studied and their GFR needs to be correlated with their sCysC concentration. 
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Summary 
 
Cystatin C (CysC) is a marker for glomerular filtration rate and tubular dysfunction. A 
pilot study has shown that cats with chronic kidney disease (CKD) have a significantly higher 
serum CysC (sCysC) and urinary CysC (uCysC) concentration compared with healthy cats. 
Hyperthyroidism may lead to kidney dysfunction and renal abnormalities are also common in 
cats with feline immunodeficiency virus (FIV). Higher sCysC concentrations have been 
observed in humans with human immunodeficiency virus or hyperthyroidism.  
The objective of this study was to investigate sCysC and uCysC in cats with hyperthyroidism 
and cats with FIV.  
 
Thirty cats with FIV, 26 hyperthyroid cats and 28 healthy cats were included. Serum 
CysC and uCysC:creatinine ratio (uCysC/uCr) were measured with a human particle 
enhanced nephelometric immunoassay (PENIA), previously validated for feline CysC 
measurement. Routine renal variables (serum creatinine (sCr), urine specific gravity (USG), 
urinary protein:creatinine ratio (UPC)) were also measured in the three groups.  
 
Cats with hyperthyroidism had significantly higher sCysC, lower sCr concentrations 
higher uCysC/uCr and higher UPC than healthy cats. Cats with FIV-infection did not show 
significantly higher sCysC concentration, but had a significantly higher sCr and UPC than 
healthy cats. Urinary CysC could be detected in only four of them. 
 
This study demonstrated that sCysC is increased in cats with hyperthyroidism, in 
contrast with sCr, but not in cats with FIV. Many hyperthyroid cats, but only four cats with 
FIV had elevated uCysC/uCr. Further studies may reveal if uCysC might be a valuable 
marker for tubular dysfunction in cats. 
 
Keywords: Feline; Creatinine; Renal variable; Glomerular filtration rate; Tubular dysfunction 
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Introduction 
 
Cystatin C (CysC) is a low molecular mass (MM) protein, responsible for the 
intracellular catabolism of peptides and proteins.
1,2
 Most of the properties for endogenous 
glomerular filtrate rate (GFR) markers apply for CysC.
3
 Studies in humans
4,5
 and dogs
6-8
 
have shown the superiority of serum CysC (sCysC) compared to serum creatinine (sCr) in the 
early detection of renal impairment. Furthermore, urinary CysC (uCysC) was used as a 
tubular marker in both human
9,10
 and canine
11
 studies. Therefore, interest in investigating 
CysC as an early renal marker in cats has increased, as chronic kidney disease (CKD) is one 
of the most common diseases in older cats, with a prevalence of up to 30% in cats older than 
15 years.
12
 Our group has recently validated a human particle enhanced nephelometric 
immunoassay (PENIA) for feline CysC measurement and has demonstrated a significant 
difference in sCysC and uCysC concentration between healthy cats and cats with CKD.
13
 We 
also reported that the biological factors age, breed and sex do not influence sCysC, in 
contrast to sCr and serum urea.
14
 The obtained reference interval (RI) for sCysC was 
(0.58‒1.95 mg/L).14  
 
Chronic kidney disease mainly affects aged cats.
15
 In this population, hyperthyroidism 
is also a common disease with a prevalence of up to 11%.
16
 Furthermore, a recent study of 
our group could demonstrate a feline immunodeficiency virus (FIV) seroprevalence of 14% 
in cats older than 6 years.
17
 This means that concurrent CKD and FIV-infection or 
hyperthyroidism might occur. In addition, both hyperthyroidism and FIV appear to have a 
negative effect on kidney function.
18,19
  
 
Hyperthyroidism causes an increased metabolism, which is associated with decreased 
vascular resistance, increased cardiac output, increased renal blood flow, increased GFR and 
hypertrophic and hyperplastic tubuli. Untreated hyperthyroidism can induce renal damage or 
exacerbate existing renal disease.
20
 Due to increased GFR, but also due to decreased muscle 
mass in hyperthyroid patients, sCr decreases, which leads to an overestimation of renal 
function.
21
 The effect of thyroid function on sCysC has been investigated in human medicine. 
After treatment for hyperthyroidism, sCysC decreases over time.
21
 This means GFR is 
underestimated when considering sCysC levels in untreated hyperthyroid patients, in contrast 
to sCr. 
Chapter V Clinical validation 
 
152 
Human patients with human immunodeficiency virus (HIV) infection have a higher 
risk of developing CKD.
22,23
 Therefore, interest raised to use sCysC as a renal marker in 
HIV-positive patients and it has been shown that sCysC is higher in patients with HIV than 
healthy controls.
24,25
 There appears to be an association between FIV and kidney 
abnormalities,
18,26
 but the effect of FIV on sCysC and uCysC has not been studied.  
 
The objective of this study was to evaluate sCysC and uCysC in cats with 
hyperthyroidism and in cats naturally infected with FIV.  
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Materials and methods 
 
Study population 
Healthy cats, FIV-positive cats and hyperthyroid cats were prospectively recruited. 
Cats were considered healthy when there was no disease history, and if no clinically relevant 
abnormalities were detected upon physical examination, complete blood cell count (CBC), 
serum biochemistry profile and urinalysis.
12
 Healthy cats were excluded when they had 
received medication within one month prior to inclusion that might influence renal function, 
such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antibiotics, β-
blocking agents, angiotensin receptor blockers (ARB) or angiotensin converting enzyme 
(ACE)-inhibitors.  
 
Feline immunodeficiency virus infection was confirmed with a positive in-house FIV 
test.
a
 Owing to ethical considerations, FIV-infected cats treated with NSAIDs and/or 
antibiotics within one month prior to inclusion were not excluded. Cats were not included 
when they showed abnormalities compatible with a concurrent disease on physical exam, 
CBC, serum biochemistry profile and/or urinalysis.  
 
Cats with hyperthyroidism were included when they demonstrated clinical signs 
compatible with hyperthyroidism, increased total thyroxine (TT4) concentration and 
increased thyroidal uptake of pertechnetate (
99m
TcO4
-
) on a diagnostic scintigraphic scan. 
Antithyroid drugs had to be stopped at least two weeks before inclusion, since all included 
hyperthyroid cats were treated with 
131
I after the sampling and it has been shown that 
concurrent administration of anti-thyroid drugs increases the risk of iatrogenic 
hypothyroidism and adversely affects the effective half-life of 
131
I.
27,28
 Methimazole was 
stopped for only three days in cats previously treated with  ≥ 10 mg methimazole per day, to 
avoid the risk of thyroid storm by two weeks discontinuation of anti-thyroid drugs.
29
 Cats 
were excluded if there was evidence of a concurrent disease on physical exam, CBC, serum 
biochemistry profile or urinalysis. 
 
In all three groups, cats with isosthenuric urine i.e. USG < 1.015 were excluded. Cats 
with USG < 1.035 were only included if concurrent azotemia i.e. sCr > 161.8 µmol/L was 
absent. It is known that low USG without concurrent azotemia does not necessarily reflect 
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impaired kidney function.
30
 In all FIV-positive cats and healthy cats TT4 was measured, and 
FIV was tested in all hyperthyroid and healthy cats. Healthy cats and FIV-positive cats were 
excluded if TT4 > 45.15 nmol/L. In addition, hyperthyroid and healthy cats that tested FIV-
positive were also excluded. 
 
Analytical methods 
A standard physical examination was performed in all cats, including thyroid gland 
palpation in the FIV-infected cats suspected of hyperthyroidism and all healthy cats older 
than six years. An in-house FIV test
a
 was performed in all cats following the test guidelines. 
 
Five mL of blood was taken by jugular venepuncture using a 23 G needle. One mL 
was collected in an EDTA-containing tube for determination of complete blood cell count in 
all cats.
b
 After centrifugation (5 mins at 1931 x g), 1 mL of serum was analysed the same 
day. Serum biochemistry
c
 was performed in all cats. Serum Cr was determined with a 
modified Jaffe assay with a RI of (64.5‒161.8 µmol/L), previously determined by our group 
according to the American Society of Veterinary Clinical Pathology (ASVCP) guidelines.
14,31 
 
Total thyroxine was measured
 
in all cats with a chemiluminescent immunoassay,
d 
previously validated in cats (RI (14.19‒45.15 nmol/L)).32 In all cats, 10 mL of urine was 
taken by cystocentesis with a 22 G needle. Urine specific gravity was determined with a 
manual refractometer. Urinalysis consisted of a urinary dipstick test,
e
 measurement of the 
urinary protein:creatinine ratio (UPC),
f 
 sediment analysis and bacterial culture.
g
 Urine was 
centrifuged (3 min at 365 x g) and urinary sediment was analysed within 30 min according to 
Paepe et al.
17
 One mL of serum and 1 mL of the urinary supernatant was frozen at -72 °C 
until batched analysis.  
 
Serum CysC and uCysC were determined with the human PENIA.
h
 This assay is 
based on the dispersion of light caused by immune complex formed by CysC and latex 
particles coated with polyclonal anti-human CysC antibodies. The human PENIA has 
recently been validated for feline CysC determination both in serum and urine.
13
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Statistical analysis 
Analyses were performed with statistical software.
i
 The uCysC concentration was 
below the detection limit (LOD) in several cats and TT4 concentration was higher than the 
upper LOD in several hyperthyroid cats. Therefore, nonparametric techniques were used and 
all measurements for uCysC below the LOD were set at 0.0464 mg/L and all measurements 
for TT4 above the LOD were set at 193.5 nmol/L. The non-parametric Wilcoxon rank sum 
test was used to compare sCysC and  uCysC/uCr ratio, sCr, UPC, USG between cats with 
hyperthyroidism or FIV and healthy cats. Spearman rank correlation coefficients were 
calculated between sCysC and sCr, between sCysC and uCysC/uCr and between UPC and 
uCysC/uCr in the cats with hyperthyroidism, cats with FIV and healthy cats; between sCysC, 
sCr and TT4 in the cats with hyperthyroidism and healthy cats. The level of significance was 
set at 0.05. 
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Results 
 
Study population 
Ninety cats (30 hyperthyroid, 30 FIV-infected and 30 healthy) were evaluated, but 
only 84 cats were included, since four of the hyperthyroid cats and two healthy cats tested 
FIV-positive. Their signalment is presented in Table 1. Within one month prior to inclusion, 
antibiotics were administered in 10 FIV-cats, NSAIDs in two FIV-cats and eight FIV-cats 
had received both. At the time of inclusion, six of them still received antibiotics, one received 
NSAIDs and one received both. Two of the hyperthyroid cats were not treated with anti-
thyroid drugs before inclusion. In 23 cats, therapy was ceased two weeks before inclusion. In 
one cat, anti-thyroid therapy was ceased three days before inclusion. 
 
Table 1. Signalment of all recruited cats. Age and body weight are presented as mean ± 
standard deviation. 
 
Cat  po- 
pulation 
 
Variable 
Cats with FIV 
(n = 30 ) 
Cats with  HT 
(n = 26) 
Healthy Cats 
(n = 28) 
Breed 29 DSH/DLH,  
1 Maine Coon 
25 DSH/DLH,  
1 Norwegian 
Forest cat 
25 DSH/DLH,  
1 Ragdoll, 
2 Peterbalds 
Gender 3 M, 24 MN, 1 F, 
2 FN 
4 M, 10 MN, 2 F, 
10 FN 
4 MN, 2 F, 
22 FN 
Age 6.7 ± 2.8 years 13.3 ± 2.0 years 10.5 ± 3.7 years 
Body weight 4.5 ± 1.0 kg 3.8 ± 0.9 kg 4.0 ± 0.9 kg 
 
FIV, feline immunodeficiency virus; HT, hyperthyroidism; DSH/DLH, domestic short-or 
longhair cats; M, male; MN, male neutered; F, female; FN, female neutered. 
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 Analytical procedures 
Serum CysC, uCysC/uCr, the routine renal variables (sCr, USG, UPC) and TT4 were 
measured in all cats. Ten hyperthyroid cats had a TT4 concentration above 193 nmol/L, the 
upper measurable concentration limit of the analytical device.
c  
 
The descriptive statistics for the variables sCr, USG, UPC, sCysC and uCysC/uCr for 
the FIV, hyperthyroid and healthy cats are presented as median (range) in Tables 2 and 3. 
Several cats had USG < 1.035 without concurrent azotemia: 5/30 FIV-positive cats, 9/26 
hyperthyroid cats and 6/28 healthy cats. For the healthy cats, there were no indications of 
early CKD at the time of inclusion since GFR was normal based on a combined exogenous 
Cr-iohexol clearance test in four of them and abdominal ultrasound revealed no renal 
abnormalities in one cat. More than two years after inclusion, USG was > 1.035 without 
concurrent azotemia in the other healthy cat. For the five FIV-cats no follow-up data were 
available. For the hyperthyroid cats, follow-up data after 
131
I-treatment were only available 
for three cats and none of them developed azotemia when they became euthyroid. Three of 
the six other cats were treated prior to sampling with antithyroid drugs and treatment was 
stopped two weeks before sampling. In these three cats, sCr, TT4 and urea remained normal 
during medical treatment for hyperthyroidism, making concurrent CKD in these cats less 
likely.  
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Table 2. Descriptive statistics for the variables of the included cats with FIV, 
hyperthyroidism and healthy cats. All variables are expressed as median (range).  
* indicates if the variable is significantly different compared with the healthy cats. 
 
Cat po- 
pulation 
 
Variable 
Cats with FIV 
(n = 30) 
Cats with HT 
(n = 26) 
Healthy cats 
(n =28) 
sCr  
(µmol/L) 
92.4 (67.2‒146.7)* 69.8 (38‒109)* 99.9 (64.5‒142.3) 
USG 1.044 (1.020‒1.065) 1.039 (1.015‒1.060) 1.047 (1.020‒1.060) 
UPC 0.21 (0.07‒0.87)* 0.52 (0.17‒1.14)* 0.18 (0.11‒0.37) 
sCysC  
(mg/L) 
0.8 (0.3‒1.7) 1.1 (0.4‒1.8)* 0.8 (0.4‒1.2) 
uCysC/uCr 
(mg/mol)  
< LOD/uCr * 
(< LOD/uCr‒118.4) 
21.1* 
(< LOD/uCr ‒618.5) 
< LOD/uCr 
 
FIV, feline immunodeficiency virus; HT, hyperthyroidism; sCr, serum creatinine; USG, urine 
specific gravity; UPC, urinary protein:creatinine ratio; sCysC, serum cystatin C; uCysC/uCr, 
urinary cystatin C:creatinine ratio; LOD, limit of detection, 0.0464 mg/L. 
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Table 3. Routine renal variables of all included cats, with the number of cats having values 
below, within and above the reference interval. 
 
Cat population 
Variable 
Cats with FIV 
(n = 30) 
Cats with HT 
(n = 26) 
Healthy cats 
(n = 28) 
sCr (µmol/L) 
< 64.5  
64.5–161.8 
> 161.8  
 
0 
30 
0
a
 
 
1 
25 
0
a
 
 
0 
28 
0
a
 
Serum urea (mmol/L) 
< 6.16  
6.16–10.82 
> 10.82 
 
4 
23 
3 
 
3 
17 
6 
 
0 
23 
5 
USG 
< 1.015 
1.015–1.035 
> 1.035 
 
0
a
 
7 
23 
 
0
a
 
9 
17 
 
0
a
 
5 
23 
UPC 
< 0.2 
0.2–0.4 
> 0.4 
 
15 
11 
4 
 
2 
8 
16 
 
16 
12 
0
a
 
  
FIV, feline immunodeficiency virus; HT, hyperthyroidism; sCr, serum creatinine; USG, urine 
specific gravity; UPC, urine protein:creatinine ratio. 
a
 Consequence of the inclusion criteria: 
healthy cats could not have UPC > 0.4; USG had to be > 1.015 and sCr < 161.8 µmol/L in all 
cats. 
 
 
Cats with hyperthyroidism had significantly higher sCysC (P = 0.01), higher 
uCysC/uCr ratio (P < 0.001), lower sCr (P < 0.001) and higher UPC (P < 0.001) than healthy 
cats.  Urinary CysC/uCr was significantly higher in FIV-positive cats compared with healthy 
cats (P < 0.001). However, only four of the FIV-positive cats had a detectable uCysC 
concentration. One of them had not received NSAIDs or antibiotics prior to sampling. The 
other three had received both NSAIDs and antibiotics within two weeks prior to sampling but 
did not receive medication at the time of blood collection. In addition, a significantly higher 
sCr concentration (P < 0.001), a higher UPC (P < 0.001), but no significantly higher sCysC 
concentration was present compared with the healthy cats. The boxplots are presented in 
Figure 1 and 2. 
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Figure 1. Box-plot of serum cystatin C (sCysC) (mg/L) for cats with hyperthyroidism 
(HyperT4; n = 26); feline immunodeficiency virus (FIV; n = 30) and healthy cats 
(healthy: n = 28). 
 
 
 
 
 
Fig 2. Box-plot of the urinary cystatin C:creatinine ratio (uCysC/uCr ratio) for cats with 
hyperthyroidism (HyperT4; n = 26); feline immunodeficiency virus (FIV; n = 30) and 
healthy cats (healthy: n = 28). 
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The correlation coefficients are presented in Table 4. Only in the hyperthyroid cats a 
significant correlation was observed between UPC and uCysC/uCr (P < 0.001) and between 
sCysC and uCysC (P = 0.03). A positive, but no significant correlation was found between 
sCysC and TT4 in the hyperthyroid cats. In contrast, sCr was negatively and significantly 
correlated with TT4 (P = 0.003). In the healthy cats however, a negative but no significant 
correlation with TT4 was observed for both sCr and sCysC. No significant correlation 
between sCysC and sCr was found in the three groups. 
 
According to our established RI of (0.58‒1.95 mg/L),14 none of the cats had a sCysC 
concentration above the upper reference limit. Two cats with FIV, one cat with 
hyperthyroidism and four healthy cats had a sCysC concentration below the RI. All healthy 
cats, 26 cats with FIV and eight cats with hyperthyroidism had uCysC/uCr below detection 
limit.  
 
 
Table 4. Spearman rank correlations for sCysC, sCr, uCysC/uCr, TT4 and UPC ratio in 
cats with FIV, hyperthyroid cats and healthy cats. 
 
Variable 1 Variable 2 Condition Correlation 
coefficient 
P 
sCysC sCr Hyperthyroidism 
FIV 
Healthy 
-0.20 
-0.05 
-0.12 
0.32 
0.81 
0.54 
sCysC uCysC/uCr Hyperthyroidism 
FIV 
Healthy 
0.42 
0.07 
0.26 
0.03 
0.73 
0.18 
UPC uCysC/uCr Hyperthyroidism 
FIV 
Healthy 
0.71 
0.27 
0.16 
< 0.001 
0.15 
0.42 
sCysC TT4 Hyperthyroidism 
Healthy 
0.24 
-0.18 
0.33 
0.43 
sCr TT4 Hyperthyroidism 
Healthy 
-0.55 
-0.09 
0.003 
0.71 
 
FIV, feline immunodeficiency virus; sCysC; serum cystatin C; uCysC/uCr, urinary cystatin 
C:creatinine ratio; TT4, serum total thyroxine; sCr, serum creatinine; UPC, urinary 
protein:creatinine ratio.  
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Discussion 
 
 Feline sCysC and uCysC were evaluated in cats with hyperthyroidism and in cats with 
FIV. Cats with hyperthyroidism had significantly higher sCysC and uCysC/uCr compared 
with healthy cats. However, only few FIV-infected cats had detectable uCysC. 
 
For the hyperthyroid group, routine renal variables, with the exception of USG, 
significantly differed from healthy cats. Thyroid dysfunction has an impact on the  kidney 
function, by influencing renal blood flow, GFR, tubular secretion and absorption, electrolyte 
pumps and kidney structure.
19
 Owing to increased GFR, but also to decreased muscle mass in 
patients with hyperthyroidism, sCr decreases, masking possible underlying CKD.
21
 Opposite 
effects are observed in patients with hypothyroidism.
33,34
 In our study, sCr was indeed 
significantly lower and UPC significantly higher in the hyperthyroid cats compared to the 
control group. Our findings are in accordance with previous studies evaluating kidney 
function in hyperthyroid cats.
35-37 
 
The hyperthyroid cats had a significantly higher sCysC concentration than the healthy 
cats, in contrast to sCr which was significantly lower. Based on our established RI for sCysC 
of 0.58–1.95 mg/L,14 hyperthyroid cats cannot be distinguished from healthy cats. There was 
no significant correlation between sCysC and TT4, and an overlap in sCysC concentration 
between healthy cats and cats with hyperthyroidism was observed (Figure 1). Our 
observations are comparable with human studies.
21,34,38
 In humans, GFR is underestimated in 
hyperthyroid patients when considering sCysC concentration
39
  and the same might be true in 
cats. The exact mechanism for a higher sCysC concentration in hyperthyroidism is not yet 
revealed. Nevertheless, several hypotheses have been proposed.
21,40,41
 Triiodothyronine (T3) 
should increase the level of transforming growth factor-β1 (TGF-β1), which might in turn 
stimulate the secretion of sCysC.
41
 This hypothesis appears the most plausible, as stimulation 
of CysC secretion by TGF-β1 in vascular smooth muscle cells has been demonstrated.42,43 
 
To our knowledge, this is the first study comparing sCysC between healthy cats and 
cats with hyperthyroidism. In an abstract by Jepson et al.,
44
 sCysC was measured in 19 
hyperthyroid cats before and after treatment with 
131
I. In contrast with human data,
45
 no 
significant change in sCysC concentration was observed while a significant change was 
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reported in the GFR and sCr concentration. The authors did not find a correlation between 
GFR and sCysC in the hyperthyroid cats before treatment. This study by Jepson et al. and our 
findings suggest that sCysC might not be a reliable GFR marker in cats with hyperthyroidism, 
which is comparable with the findings in human medicine.
46
 However, additional studies with 
GFR measurement and comparison with healthy cats are warranted. 
 
Hyperthyroid cats had significantly higher uCysC/uCr than the control group. 
However, not all hyperthyroid cats had a detectable uCysC concentration. Moreover, the 
correlation coefficient between UPC and uCysC/uCr was significant (Table 4). The cats 
without a detectable uCysC concentration, did not have proteinuria, while all hyperthyroid 
cats with UPC > 0.4 did have a detectable uCysC concentration. However, we observed a 
significant correlation between sCysC and uCysC/uCr, which suggests that uCysC is not 
independent from sCysC. Further studies will reveal if uCysC is a good marker for proximal 
tubular damage in hyperthyroid cats. Other tubular markers, such as urinary N-acetyl-β-D-
glucosaminidase (uNAG)
36
 and urinary retinol-binding protein (uRBP),
35
 do fulfil the 
required properties to detect tubular damage in hyperthyroid cats. 
 
Cats with FIV had significantly higher uCysC/uCr but no significantly higher sCysC 
concentration. However, only 4/30 cats had a detectable uCysC concentration, and three of 
them had received both NSAIDs and antibiotics within two weeks prior to blood collection 
which could have influenced the results. However, uCysC could not be detected in all FIV-
positive cats that had received medication prior to sampling. Further studies are required to 
investigate if presence of uCysC is due to FIV or administration of NSAIDs. In contrast to the 
hyperthyroid cats, there was no significant correlation between uCysC/uCr and UPC, since 
not all of the proteinuric cats had a detectable uCysC concentration. None of our cats with 
FIV had a sCr concentration above the upper reference limit (161.8 µmol/L) of the RI we 
established in a recent study.
14
 Nevertheless, it has been described that cats with FIV can have 
tubular abnormalities, without concurrent azotemia
47
 and several studies describe an 
association between proteinuria and FIV-infection.
18,48
 Our study suggests that tubular 
dysfunction is absent or not severe enough in most FIV cats to cease tubular catabolism of 
CysC, leading to CysC appearance in the urine. The presence of CysC in urine of HIV-
infected persons has only been reported in patients receiving a combination antiretroviral 
therapy (cART),
49
 but not in non-treated HIV-patients. Serum CysC was not significantly 
different between healthy cats and cats with FIV, even though sCr was significantly higher in 
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the FIV cats. A higher prevalence of azotemia in FIV-infected cats has been described,
48,50
 but 
other reports claim no association between FIV and renal azotemia.
18,51
 Our results are in 
contrast with human reports, where a significantly higher sCysC concentration was observed 
in HIV-infected patients.
25,52
 In addition, a correlation of HIV-RNA and CD4
+
 T-cell count 
with a decreased sCysC concentration after therapy has been demonstrated,
25
 suggestive for 
an association of HIV-replication with the sCysC level,
53
 and an underestimation of GFR in 
non-treated HIV-patients. However, in no human report, GFR was measured by a gold 
standard method, so it is unclear if HIV-associated renal disease also played a role in the 
higher concentration of sCysC. 
 
We did not observe a significant correlation between sCysC and sCr in the three 
groups. This might have been due to non-renal factors influencing sCr and/or sCysC, such as 
FIV or hyperthyroidism, hydration status and drugs.
54
 Sex and age distributions differed 
between the groups. In particular, male neutered cats were overrepresented in the FIV-
infected group, which is similar to other reports.
55-57
 However, no effect of age and sex on 
sCysC could be observed in a recent study by our group. The effect of age and gender on 
uCysC has not yet been evaluated.
14
 Besides non-renal factors, other reasons might explain 
the lack of correlation between sCr and sCysC. Serum CysC could be influenced by early 
mild kidney dysfunction or might not be a reliable GFR marker. Several healthy cats, cats 
with hyperthyroidism and FIV-infected cats had USG < 1.035 without concurrent azotaemia. 
It is hypothesized that normal range for feline USG is between 1.001 and 1.065
58
 or even 
1.080,
59
 but no large-scale studies have confirmed this. Because GFR was unavailable in the 
majority of the included cats, we cannot rule out that none of our included cats had early 
CKD, which might have affected the results of the present study. The GFR of healthy cats and 
cats with CKD measured with a gold standard method needs to be correlated with both sCr 
and sCysC, to study the sensitivity of sCysC to detect early kidney dysfunction in cats. 
 
Our study is limited by the absence of a gold standard method to measure GFR. We 
cannot exclude that early kidney impairment was absent in our studied groups. A second 
limitation was the use of NSAIDs and antibiotics in the cats with FIV prior to inclusion, 
which might have influenced kidney function.  
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Conclusion 
 
Cats with hyperthyroidism had a significantly higher sCysC concentration and most 
hyperthyroid cats had higher uCysC/uCr compared with healthy cats. However, based on the 
RI of sCysC, hyperthyroid cats cannot be distinguished from the healthy cats. Our study 
suggests that sCysC might not be a reliable GFR marker in hyperthyroid cats. Further studies 
with GFR measurement are required to reveal the mechanism of a possible increased sCysC 
in feline hyperthyroidism. Further studies must reveal the mechanism of the increased 
uCysC/uCr ratio in hyperthyroid cats. 
 
Feline immunodeficiency virus infection did not influence sCysC, in contrast to HIV. 
Only a few cats had uCysC/uCr above the detection limit. Further studies are required to show 
if only a subset of FIV cats have tubular dysfunction or that only severe tubular dysfunction is 
detected by measuring uCysC. 
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Summary 
 
Serum cystatin C (sCysC) and urinary cystatin C (uCysC) are potential biomarkers for 
early detection of feline chronic kidney disease (CKD). An in-depth clinical validation is 
required. 
 
We aimed to evaluate CysC as marker for feline CKD. We compared sCysC and 
uCysC between CKD and healthy cats, correlated sCysC and sCr with glomerular filtration 
rate (GFR) and calculated sensitivity and specificity of sCysC for detecting decreased GFR. 
We also aimed to compare assay performance of the turbidimetric assay (PETIA) with the 
previously validated nephelometric assay (PENIA). 
 
Ninety cats were included: 49 CKD and 41 healthy cats. Serum CysC and uCysC were 
measured in all cats. Based on plasma exo-iohexol clearance test (PexICT), sCysC was 
evaluated to distinguish normal, borderline and low GFR. Sensitivity and specificity to detect 
PexICT < 1.7 mL/min/kg were calculated. PETIA was validated and sCysC results of PENIA 
and PETIA were correlated with GFR. Statistical analysis was performed using general linear 
modelling. 
 
Serum CysC and uCysC were significantly higher (P < 0.001) in CKD cats. Urinary 
CysC was detected only in 35/49 CKD cats. R
2
 values between GFR and sCysC or sCr were 
0.39 and 0.71 respectively. Sensitivity and specificity were 22% and 100% for sCysC and 
83% and 93% for sCr. Serum CysC could not distinguish healthy from CKD cats, nor normal 
from borderline or low GFR, in contrast to sCr.  
 
Serum CysC is not a reliable GFR marker in cats and uCysC could not be detected in 
all CKD cats.  
 
Keywords: Feline; Chronic kidney disease; Glomerular filtration rate; Early diagnosis; 
Validation; Creatinine 
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Introduction 
 
Chronic kidney disease (CKD) is common in geriatric cats, with a prevalence from 
30% up to 40% in cats older than 10 years.
1-3
 Since CKD is an irreversible and progressive 
disease, early detection and treatment is of major importance, aiming to slow down disease 
progression and to improve quality of life and longevity.
4,5
 Glomerular filtration rate (GFR) is 
considered the gold standard variable to evaluate kidney function, but measurement is time-
consuming and unpleasant for the patient. Therefore, the indirect GFR markers, serum 
creatinine (sCr) and urea, are routinely measured to estimate GFR. However, these markers 
are insensitive, since their serum concentration only increases when approximately 75% of 
the functional renal mass is lost.
6
 Moreover, they are both influenced by muscle mass, age, 
feeding status, sex and intra-individual variation.
7-9
 All those disadvantages support the need 
for new indirect biomarkers that can be measured easily and reliably. 
 
Cystatin C (CysC), a 13 kDa protein, is a proteinase inhibitor, produced in every 
nucleated cell at a constant rate, that is responsible for intracellular protein catabolism.
10,11
 
Most of the properties required for an ideal endogenous GFR marker apply for CysC.
12
 
Compared to sCr, several human
13-16
 and canine studies
17,18
 have shown a better correlation of 
sCysC with GFR. In addition, urinary Cystatin C (uCysC) is a biomarker for tubular damage 
in humans
19,20
 and dogs.
21
 In a pilot study, our group observed a significant difference in 
sCysC and uCysC concentration between CKD and healthy cats. We also validated the human 
particle enhanced nephelometric immunoassay (PENIA) for feline CysC measurement
22
 and 
established a reference interval (RI) of 0.58–1.95 mg/L for sCysC. In addition, we 
demonstrated that there is no influence of breed, age and sex on feline sCysC
7
 and that it is 
not mandatory to fasten cats prior to evaluation of feline sCysC.
23
 These findings make sCysC 
a promising marker to estimate GFR in feline medicine. 
 
Three human CysC quantitation devices are currently available: ELISA,
24
 particle 
enhanced turbidimetric assay
14
 (PETIA) and particle enhanced nephelometric assay 
(PENIA).
25
 The latter two analytical methods are more suitable for clinical use. No 
commercial veterinary assays are currently available, which requires validation of human 
assays. The assay validation of both PENIA and PETIA has been described in Chapter III. 
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The objectives of this study were fourfold. Firstly, sCysC and uCysC were compared 
between a large number of CKD and healthy cats. Secondly, the correlation of  sCysC and sCr 
with GFR measured using plasma exogenous creatinine clearance test (PECCT), plasma 
endo-iohexol clearance test (PenICT) and plasma exo-iohexol clearance test (PexICT), was 
compared. In addition, the sensitivity and specificity of sCysC to detect decreased GFR were 
determined and compared with sCr. Thirdly, to determine which assay would be most suitable 
for clinical use, PENIA versus PETIA measurements of sCysC were each correlated with 
GFR estimated by PECCT, PenICT and PexICT.  
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Materials and methods 
 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol 
was approved by the Local Ethical and Deontological Committee of the Faculty of Veterinary 
Medicine, Ghent University (EC2011_197). All owners whose animal participated in the 
study signed an informed consent. 
 
Study population 
Adult CKD and healthy cats were included, regardless of breed and gender. In all cats, 
physical examination, complete blood cell count (CBC), serum biochemistry (BC) ‒ including 
total thyroxine (TT4) measurement in cats older than 6 years ‒ and urinalysis were performed 
to assess the general health status. Diagnosis of CKD was made prior to inclusion. Cats were 
diagnosed with CKD based on the presence of compatible clinical and laboratory findings 
(i.e. renal azotemia (sCr and urea exceeding the RI we established in Chapter IV §4.2, i.e. 
(64.5–161.8 µmol/L) for sCr and (6.2–12.7 mmol/L) for serum urea) and urine specific 
gravity (USG) < 1.035). Cats with CKD were classified into four stages according to the IRIS 
guidelines.
26
 Cats with borderline sCr, but abnormal renal ultrasonographic findings at time of 
inclusion, with available follow-up data confirming CKD, were also included. CKD cats with 
evidence of significant concurrent systemic diseases based on their history, physical 
examination, CBC, BC or urinalysis were excluded. In CKD cats, treatment with angiotensin-
converting enzyme (ACE)-inhibitors, calcium antagonists or angiotensin receptor blockers 
(ARB) had to be ceased at least one week prior to inclusion. Renal diet and phosphorus 
binders did not have to be withdrawn. 
 
Cats with lack of significant abnormalities in history, physical examination, CBC, BC 
and urinalysis were defined as “healthy”. Criteria for normal urinalysis were: USG > 1.035,  
inactive urine sediment, urinary protein:creatinine ratio (UPC) < 0.4 and negative bacterial 
urine culture.
27
 Healthy cats receiving medication, within one month prior to inclusion, with 
potential effect on the kidney i.e. non-steroidal anti-inflammatory drugs (NSAIDs) 
corticosteroids, antibiotics, β-blocking agents, calcium antagonists, and ACE-inhibitors or 
ARB, were excluded.  
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Procedures 
A standard physical examination was performed in all cats including systolic blood 
pressure (SBP) measurement using the Doppler ultrasonic technique and a standardized 
procedure according to the ACVIM consensus guidelines.
28
 Cats were considered 
hypertensive if SBP > 160 mmHg.
28
 Thyroid gland palpation was performed in cats older than 
6 years, as previously described.
29
 All cats were fasted at least 10 h before the sampling 
procedure. Five mL of blood  was taken by jugular venipuncture using a 23 G needle. After 
centrifugation (5 min at 1931 x g), serum was analysed the same day. The CBC
a
 and BC
b
 
were performed in all cats. Ten mL of urine was taken by cystocentesis with a 22 G needle. 
The USG was determined using a manual refractometer
c
. Urinalysis consisted of a urinary 
dipstick test,
d,e
 measurement of UPC,
f
 sediment analysis and bacterial culture.
g
 Urine was 
centrifuged (3 min at 355 x g) and the urinary sediment was analysed within 30 min according 
to Paepe et al.
30
 The supernatant and remaining serum were divided in aliquots of 300 µL and 
stored at -72 °C until batched analysis.  
 
Glomerular filtration rate was measured by the combined plasma exogenous 
creatinine-iohexol clearance test (PEC-ICT), using a protocol previously described by van 
Hoek et al.
31
 Briefly, a 22 G catheter was placed in the cephalic vein. Creatinine was 
dissolved in 4 mL of 0.9% sodium chloride. First iohexol
h
 (64 mg/kg (0.1 mL/kg)), followed 
by Cr (40 mg/kg) and 3 mL of 0.9% sodium chloride was injected. Blood samples were taken 
by jugular venipuncture just before the injection and 5, 15, 30, 60, 120, 180, 360, 480, 600 
minutes after injection. The samples were placed in EDTA tubes, centrifuged (5 min at 1931 
x g) and plasma was stored in aliquots of 300 µL at -72 °C until analysis. 
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Assays 
Serum CysC and uCysC were analysed with PENIA
k
 using the nephelometer,
l
 and 
with PETIA
i
 using the Cobas auto-analyser.
j 
Both assays were validated for feline CysC 
determination (Chapter III). Urinary CysC was expressed as a ratio to the urinary Cr (uCr) 
concentration, to compensate for differences in urine flow rates.
32
 Plasma Cr was analysed 
with an enzymatic assay
q
 and plasma concentrations of the stereo-isomers endo-and exo-
iohexol were determined by high performance liquid chromatography with ultraviolet UV 
detection, both validated by van Hoek et al.
31
 Serum Cr measured in BC
b 
was analysed with a 
modified Jaffe assay, validated by a veterinary commercial laboratory.
n 
 
Pharmacokinetics for GFR determination 
All analyses were performed using WinNonlin.
o 
The data were subjected to non-
compartmental analysis, as described by Watson et al.
33
 The area under the plasma 
concentration versus time curve (AUC) was calculated using the trapezoidal rule with 
extrapolation to infinity. The plasma clearance of Cr, endo- and exo-iohexol was determined 
by dividing the dose administered by AUC and indexed to bodyweight (mL/min/kg). 
 
Statistical analysis 
Statistical analyses were performed using statistical software
p
 and at the 0.05 
significance level. The effect of status (CKD, healthy) on sCysC and uCysC, the effect of the 
IRIS stage on sCysC and uCysC, the relationship between uCysC/uCr and UPC and the 
comparison between sCysC measured with PENIA versus PETIA were tested by ANOVA. In 
case of a significant effect, pairwise comparisons were performed with the Tukey’s test. If the 
uCysC concentration was <  limit of detection (LOD), it was arbitrarly fixed to zero. 
 
The correlation between GFR and either sCysC or sCr were determined with ANOVA 
using general linear model (GLM): Marker = μ + GFR + ε with marker being sCr, 
sCysCPENIA, sCysCPETIA, 1/sCr, 1/sCysCPENIA, 1/sCysCPETIA; GFR is GFR Cr, GFR 
exo, GFR endo; ε, error term of the model. For each marker, the R2 of the regression was 
determined.  
 
We also studied if sCysC could distinguish cats with normal, borderline or low GFR, 
based on PexICT, compared with sCr. The cut-off concentrations for normal GFR were 
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defined as GFR ≥ 1.7 mL/min/kg, for borderline GFR as GFR 1.2–1.7 mL/min/kg and for low 
GFR as GFR < 1.2 mL/min/kg, as determined previously by our group.
34 
 
Sensitivity and specificity of sCr and of sCysC to detect decreased GFR (PexICT < 1.7 
mL/min/kg) were calculated. “Positive test” and “negative test” were defined as > 
respectively < 161.8 µmol/L  for sCr,  and > respectively < 1.95 mg/L for sCysC, based on 
the RIs we established in a previous study.
7
 The nonparametric receiver-operating- 
characteristic (ROC) curve for sCysC and sCr were additionally configured. 
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Results 
 
Study population 
In total, 90 cats were recruited (age range: 1.1 years to 19 years), namely 49 CKD and 
41 healthy cats. 
 
For the 49 CKD cats, breed distribution was: one Siamese, one Oriental Shorthair, one 
Persian, one Maine Coon, one Burmese, two Ragdolls, two Birmans, four British Shorthair 
cats and 36 DSH/DLH. Four cats were female intact, 19 female neutered and 26 male 
neutered. Mean ± SD age was 10 ± 4.7 years and mean ± SD body weight 4.1 ± 1.2 kg.  One 
cat had IRIS stage 1 non proteinuric CKD and was diagnosed based on ultrasonographic 
findings, low USG and borderline sCr. The cat had IRIS stage 2 CKD and IRIS stage 3 CKD, 
five months and two years after inclusion, respectively. Twenty cats had IRIS stage 2 CKD, 
of which five were proteinuric (UPC ≥ 0.4), five borderline proteinuric (UPC (0.2–0.4)) and 
10 did not have proteinuria. Thirteen cats had IRIS stage 3 CKD. Six of those cats were 
proteinuric, three were borderline proteinuric and the other four cats did not have proteinuria. 
Fifteen cats had IRIS stage 4 CKD, of which 11 were proteinuric and four borderline 
proteinuric. One cat with severe proteinuria (UPC = 4.22) also had glucosuria without 
hyperglycemia. Three CKD cats were treated with ACE-inhibitors but therapy was ceased one 
month prior to inclusion. One CKD cat was treated with ARB, and therapy was stopped two 
weeks prior to inclusion. 
 
For the 41 healthy cats, breed distribution was: one Birman cat, one Persian cat, two 
Ragdolls, two British Shorthair and 35 domestic short-or longhair (DSH/DLH) cats. Two cats 
were female intact, 25 female neutered and 14 male neutered. Mean ± SD age was 9.9 ± 3.5 
years and mean ± SD body weight 4.4 ± 1.2 kg. 
 
Systolic blood pressure measurement was performed in 45 CKD and 37 healthy cats. 
The other eight cats were not cooperative enough, to reliably determine SBP. Four CKD cats 
were hypertensive, of which only one was proteinuric. Also four of the healthy cats had SBP 
> 160 mmHg. Those cats were very stressed during the measurement, so white-coat 
hypertension is a likely explanation.
28
 Systolic blood pressure, sCr, serum urea, sCysC, USG, 
UPC, of both CKD and healthy cats are presented in Table 1. 
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Table 1. Descriptive statistics of both CKD and healthy cats. The variables are presented 
as mean ± SD.  The level of significance is indicated by 
a
 (P < 0.01) and 
b
 (P < 0.001). 
 
Variable (unit) CKD (n = 49) Healthy (n = 41) 
SBP (mmHg) 135 ± 27 142 ± 20 
sCr (µmol/L)
 b
 358.7 ± 223.6 108.9 ± 23 
Serum Urea (mmol/L)
b
 26.6 ± 19.4 9.4 ± 2.1 
sCysC (mg/L)
 b
 1.4 ± 0.5 1.0 ± 0.3 
USG
 b
 1.019 ± 0.009 1.045 ± 0.007 
UPC
 a
 0.67 ± 0.92 0.21 ± 0.14 
uCysC/uCr (mg/mol)
 b
 291 ± 411 0.32 ± 0.97 
 
CKD, chronic kidney disease; SBP, systolic blood pressure; sCr, serum creatinine; sCysC, 
serum cystatin C; USG, urine specific gravity; UPC, urinary protein:creatinine ratio; 
uCysC/uCr, urinary cystatin C:creatinine ratio.  
 
 
Comparison of sCysC and uCysC between cats with CKD and healthy cats 
Serum CysC was measured in all cats and uCysC in 44 CKD cats and all healthy cats. 
Urinary CysC was < LOD (0.049 mg/L) in 15/44 CKD cats and in all but five healthy cats. 
We observed that there was a significant effect (P < 0.001) of the status (CKD or healthy) on 
sCysC and uCysC/uCr with significantly higher concentrations in CKD cats (Table 1). The 
corresponding boxplots of sCysC and uCysC/uCr of healthy cats and CKD cats are presented 
in Figure 1, illustrating the overlap in sCysC between the groups. The IRIS stage also had a 
significant positive effect (P < 0.001) on both sCysC and uCysC/uCr, with increasing mean 
concentrations as IRIS stage increased (Table 2). However, R
2
 between IRIS stage and CysC 
was weak (0.31 for sCysC and 0.29 for uCysC). Also UPC had a significant effect (P < 0.001) 
on uCysC/uCr in the whole population and in cats with CKD. R
2
 was 0.54 for the whole 
population and 0.50 for the cats with CKD. 
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Table 2. Serum CysC (sCysC) and urinary cystatin C:creatinine ratio (uCysC/uCr) 
measured met the nephelometric assay in the healthy cats and cats with CKD for each 
IRIS stage. Data are presented as mean ± SD. n represents the number of cats. 
 
Status sCysC (mg/L) uCysC/uCr (mg/mol) 
Healthy (n = 41) 1.0 ± 0.28 0.32 ± 0.95 
CKD IRIS stage 1 (n = 1) 1.065 7.40 
CKD IRIS stage 2 (n = 20) 1.26 ± 0.40 123.62 ± 374.4 
CKD IRIS stage 3 (n = 13) 1.50 ± 0.50 254.0 ± 206.0 
CKD IRIS stage 4 (n = 15) 1.67 ± 0.57 526.80 ± 489.87 
 
CKD, chronic kidney disease; IRIS, international renal interest society; SD, standard 
deviation; LOD, limit of detection. 
 
 
Figure 1. Boxplot of serum cystatin C (sCysC) (mg/L) (A) and the urinary cystatin C: 
creatinine ratio (uCysC/uCr) (mg/mol) (B) for 49 cats with chronic kidney disease (CKD)  
and 41 healthy cats. 
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Comparison of correlation between GFR and sCysC versus sCr 
The PEC-ICT was performed in 17 CKD and 15 healthy cats. The mean ± SD Cr, 
endo- and exo-iohexol clearances of the CKD and healthy cats are presented in Table 3. In 
one healthy cat, the serum sample 60 min after injection was not available, and therefore the 
GFR of that cat was calculated based on nine samples instead of 10 samples. Both for the 
PENIA and the PETIA, there was a significant correlation between GFR and sCysC. The 
scatter plots of sCr and sCysC PENIA, sCysC PETIA versus PexICT are presented in Figure 
2. The other GFR-markers showed comparable results. The regression coefficients with P-
values are presented in Table 4.  
 
Table 3. Mean ± SD of plasma clearance (mL/min/kg) of creatinine, exo-iohexol and 
endo-iohexol in CKD and healthy cats.  
 
 CKD 
(n = 17) 
Healthy 
(n = 15) 
PECCT 0.9 ± 0.3 2.3 ± 0.6 
PexICT 0.9 ± 0.4 2.1 ± 0.5 
PenICT 1.2 ± 0.5 2.9 ± 0.7 
 
Cr, creatinine; CKD, chronic kidney disease; PECCT, plasma exogenous creatinine clearance 
test; PexICT, plasma exo-iohexol clearance test; PenICT, plasma endo-iohexol clearance test. 
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Figure 2. Scatter plots of the glomerular filtration rate (GFR) determined with a plasma 
exogenous iohexol clearance test (PexICT), cystatin C analysed with the particle enhanced 
nephelometric immunoassay  (sCysC PENIA) (A) and cystatin C analysed with the particle 
enhanced turbidimetric immunoassay (sCysC PETIA) (B) and serum creatinine (sCr) (C). 
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Table 4. R
2
 values and associated P-values of sCr and sCysC measured with the PENIA 
and PETIA versus plasma clearance of creatinine, exo- and endo-iohexol. 
 
  PECCT PexICT PenICT 
sCysC PENIA 0.46 (P < 0.001) 0.34 (P < 0.001) 0.37 (P < 0.001) 
sCysC PETIA 0.44 (P < 0.001) 0.31 (P = 0.003) 0.36 (P = 0.001) 
sCr 0.74 (P < 0.001) 0.68 (P < 0.001) 0.67 (P < 0.001) 
 
sCr, serum creatinine; sCysC, serum cystatin C; PENIA, particle enhanced nephelometric 
immunoassay; PETIA, particle enhanced nephelometric immunoassay; PECCT, plasma 
exogenous creatinine clearance test; PexICT, plasma exo-iohexol clearance test; PenICT, 
plasma endo-iohexol clearance test. 
 
Determination of sensitivity and specificity of sCysC to detect decreased GFR 
Results from the clearance test demonstrated that one cat classified as “healthy”  
actually had borderline GFR and another cat classified as “healthy” had low GFR. In addition, 
one “CKD” cat actually had borderline GFR and another had normal GFR. The boxplots of 
sCysC and sCr from cats classified with normal, borderline and low GFR are presented in 
Figure 3. For sCysC, the overlap was much larger compared to sCr between cats with normal 
GFR, cats with borderline and low GFR. Serum CysC exceeded the RI previously established 
by our group, in only four of 16 cats with low GFR. In contrast, sCr exceeded the RI in all of 
them. Indeed, the sensitivity of detecting decreased GFR (< 1.7 mL/min/kg) was 22% for 
sCysC compared with 83% for sCr. In contrast, the specificity for sCysC was 100% compared 
with 93% for sCr. The ROC is presented in Figure 4. 
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Figure 3. Boxplot of serum cystatin C (sCysC) (A) and sCr (B) for cats with normal 
GFR (GFR ≥ 1.7 mL/min/kg), borderline GFR (GFR (1.2–1.7 mL/min/kg)) and low GFR 
(GFR < 1.2 mL/min/kg). GFR determination was based on an exo-iohexol clearance test 
(PexICT). 
 
 
 
 
 
Figure 4. Nonparametric receiving-operating-characteristics (ROC) plots of the 
sensitivity and specificity of sCysC and sCr for distinguishing cats with normal and 
reduced GFR (< 1.7 mL/min/kg) determined with plasma exo-iohexol clearance test 
(PexICT). 
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Comparison between PETIA and PENIA for sCysC analysis 
The two methods were highly correlated (R
2
 = 0.94, P < 0.001), but sCysC 
concentrations measured with PETIA was significantly higher (P < 0.001) than those 
measured with PENIA. No significantly better correlation between sCysC PETIA and GFR 
(whatever the marker) than between sCysC PENIA and GFR could be observed (Fig 2, Table 
4 ). Figure 5 presents the Bland-Altman Plot in which PENIA and PETIA are compared. The 
mean ± SD difference was calculated as 1.84 ± 0.95 mg/L. The limits of agreement are wide, 
and the difference tends to get larger as the mean increases.  
 
 
Figure 5. Bland-Altman Plot of serum cystatin C analysed with the particle enhanced 
tubidimetric immunoassay (PETIA) and particle enhanced nephelometric immunoassay 
(PENIA). 
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Discussion 
 
The striking results of this study are: i) sCysC was significantly higher in cats with 
CKD, compared with healthy cats, but a significant overlap was present; ii) urinary CysC was 
not present in all CKD cats; iii) the correlation between GFR measured with PEC-ICT and 
sCysC was weaker than that between GFR and sCr, regardless of the sCysC assay.  
 
Although sCysC was significantly higher in CKD versus healthy cats, several other 
findings disfavor feline sCysC: an obvious overlap in sCysC between both groups was 
present, as previously described in cats
22,35
 and dogs.
36
 In addition, only six of the 49 CKD 
cats had sCysC above the upper limit (1.95 mg/L) of the RI, determined in a previous study.
7
 
Further, although significant, the correlations between sCysC and IRIS stage were weak and 
probably not clinically relevant, since not all cats with CKD IRIS stage 3 or 4 had a higher 
sCysC concentration compared with the healthy cats or cats with CKD IRIS stage 2.  
 
Urinary CysC was also significantly different between CKD and healthy cats. In 
contrast with sCysC, an overlap for uCysC was absent. As for sCysC, a significant but weak 
correlation between uCysC/uCr and the IRIS stage was present, and not all CKD cats with 
IRIS stage 3 or 4 had higher uCysC/uCr compared to healthy cats and CKD cats with IRIS 
stage 2. Indeed, five of the 41 healthy cats had a detectable uCysC concentration. With 
normal kidney function CysC is completely reabsorbed and catabolized in the tubules.
37,38
 
Small quantities can still be found in the urine, but one would expect this concentration to be 
< LOD.
39
 Two of the five healthy cats with detectable uCysC were borderline proteinuric. 
None of those five cats had overt proteinuria, azotemia or isosthenuric urine, so CKD is 
unlikely. Nevertheless, no follow-up or GFR results are available for those cats, so early CKD 
cannot be excluded.  Unexpectedly, 15 of the 49 CKD cats had uCysC < LOD, of which two 
cats were proteinuric and two borderline proteinuric. In a previous study
40
 of our group, 
uCysC could also not be detected in five of the 10 included cats with CKD. Those 
observations are surprising. Most of the cats with CKD have tubulo-interstitial lesions. 
Therefore, we expected detectable uCysC in most of the CKD cats. However, without 
histopathology, a more atypical form of CKD cannot be excluded. In contrast, uCysC seemed 
to be valuable as marker for local proximal damage in hyperthyroid cats.
41
 Therefore, the 
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prognostic value and ability to detect early tubular damage of uCysC should be evaluated 
further with investigation of renal biopsies. 
 
The major objective of the present study was to compare the correlation of GFR with 
sCysC and sCr. In contrast with human studies
14,15,42
 and studies in dogs
17,18
 a weaker 
correlation was found between PECCT, PenICT, PexICT and sCysC measured with PENIA 
or PETIA compared with sCr. In addition, the use of the inverse values increased R
2
 value for 
sCr, but not for sCysC PETIA or sCysC PENIA. From these findings we can conclude that 
sCysC does not appear to be advantageous over sCr for detection of feline CKD. 
 
Our results are different from a similar study in cats, demonstrating a significantly 
better correlation of sCysC with PICT compared to that with sCr.
35
 In the study of 
Poświotowska-Kaszczyszyn a one-compartmental model and the slope-intercept method 
corrected with the Brochner-Mortensen formula was used to calculate GFR.
43
 It has been 
shown that one-compartmental models overestimate true GFR, due to underestimation of 
AUC, and the slope-intercept method with the Brochner-Mortensen formula can cause 
increasing errors with increasing clearances.
44
 Since we used a different method for GFR 
calculation, it is difficult to compare the results from the present study with the study from 
Poświotowska-Kaszczyszyn. In addition, we determined GFR with three different markers 
(Cr, endo-and exo-iohexol) to evaluate sCysC. However, no better correlation of each of the 
three methods with sCysC could be observed. 
 
Early kidney impairment in some of the healthy cats could not be excluded. Therefore, 
in the subgroups in which GFR was measured, we correlated sCysC and sCr with renal 
function. Only two of the 15 cats previously classified as “healthy” had low and borderline 
GFR respectively. These two cats did not show high sCysC value exceeding the RI. Serum 
CysC overlapped between cats with low, borderline and normal GFR, indicating that sCysC 
cannot distinguish between those three groups. For sCr, the overlap was less severe and could 
mainly be observed between cats with low and borderline GFR. In dogs on the other hand, a 
significantly better correlation between sCysC and PECCT
18
 or PICT
17
 has been shown. 
However, an overlap in sCysC between healthy dogs and dogs with CKD was also 
present,
17,45,46
 but GFR measurement was only performed in one of those studies.
17
 In contrast 
to canine studies,
17,18
 no higher sensitivity of sCysC than of sCr to detect decreased GFR 
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could be observed. In contrast, a higher specificity was present, which means that if feline 
sCysC is elevated, CKD is definitely present. 
 
The findings of the present study do not encourage the clinical use of feline CysC. 
However, suboptimal feline CysC determination cannot be completely ruled out. We obtained 
a signal with the PETIA and PENIA, but we cannot exclude that the human assays measure 
feline CysC suboptimal. Western blot analysis with antibodies from the PENIA
22
 could not 
demonstrate good cross reactivity at 13 kDa, in contrast with the antibodies from the PETIA 
(Chapter III). For both assays, bands at 26 and 52 kDa were visible. In humans, it has been 
shown that denaturing agents or high temperature can cause di-or polymerization of CysC.
47
 
This is unknown for dogs and cats, but it could explain the higher molecular weight bands. 
Alternatively, the human polyclonal anti-human CysC antibodies might detect polymers and 
not 13 kDa feline CysC. Another explanation for suboptimal testing could be the relatively 
limited homology between human and feline CysC. A homology of 70% between feline and 
human CysC has been described,
48,49
 but the epitope sequence to which the antibody binds is 
not provided by the manufacturers, which makes evaluation of cross reactivity between the 
anti-human CysC antibodies and feline CysC difficult. Therefore, a feline assay should be 
developed, followed by a re-evaluation of this marker. Until then, we do not recommend the 
use of feline CysC as renal marker in cats. 
 
Conclusion 
 
Serum CysC was not able to distinguish healthy cats from cats with CKD. 
Furthermore, uCysC was not present in all CKD cats, but studies with renal biopsies are 
needed to confirm the usefulness of uCysC as proximal tubular marker. Whatever the marker 
for GFR determination and assay for CysC measurement, a markedly weaker correlation 
between GFR and sCysC compared with sCr could be demonstrated. Therefore, we do not 
advise to use feline sCysC as an indirect marker for GFR. 
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Chronic kidney disease (CKD) is common in cats, with a prevalence ranging from 
30%–40% in aged cats.1-3 CKD is routinely diagnosed based on clinical findings, serum 
creatinine (sCr), urea and urine specific gravity (USG). However, these parameters have their 
limitations for the detection of early CKD, as described in part one of Chapter I. The 
limitations of the available tests encourage the need for a new renal marker, that can easily 
and reliably be measured.  
 
Cystatin C (CysC) appears to have all characteristics required to be an ideal renal 
marker. At the start of this thesis, several studies in human medicine had described the 
advantages of serum Cystatin C (sCysC) over sCr: it has a better correlation with GFR,
4-12
 is 
less influenced by muscle mass,
13,14
 food intake,
15
 and is a very stable protein that can be 
stored for more than 10 years at -25°C.
16
 In addition,  urinary CysC (uCysC) can also be used 
as a marker for tubular dysfunction. Indeed, it is normally completely catabolized in the 
proximal tubule and therefore CysC appearance in urine is an indicator of proximal tubular 
damage.
17,18
 Due to all those advantages, interest raised to investigate this marker in 
veterinary medicine. In dogs, several studies claimed CysC to be a better glomerular filtration 
rate (GFR) marker than sCr.
19-22
 In cats, contradictory results were available.
23,24
 An overview 
of current knowledge on CysC in small animal medicine has been described in part two of 
Chapter I. 
 
Before a new marker can be routinely used, it needs to be validated (Chapter I). 
Validation is a term that is mostly used unfittingly. The correct definition is the evaluation of 
the quality of a measurement, in order to identify the presence of an analyte, and to evaluate 
the status of the test subject.
25
 Prior to this thesis, several veterinary laboratories offered 
analysis of CysC. However, this marker was not yet appropriately validated. Moreover, in 
feline medicine, only few CysC studies had been performed.  
 
As described in Chapter II, the objectives of this thesis were to evaluate 
‒ how feline CysC could be appropriately measured 
‒ the influence of biological factors on feline sCysC 
‒ the influence of clinical factors on feline sCysC and uCysC 
‒ if CysC was a better marker than sCr for the detection of feline CKD 
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1. Measurement of feline cystatin C 
 
In Chapter III, analytical validation of feline CysC was performed. We determined 
how feline CysC can be measured. As no veterinary assays were available, we needed to 
evaluate if the available human assays were able to determine feline CysC. At the start of the 
study, three human assays were available: particle-enhanced turbidimetric immunoassay 
(PETIA), particle-enhanced nephelometric immunoassay (PENIA) and enzyme-linked 
immunosorbent assay (ELISA). Since the objective of our thesis was to evaluate if sCysC 
could be used in practice, we did not evaluate ELISA, as this test is labour-intensive, 
expensive and not suitable for daily use in practice. A disadvantage of using human assays for 
feline samples is that the obtained concentrations are relative values. We do not know the 
exact feline CysC concentration. Therefore, we wanted to produce purified feline CysC, to 
know which correction factor is required to calculate the actual measured feline CysC 
concentration. It was described that feline recombinant CysC can be expressed in Escherichia 
coli with antibody production.
26
 Based on this information, we cloned the feline CysC gene 
into a plasmid, followed by cloning into an expression vector (Escherichia coli) with a fusion 
protein for protein purification. However, despite several attempts to produce recombinant 
feline CysC not only in Escherichia coli, but also in Pichia pastoris and mammalian cells, 
recombinant feline CysC could not be produced. Possible explanation is that the fusion 
protein could not be removed due to non-recognition, or that transcription of translation was 
stopped too early. Further experiments to produce feline CysC were not undertaken, since this 
was beyond the scope of this thesis. Therefore, the human CysC standard was used for the 
validation of CysC and relative feline CysC concentrations were measured.  
 
Like ELISA, PENIA and PETIA are two assays based on antigen-antibody reaction. 
Therefore, cross-reactivity between the polyclonal anti-human CysC antibodies, used in the 
immunoassays, and feline CysC was demonstrated with Western blotting. Both healthy cats 
and CKD cats with and without proteinuria were selected. On Western blot with antibodies 
from PETIA, small bands could be demonstrated in urine and in serum of a non proteinuric 
cat with CKD. Western blot with antibodies from PENIA could demonstrate bands in urine 
samples from the proteinuric CKD cats, but no bands could be detected at the expected 13 
kDa MM of either cat. Surprisingly, both for PENIA and PETIA, bands could be detected at 
26 and 52 kDa, especially in serum. Only one study using PETIA antibodies has shown 
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photographs of Western blots with comparable findings, but these results were not 
discussed.
19
 It has been described in humans that denaturing agents and high temperature 
conditions, result in polymer formation of CysC.
27
 In our protocol, samples were boiled for 10 
min at 95 °C and incubated with laemli buffer, which contains disulphide bond reducing 
agents, sodium dodecyl sulphate and dithiothreitol. In the study of Almy et al.
19
 with 
comparable results, another reducing agent, β-mercapto-ethanol, prior to the electrophoresis 
step was added. Therefore, we assume that the bands at 26 kDa and 52 kDa, a two- and 
fourfold of 13 kDa respectively, were caused by polymer formation induced by the applied 
conditions. However, this could not explain the stronger signal in urine compared to serum. In 
humans, it has been shown that uCysC lacks 4 to 8 amino-acids at the N-terminal compared to 
the sCysC homologue, and that it remains reactive to anti-CysC antibodies from the PETIA.
17
 
However, it is unknown if this also applies for PENIA antibodies, and for feline CysC. 
Furthermore, both PENIA and PETIA antibodies are polyclonal rabbit anti-human CysC 
antibodies, but it is unlikely that the antibodies from PENIA and PETIA are identical. In 
addition, a homology of only 70% between feline and human CysC has been reported,
26,28
  
and the epitope sequence to which the human antibodies bind is not provided by the 
manufacturer. Therefore, a further evaluation of difference in cross reactivity between 
antibodies from PENIA and PETIA on one hand, and feline sCysC and uCysC on the other, is 
currently not possible. In addition, there is no information available on Western blot results 
with human samples. We could not exclude that CysC is not suited for Western blot analyses.  
 
Although cross reactivity between feline CysC and the human CysC  antibodies could 
not be clearly demonstrated, we analyzed a few feline samples with PENIA and PETIA and a 
signal could be detected. In a study in dogs, the PETIA antibodies gave similar results on 
western blotting
19
 and sCysC could be detected in those dogs. Therefore, we assumed that 
feline sCysC could be detected with PENIA and PETIA. One study in dogs has compared 
PENIA with PETIA for measuring sCysC among dogs with different IRIS stages.
29
 Clinically 
important differences in canine sCysC concentrations between all IRIS stages were observed 
for sCysC measured with PENIA, in contrast to sCysC measured with PETIA.
29
 In addition, 
studies with human serum samples showed less interference of triglycerides, bilirubin, 
hemoglobin of PENIA compared with PETIA.
6,7,30
 Based on the validation parameters, but 
also due to practical reasons, we analysed feline CysC with the human PENIA. In the pilot 
study described in Chapter III, a significantly higher sCysC concentration was observed in 
CKD cats compared to healthy cats, but an overlap was present. These preliminary findings 
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were confirmed by the study described in Chapter V, §5.2. More CKD cats were included in 
that study, and an overlap in sCysC between the different IRIS stages could be observed. In 
the pilot study of Chapter III, uCysC was measured in one cat with lower UTI, and this cat 
did not have higher uCysC/uCr compared to the other cats. This was a preliminary finding, 
since we did not evaluate the effect of hemoglobin on measurement of uCysC in more 
samples or with PETIA, so we do not know if hemoglobin might have influenced our 
measurement. It is also worth mentioning that PENIA can be used with only one specialized 
automated nephelometer in contrast to PETIA, causing less analytical variability. However, to 
decide which assay was most suited for use in practice, a thorough analytical validation of 
both assays (Chapter III) was needed and correlation of GFR with feline sCysC measured 
with both assays (Chapter V, §5.2) practice, was performed. 
 
In Chapter III, analytical validation of both PENIA and PETIA was performed 
according to the recommendations described in Chapter I. PENIA showed good precision 
and linearity, both for serum and urine. In contrast, sCysC and uCysC appeared mildly less 
linear for PETIA. In addition, PETIA had a high detection limit of  0.39 mg/L compared with 
0.049 mg/L for PENIA, impeding CysC measurement in urine. In Chapter V, §5.2, sCysC 
was measured with PETIA and PENIA in both healthy and CKD cats and correlated with 
plasma exo-iohexol clearance test (PexICT). We observed significantly higher sCysC 
concentrations determined with PETIA compared to PENIA, but no significantly better 
correlation of PexICT and sCysC PETIA than of PexICT and sCysC PENIA. The Bland-
Altman plot showed a mean difference higher than 0, indicating that PENIA and PETIA are 
systematically producing different results. For sCysC measurement, both PENIA and PETIA 
can be used, but for uCysC, we recommend PENIA. In addition, the findings from Chapter 
V, §5.2 indicate that the same assay should be used, and sCysC results from PENIA and 
PETIA cannot be used interchangeably. 
 
To use CysC in practice, it also mandatory to know at which temperature and for how 
long samples can be stored, before CysC concentration decreases. For the storage study 
(Chapter IV, §4.1), only 4 CKD and 3 healthy cats were included, due to practical reasons. 
Because uCysC was undetectable in most included cats, only sCysC was investigated for this 
study. Based on our findings, samples can be stored at room temperature (RT) if sCysC is 
analyzed within 24 h and at 4 °C for 1 week and one freeze-thaw cycle is allowed. If longer 
storage is required, we advise storage at -20 °C and -72 °C for up to 5 months. Longer storage 
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is not recommended, since a 21% decrease in sCysC concentration was observed. Some 
studies in dogs
31
 and cats
23
 had measured plasma CysC (pCysC) instead of sCysC. To use in 
practice, it was important to know what the difference was between sCysC and pCysC and 
this had not been investigated earlier. Plasma CysC concentrations were significantly lower 
than sCysC concentrations, indicating that always the same medium must be used in patient 
follow-up. 
 
The studies from Chapter III and Chapter IV, §4.1 provided us the required 
information for CysC measurement. Feline sCysC can be measured both with PENIA and 
PETIA, feline uCysC is preferably measured with PENIA, the feline CysC concentrations can 
only be interpreted relatively, and prolonged storage of feline sCysC samples is not 
recommended. 
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2. Biological factors influencing feline serum cystatin C 
 
In Chapter IV, §4.1, we investigated if it was mandatory to fasten cats prior to sCysC 
evaluation. This could be an advantage over sCr. If a renal marker can be measured regardless 
of feeding status, false positive or negative results due to feeding can be excluded. In cats, 
only two studies have investigated the effect of feeding on sCr. One study observed a 
postprandial increase,
32
 whilst the other observed a decrease.
33
 In the study of Chapter IV, 
§4.1, we investigated the effect of feeding versus fasting, and diurnal variation on both sCysC 
and sCr in a cross-over study with 10 healthy laboratory cats. There was no significant 
difference in sCysC and sCr between fasted and fed cats. For sCysC, our results were 
different from a similar study in dogs.
31
 In that study, a postprandial decrease followed by an 
increase in pCysC could be observed. The authors attributed the decrease in pCysC to 
increased GFR, caused by increased renal blood flow. However, these dogs were fed a 
commercial diet, and dietary effect on GFR has only been demonstrated after consumption of 
raw and cooked meat.
34,35
 Our findings for sCr were also different from previous studies in 
cats,
32,33
 in which the authors attributed a postprandial increase to a high creatine content of 
the food
32
 and the postprandial decrease to increased GFR.
33
 An increased GFR 
postprandially has been demonstrated in cats fed a high protein diet,
36
 but not in cats fed a 
normal protein diet, as was given in our study and the study from Reynolds and coworkers.
33
 
Currently, it is not proven that feeding cats a normal protein diet causes increased GFR. We 
only observed significant differences for sCysC between the morning and the evening 
samples, but the differences were small and probably not clinically relevant. For sCr no 
differences were observed in contrast to another study.
33
 We observed large inter-individual 
differences in sCysC and sCr concentrations during the day, which could explain the 
differences between our study and the study from Reynolds and colleagues.
33
 
 
Based on our findings, it is not mandatory to fasten cats prior to sCr and sCysC 
evaluation and samples can be taken at any moment during the day. 
 
Even though sCysC concentrations are relative values, it is necessary to know what 
sCysC concentration is normal for healthy cats. In Chapter IV, §4.2, we established a 
reference interval (RI) for sCysC according to the ASVCP guidelines.
37
 One hundred and 
thirty cats of different breeds, ages (young, middle-aged, old) and sex were included to 
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characterize biological variation and to determine if separate RIs would be required. Systolic 
blood pressure (SBP), sCr, urea, USG and urinary protein:creatinine ratio (UPC) were also 
compared between the different groups. We could not observe an effect of age, breed and sex 
on feline sCysC, as also observed by another research group.
24
 This was an advantage over 
sCr. For sCr, we observed a small but significant difference between the separate age groups. 
However, a clear overlap was present. Therefore, no separate RIs were determined. In 
addition, no influence of breed on sCr could be observed, in contrast with other studies.
38-40
 
However, we included only 56 purebred cats of seven different breeds. In the studies from 
Paltrinieri et al. and Reynolds et al. more cats per breed were included, making these studies 
more representative. They proposed a breed-specific sCr RI for Birman, Maine Coon, 
Chartreux, Abyssinian and Persian Cats.
39,40
 However, it should be kept in mind that their 
results cannot be extrapolated to other laboratory conditions.
39
 In a study performed in our 
laboratory, sCr concentrations did not differ between healthy cats and Ragdoll cats.
41
 We are 
convinced that further investigation is warranted, with larger populations of healthy purebred 
cats, and additional studies should be undertaken to understand the underlying causes for the 
differences.  
 
We also observed interesting differences between the groups for other renal 
parameters. In our study age and sex influenced serum urea, which is known to be more 
influenced by extra-renal factors.
42,43
 We observed a significantly higher UPC in male intact 
cats compared to female intact and female neutered cats, but not compared to male neutered 
cats. It is assumed that male intact cats have higher UPC than male neutered cats due to 
higher urinary cauxin concentrations, regulator of a pheromone precursor.
44,45
 However, 
additional studies are needed, as only 10 male intact cats were enrolled and UPC values 
overlapped between the two groups. The systolic blood pressure (SBP) was significantly 
higher in geriatric cats compared to the middle-aged and young cats. Some studies observed 
an effect of age on SBP in cats,
46,47
 whilst others did not.
48,49
 None of our geriatric cats had 
SBP over 180 mmHg, and only two had SBP > 160 mmHg. Possible explanations are age-
specific changes in the cardiovascular system or co-existing diseases such as declining kidney 
function or hyperthyroidism. Longitudinal studies evaluating SBP, renal and thyroid function 
are needed, to determine if SBP is independently age-related or related to co-existing 
diseases. 
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Since no effect of age, sex and breed on feline sCysC could be demonstrated, sCysC 
results from the entire population could be included in the RI calculations. According to the 
ASVCP guidelines, a minimum of 120 cats should be included, and the RI should be 
determined with a nonparametric method with the 2.5th and 97.5th percentile serving as lower 
and upper reference limit, respectively.
37
 The obtained RI was 0.58‒1.95 mg/L. This does not 
correspond with a previously reported RI of 0.34–4.11 mg/L.23 However, in that study, pCysC 
was measured with PETIA, not validated at the time of that study. In addition, no clinical data 
of the cats were described, so concurrent diseases cannot be excluded. Finally, the RI was 
calculated with less than the required 120 cats. Remarkably, sCysC concentrations of CKD 
cats from previous studies,
24,50
 fell within our RI. In the Polish study, GFR measurement was 
performed and sCysC was also measured with PENIA, but an overlap in GFR between CKD 
and healthy cats was observed, which could explain why sCysC from CKD cats fell within 
our RI.  
 
 It is mandatory to determine laboratory-specific RI.
37
 Many inadequate RI are used in 
veterinary medicine., often due to an inadequate reference population.
37
 The RI for sCr 
(44.2‒141.2 µmol/L), used in the study of Chapter III, is based on sCr concentrations of cats 
aged 6 months to 1 year. This is probably not suited to interpret sCr of aged cats.
47
 In the  
study of Chapter IV §4.2, 7 cats of our population exceeded that RI for sCr. None of these 
cats showed clinical signs of CKD or had a USG < 1.035, making early CKD unlikely. This 
encouraged the need for determination of laboratory-specific RIs according to general 
guidelines.
37,51
 We calculated a sCr RI of 64.5‒161.8 µmol/L according to the ASVCP 
guidelines.
37
 Not only the RI has to be taken into account before sCr evaluation, also the assay 
variation has to be considered.
37
 Serum Cr was measured with a modified Jaffe method, and 
none of our cats exceeded the upper reference limit (177 µmol/L) of a published RI for sCr 
measured with the modified Jaffe method.
52
 Compared to the original Jaffe method, the 
modified Jaffe method minimizes the influence of pseudo-Cr chromogens i.e. proteins, 
ketones and glucose, which can overestimate true Cr.
53,54
 However, the enzymatic method 
deals more effectively with the interferences, but a small overestimation is still possible 
compared with the former golden standard method, high performance liquid chromatography 
(HPLC).
55,56
 Nevertheless, the modified Jaffe method is still most commonly used in Belgium 
and is less expensive than the enzymatic method. As described in Chapter I, we have to be 
aware that in human medicine, a new golden standard method i.e. gas-chromatography-
isotope dilution mass spectrophotometry (IDMS) and a Cr  standard are used, possibly also 
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influencing sCr results in cats.
53,57
 In Chapter IV §4.2, 25 cats had USG < 1.035, without 
elevated sCr, or signs of CKD. More than two years after the inclusion, 20 of them were 
contacted again, and none of them had developed CKD. In Chapter V §5.1, we observed not 
only in six out of 28 healthy cats, but also in five out of 30 FIV-positive and nine out of 26 
hyperthyroid cats, USG < 1.035 without concurrent azotemia. No GFR measurement was 
available in both studies, hence we cannot exclude that early kidney dysfunction was present 
in some cats. This was a limitation of both studies. However, it has been shown that USG has 
a daily variation,
58
 and it is hypothesized that normal feline USG range is between 1.001-
1.065
59
 or even 1.080.
60
 A recent study demonstrated that there was an association with USG 
< 1.035 and age and dietary moisture content in healthy cats.
61
 In our study, not only aged, 
but also young cats had USG  < 1.035. This was also observed in another study of our group 
and by Rishniw and colleagues.
61,41
 An underlying cause could be identified in 22 out of 121 
adult cats by Rishniw, in contrast with the young cats.
61
 These three studies
41,61,62
 emphasized 
the need for more studies investigating the clinical importance of USG < 1.035 in cats. 
 
Even though our results are preliminary, since only small subgroups of cats were 
included, our observations encourage the need for studies evaluating the effect of biological 
factors on several renal parameters in large cat subgroups. Not only the factors age, breed and 
sex are important to evaluate, the within- and between-subject components of biological 
variation are also important to be considered, to decide if subject-based or population-based 
RI have to be used. The analyte’s index of individuality should be determined, based on intra-
individual, inter-individual and analytical variation.
63,64
 For variables with high individuality, 
subject-based RI are more appropriate than population based RI.
64
 In practice, subject-based 
RI refer to reference change values, calculated per analyte, based on individual biological 
variation.
63
 This biological variation also includes imprecision, accuracy and total error of the 
laboratory assays.
63
 Therefore, reference change values are also laboratory-dependent. For 
both sCr and sCysC, it was shown in dogs that population-based RI should be used.
65
 This 
means that sCysC has no advantage over sCr for follow-up of a patient, in contrast to humans, 
since  human sCysC had a higher index of individuality compared to sCr.
63,64,66
 In cats, it has 
been shown that subject-based RI are more appropriate for sCr.
63
 We intended to determine 
the index of individuality for feline sCysC, but the study was not undertaken, since the results 
of the study described in Chapter V §5.2 disfavored feline sCysC over sCr. 
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The studies of Chapter IV showed that feline sCysC is not influenced by age, sex and 
breed and that the concentration is uninfluenced by feeding status. We also determined a RI 
according to the ASVCP guidelines of 0.58–1.95 mg/L  for sCysC and of 64.5‒161.8 µmol/L 
for sCr. 
 
3. Clinical factors influencing feline CysC 
 
Our previous studies showed more advantages of CysC over sCr at analytical and 
biological level. However, the clinical performance of feline CysC still needed to be 
elucidated.  
 
3.1 Serum cystatin C 
In Chapter V, §5.1, the influence of two common diseases on feline CysC was 
investigated. As hyperthyroidism and human immunodeficiency virus (HIV) may cause 
increased sCysC concentrations in humans,
67-69
 we investigated the influence of both 
hyperthyroidism and feline immunodeficiency virus (FIV) on feline CysC. We included 30 
cats with FIV, 26 hyperthyroid and 28 healthy cats. Serum CysC and uCysC were measured 
in all cats in addition to the routinely measured renal variables sCr, USG, UPC and total 
thyroxine (TT4). The hyperthyroid cats had significantly higher sCysC and uCysC/uCr ratio 
and UPC compared to the healthy cats in contrast to sCr, which was significantly lower. Our 
observations were comparable with human studies.
67,70
 We did not observe a significant 
correlation between TT4 and sCysC, in contrast with sCr. In addition, none of the 
hyperthyroid cats exceeded the RI (0.58-1.95 mg/L) we established in Chapter IV, §4.2, and 
sCysC also seemed to overlap between the healthy and hyperthyroid cats. Not only in healthy 
and CKD cats (Chapter V, §5.2) but also in hyperthyroid cats, we demonstrated that sCysC is 
not a reliable GFR marker. The study in hyperthyroid cats was limited by lack of GFR 
measurement, but preliminary data with GFR measurement,
71
 demonstrated no change in 
sCysC before and after treatment of hyperthyroidism in cats, in contrast to GFR and sCr.  
 
In contrast to human studies,
68,72
 no significantly higher sCysC concentration could be 
observed in FIV-positive cats. It was suggested in humans that sCysC was associated with 
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HIV-replication,
73
 but GFR was not measured by a gold standard method, so renal disease 
could not be excluded to play a role in the higher sCysC concentration.  
 
In all three groups, we could not observe a correlation between sCr and sCysC. This 
could be due to non-renal factors, such as FIV, hyperthyroidism or hydration status, the 
influence of early/mild kidney dysfunction or absence of a correlation. The latter was 
confirmed in Chapter V, §5.2.  
 
In the final study of this thesis, described in Chapter V, §5.2, we evaluated cystatin C 
as a marker for CKD by comparing sCysC and uCysC between CKD and healthy cats, by 
correlating sCysC and sCr with GFR and by calculating sensitivity and specificity for 
decreased GFR. Previously, we had observed an overlap in sCysC between CKD and healthy 
cats in the pilot study (Chapter III). In addition, 7 out of 10 CKD cats of our pilot study and 
46/46 cats of the study of Poświatowska-Kaszczyszyn fell withing the RI (0.58-1.95 mg/L) 
we established in Chapter IV, §4.2. However, a limitation in our previous studies was the 
lack of GFR measurement, unmasking possible early CKD. Therefore, in the study of 
Chapter V, §5.2, GFR was measured with the combined plasma exogenous Cr-iohexol 
clearance test (PEC-ICT) in 17 CKD and 15 healthy cats. We observed no significantly better 
correlation between sCysC and GFR compared to sCr for none of the three methods (Cr, 
endo- and exo-iohexol). Our results were in contrast with the study of Poświatowska-
Kaszczyszyn, in which they found a significantly better correlation of sCysC with PICT than 
of sCr.
24
 The contradictory result of both studies can be explained by the methods of GFR 
estimation. Based on our findings, we conclude that there is no better correlation between 
GFR and sCysC than with sCr. 
 
As in our pilot study, we observed a significantly higher (P < 0.001) sCysC 
concentration in 49 CKD cats compared with 41 healthy cats. We observed a significant (P < 
0.001) effect of IRIS stage on sCysC, with increasing concentrations as IRIS stage increased. 
However, all observed correlations were poor and probably not clinically relevant. More 
importantly, we observed a significant overlap in sCysC between CKD and healthy cats, 
again, as in our pilot study in Chapter III. In the study of Poświatowska-Kaszczyszyn,24 
GFR was also found to overlap, explaining the overlap in sCysC between CKD and healthy 
cats. Therefore, in our study, we correlated sCysC and sCr with the degree of renal function 
i.e. correlation with GFR. This was based on plasma exo-iohexol clearance test (PexICT), 
Chapter VI General Discussion 
 
208 
since it was shown that PexICT has the largest accuracy and reproducibility.
74
 The cut-off 
concentrations for normal GFR were defined as GFR ≥ 1.7 mL/min/kg, for borderline GFR as 
GFR 1.2-1.7 mL/min/kg and for low GFR as GFR < 1.2 mL/min/kg, determined in a previous 
study of our group.
75
 Only two cats defined as “healthy” had low and borderline GFR 
respectively. These two cats did not show high sCysC concentrations exceeding the RI (0.58-
1.95 mg/L). Serum CysC overlapped between cats with low, borderline and normal GFR, 
indicating that sCysC cannot distinguish between those three groups. For sCr, the overlap was 
less severe, and mainly present between cats with low and borderline GFR. Other studies also 
showed that a mild decrease in GFR does not cause increased sCr.
59,76
 In addition, the 
sensitivity of sCysC to detect decreased GFR (PexICT < 1.7 mL/min/kg) was only 22% 
compared with 83% for sCr, and the specificity 100% compared with 93% for sCr. This 
means that a cat with early CKD will not have increased sCysC prior to increased sCr. 
However, if sCysC is elevated, CKD is definitely present. Our findings are different from 
canine studies, in which a significantly better correlation between GFR and sCysC was 
observed compared with sCr.
20,22,77
 However, an overlap in sCysC between healthy and CKD 
dogs could also be observed. Unfortunately GFR was measured in only two studies,
20.22
 but 
no GFR data were provided in the study from Miyagawa et al. In the study from Wehner and 
colleagues, an overlap could be observed between dogs with borderline and normal GFR. 
Nevertheless, dogs with various diseases were included, which could have influenced sCysC 
concentration. Therefore, the reason for overlap of sCysC in dogs is currently unclear. Our 
study showed that sCysC is not a more sensitive marker for detection of feline chronic kidney 
disease than sCr. 
 
3.2 Urinary cystatin C 
Tubulo-interstitial nephritis is most commonly observed in cats with CKD,
78
 making 
uCysC also a possible marker for detection of feline CKD. As observed in our pilot study in 
Chapter III, cats with CKD had significantly higher uCysC/uCr compared with healthy cats 
in the final study of Chapter V, §5.2 , and no overlap was present. We observed a significant 
(P < 0.001) effect of IRIS stage on uCysC/uCr, with increasing concentrations as IRIS stage 
increased. Also UPC had a significant (P < 0.001) effect on uCysC/uCr. However, as for 
sCysC, the correlations were low and probably not clinically relevant. Nevertheless, some 
remarks have to be made. Five of the 41 healthy cats had detectable uCysC concentrations. 
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Since CysC is normally completely reabsorbed and catabolized in the kidney,
79,80
 one would 
expect the concentration to be below the detection limit in the healthy cats. However, early 
CKD or tubular damage could not be excluded, since no GFR was performed and no kidney 
biopsies were taken in those cats, and no follow-up was available. In the CKD cats on the 
other hand, 15/49 had uCysC below LOD of which two were borderline proteinuric and two 
proteinuric. Since tubulo-interstitial lesions are most commonly present in cats with CKD, we 
expected presence of uCysC in all CKD cats. Both in the CKD and healthy cats, no other 
tubular markers were measured that could give an indication of presence or absence of tubular 
damage and no histopathology reports of the kidneys were available. We also observed 
presence of uCysC in hyperthyroid cats described in Chapter V, §5.2. Eighteen out of 26 
hyperthyroid cats had a detectable uCysC concentration and a significant correlation with 
UPC was present. However, we observed a significant correlation between uCysC and sCysC 
in the hyperthyroid cats, indicating that uCysC is not independent from sCysC. For the FIV-
positive cats on the other hand, only 4 out of 30 FIV-positive cats had detectable uCysC 
concentration. Three of those cats had received both antibiotics and NSAID’s prior to sample 
collection. The effect of those drugs on CysC metabolism is unknown, but they may affect 
kidney function, which could have influenced our results.
81
 In contrast to the hyperthyroid 
cats, not all proteinuric FIV-positive cats had detectable uCysC. Both glomerular and tubular 
pathologies have been described in FIV-positive cats.
82,83
 As in the study described in 
Chapter V, §5.1, no biopsies were performed in the hyperthyroid and FIV-positive cats. 
Therefore, studies involving renal biopsy and correlation with other tubular markers are 
necessary to examine the ability of uCysC to detect early tubular damage.  
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4. Future perspectives 
 
Our results showed that with the evaluated human assays, feline sCysC was not a 
reliable indirect marker to estimate GFR. Serum CysC was not able to distinguish healthy cats 
from cats with CKD. This was observed in a preliminary study in Chapter III, and was 
confirmed in Chapter V. Therefore, current data do not recommend to use feline sCysC as 
marker for feline CKD detection, at least with PENIA or PETIA. 
 
Urinary CysC, a proximal tubular marker was not present in all CKD and hyperthyroid 
cats. However, we cannot conclude that uCysC is not useful. Indeed, tubulo-interstital lesions 
are most commonly observed in cats with CKD,
78
 but both glomerular and tubular damage 
can be present in hyperthyroid cats and cats with CKD.
78,84
 Additional studies with renal 
biopsy confirmation are valuable, to further investigate the use of uCysC in cats. 
  
Are additional studies with feline sCysC valuable? It was a major disadvantage that no 
feline assays were available. Although, we obtained a signal with the human PENIA and 
PETIA, we could not be completely sure that feline CysC with MM of 13 kDa was measured 
appropriately. A homology of 70% between cat and human CysC has been described,
26,28
 but 
epitope sequence to which the antibodies bind, has not been provided by the manufacturer. A 
feline assay should be developed, followed by a re-evaluation of feline CysC. Monoclonal 
antibodies to feline CysC have been produced,
26
 but a commercial assay is not yet available. 
If new antibodies become available, it is worthwhile to investigate if these detect feline CysC. 
Until a feline assay is available, we do not recommend the use of feline CysC for kidney 
function evaluation. 
 
This means that veterinary science needs to follow other pathways to detect early 
feline CKD. The use of limited sampling strategies for GFR estimation seems promising. 
Many different strategies have been used, and there is need for a consensus to define which 
method is most suitable, how many samples at which time points are required.
75,85-89
 GFR in 
cats is mostly estimated by iohexol or exogeneous Cr. The analysis of iohexol still requires 
specialized devices, and analysis cannot yet be performed in-house. Exogenous Cr has the 
advantage that it can be analyzed more easily, but is not commercially available. Although the 
limited sampling strategy requires fewer samples, this method is still not practical for routine 
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use. In humans, formulas based on demographic variables to estimate GFR are routinely used. 
An attempt was made for cats, based on the routine renal variables sCr, urea and UPC,  but 
the formulas have not been evaluated in a large cat population and specificity has not been 
investigated yet.
75
  
 
Another possible renal marker is symmetric dimethylarginine (SDMA). It is an 
arginine residual and is released into circulation after proteolysis.
90
 Plasma SDMA is 
increased in cats with CKD and correlates with plasma Cr concentration.
91
 Two studies have 
found a similar correlation of SDMA and plasma Cr with GFR.
90,92
 In addition, SDMA 
increased before sCr, which is a major advantage.
92
 However, further studies are warranted. 
Firstly, only analysis of SDMA with the sophisticated HPLC-method has been described. 
Secondly, the marker was only tested with retrospective samples in a large group of 
laboratory cats,
92
 and prospectively in a small number of client-owned cats.
90
 Thirdly, GFR 
was estimated with the one-compartment method with only three blood samples, and might 
overestimate true GFR.
93
 Fourthly, no RI according to the ASVCP guidelines or a cut-off 
concentration was determined.
37
 Also the specificity needs to be further elucidated. 
Nevertheless, at this moment, this is the most promising marker for detection of feline CKD. 
 
Besides early detection, we need to investigate which actions are required to slow 
down, arrest, or ideally, reverse disease progression.
94
 We need to determine what therapies 
are of real value at the different stages of CKD and what therapies can improve quality and 
longevity of life.
94
 We still have much to investigate in cats to understand CKD and prevent 
progression.  
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5. Conclusions of this thesis 
 
In this thesis, we have investigated the possible use of CysC as marker for the 
detection of feline CKD. We have performed a thorough validation at analytical, biological 
and clinical level. First, we investigated how feline CysC can be measured in serum and urine 
and how samples can be stored. Since no feline assays were available, we validated the 
human nephelometric and turbimetric assay. Based on the validation results, we decided that 
sCysC can be analysed both with the turbidimetric and nephelometric assay, but that the 
human nephelometric assay was the best way to determine feline uCysC. Storage of feline 
sCysC for more than 5 months was not recommended. In a pilot study, we observed a 
significant difference in sCysC and uCysC between CKD and healthy cats, but an overlap 
between the two groups was present. At this point in the research, it was too preliminary to 
conclude that CysC did not have the required properties for renal marker, since kidney 
function was not evaluated properly.  
 
In the second part of this thesis, we investigated if sCysC was influenced by age, 
breed, sex and food in order to determine sampling conditions and if separate RIs were 
required. Serum CysC was not influenced by the different biological factors. This was an 
advantage over sCr. However, it was of major concern that the majority of cats with CKD of 
previous studies fell within the RI we determined.  
 
In the third part of the thesis, we partially investigated specificity of CysC, by 
observing the effect of FIV and hyperthyroidism on sCysC and uCysC. Serum CysC was 
increased in cats with hyperthyroidism, in contrast with sCr, but not in cats with FIV. Many 
hyperthyroid cats, but only four cats with FIV had an elevated uCysC/uCr ratio.  
 
In the final study, we evaluated CysC as marker for CKD by comparing sCysC and 
uCysC between CKD and healthy cats, by correlating GFR with sCysC and sCr and by 
calculating sensitivity and specificity for detecting decreased GFR. Serum CysC could not 
distinguish CKD from healthy cats, nor normal from borderline or low GFR in contrast to 
sCr. Serum CysC also had a lower sensitivity to detect decreased GFR than sCr. Therefore, 
we conclude that sCysC is not a valuable marker to detect feline CKD. Urinary CysC could 
not be detected in all CKD cats. Further studies with renal biopsies are needed to further 
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investigate the possible use of uCysC. This thesis has validated CysC thoroughly at analytical, 
biological and clinical level.  
Despite the fact that we observed a few advantages over sCr, we do not advise to measure 
CysC for the detection of feline chronic kidney disease with the currently available human 
nephelometric and turbidimetric assay. Other renal markers should be studied and the 
influence of early diagnosis on the prognosis of CKD should be investigated. 
 
Despite good analytical and biological validation results, the clinical validation results 
for sCysC were inadequate. This thesis emphasized how important a solid and complete 
validation is.    
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Chronic kidney disease (CKD) is a common progressive and irreversible disease in 
cats. Early diagnosis is important to slow down disease progression. The best method to 
evaluate kidney function, is estimation of glomerular filtration rate (GFR). However, this 
method is time-consuming and labour-intensive, and therefore not routinely used. The indirect 
GFR-markers, serum creatinine (sCr) and urea, are routinely measured, but are insensitive and 
unspecific. Therefore, markers that can easily and rapidly detect kidney dysfunction in an 
early stage are urgently needed. A possible marker is cystatin C (CysC). Serum cystatin C 
(sCysC) fulfills many properties ideal for a GFR marker. Studies in humans and dogs have 
shown its superiority over sCr, but studies in cats were lacking. In addition, urinary CysC 
(uCysC) can be used as a marker for proximal tubular damage.  
 
 In Chapter I, the anatomy and physiology of the kidneys were explained, to better 
understand the pathophysiology of feline CKD. In this chapter, current knowledge on CysC in 
human and veterinary medicine was summarized, followed by a brief overview of the 
principles of appropriate validation. We concluded that CysC has the potential to become a 
valuable renal marker, but several studies were required. This led us to the objectives of this 
thesis (Chapter II): the analytical, biological and clinical validation of feline CysC. 
 
At the start of this thesis, no veterinary assays and no analytical validation reports 
were available on feline CysC. In Chapter III, the human particle-enhanced nephelometric 
(PENIA) and turbidimetric (PETIA) assay were validated, followed by a pilot study with 
CysC measurement in serum and urine in both CKD and healthy cats. To know which 
proportion of feline CysC was detected with these human assays, we aimed to produce feline 
recombinant CysC. Therefore the feline CysC gene (CST3) was isolated from white blood 
cells and the plasmid with CST3 was cloned into 3 different expression vectors: Escherichia 
coli, Pichia pastoris and HEK293T mammalian cells. However, feline recombinant CysC 
could not be produced. Therefore, the obtained feline CysC concentrations are relative. Both 
PENIA and PETIA are based on antigen-antibody reaction. Hence, a Western blot analysis 
was required to demonstrate cross reactivity between feline CysC in serum and urine, and the 
antibodies from the assays. Bands could not be detected in serum at the expected MM of 13 
kDa, but at 26 kDa and 52 kDa. We assumed that polymer formation was caused by 
denaturing agents. However, the absence of a band in serum could not be readily explained. 
We hypothesized that this was due to difference in epitope sequence between feline and 
human CysC. PENIA showed a good precision, linearity and good sensitivity, both in serum 
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and urine. PETIA had a high LOD, impeding uCysC measurement and was somewhat less 
accurate. Based on these observations, but also due to practical reasons, we used PENIA for 
further measurement of feline CysC. The pilot study demonstrated that cats with CKD had a 
significantly higher sCysC and uCysC/uCr ratio compared with healthy cats. However, an 
overlap in sCysC could be observed. Since no GFR was determined, the reason for overlap 
was unclear at that time. 
 
In the second part of this thesis, feline CysC was validated biologically. In Chapter 
IV, §4.1,  we evaluated which sample storage conditions were appropriate, if it was 
mandatory to fasten cats prior to sCysC evaluation and if a diurnal variation could be 
observed. We demonstrated that  samples can be stored at room temperature (RT) if sCysC is 
analysed within 24 h and at 4 °C for 1 week. If longer storage is required, we advise storage at 
-20 °C or -72 °C for up to 5 months. Longer storage is not recommended. One freeze-thaw 
cycle is allowed. Caution is warranted if pCysC has to be compared with sCysC, since pCysC 
results were significantly lower. We evaluated the effect of feeding versus fasting on both sCr 
and sCysC in a crossover study with 10 healthy laboratory cats. We observed no significant 
difference in sCysC and sCr between fasted and fed cats. A significant difference between 
morning and evening samples could be observed for sCysC, but the differences were only 
small, and not clinically relevant. In addition, we observed large discrepancies between the 
individual cats. Based on our findings, it is not mandatory to fasten cats prior to feline sCysC 
or sCr evaluation.  
 
After our encouraging findings in the pilot study of Chapter III, it was essential to 
determine a reference interval (RI) in a healthy cat population (Chapter IV, §4.2). One 
hundred and thirty cats of different ages, breeds and sexes were included. First we evaluated 
if there was an influence of age, breed, and sex on feline sCysC, in order to determine if 
separate RIs were necessary. The routinely measured renal parameters, sCr, urea, SBP, USG 
and UPC, were also compared between the different groups. We could not observe an effect 
of age, breed and sex on feline sCysC, in contrast with sCr. Significantly higher sCr 
concentrations were measured in geriatric cats, compared to young cats. Interestingly, systolic 
blood pressure (SBP) was significantly higher in geriatric cats compared to middle-aged and 
young cats; UPC was significantly higher in male intact cats compared to female intact and 
neutered cats; and urea was influenced by age and gender. However, longitudinal studies 
should be performed to further elucidate those observations. Since no separate RI for sCysC 
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was required, we determined a RI for sCysC according to the ASVCP guidelines of 0.58–1.95 
mg/L. In addition, we also established a RI for sCr of 64.5–161.8 µmol/L, analysed with the 
modified Jaffe method, that corresponded with previously published RI with the same 
method. 
 
It was described in humans that HIV and hyperthyroidism may cause increased sCysC 
concentrations. In Chapter V, §5.1, we investigated the influence of hyperthyroidism and 
FIV on both sCysC and uCysC. This is important information for use in practice. We 
measured sCysC and uCysC in  cats with FIV, hyperthyroid and  healthy cats. Also sCr, urea, 
USG, UPC and TT4 were measured in those cats. In hyperthyroid cats, we expected lower sCr 
and lower sCysC, since hyperthyroidism leads to increased GFR. However, we observed a 
significantly higher sCysC and uCysC/uCr compared with healthy cats. Serum Cr was 
significantly lower, as expected. We also observed an overlap in sCysC between the healthy 
and hyperthyroid cats and not all hyperthyroid cats had a detectable uCysC concentration. Our 
findings suggested that sCysC is not a reliable GFR marker in hyperthyroid cats, as 
previously reported. Additional studies with renal biopsies are needed to evaluate uCysC as 
tubular marker in hyperthyroid cats. In the FIV-positive group, we did not observe a 
significantly higher sCysC concentration, and only 4/30 cats had uCysC > LOD. These results 
could have been influenced by an effect of non-steroidal anti-inflammatory drugs and 
antibiotics on renal function. Interestingly, in the three groups, there was no association 
between sCysC and sCr, indicating that non-renal factors, mild kidney dysfunction might 
have influenced our results or that CysC is not a good GFR marker.  
 
In the final study of this thesis (Chapter V, §5.1), we evaluated the value of CysC for 
the detection of feline CKD by comparing sCysC and uCysC between CKD and healthy cats, 
by correlating sCysC and sCr with GFR and by calculating sensitivity and specificity for 
decreased GFR. GFR was measured with PEC-ICT in 17 CKD and 15 healthy cats. No 
significantly better correlation between sCysC and GFR compared to sCr was observed for 
the three methods (Cr, endo-and exo-iohexol). Serum CysC was significantly higher in cats 
with CKD (n = 49) compared with the healthy cats (n = 41), but an overlap was observed.  
Therefore, we classified the cats in having normal, borderline or low GFR based on PexICT. 
Serum CysC overlapped between the three groups, in contrast with sCr, indicating that sCysC 
is not able to distinguish between those three groups. The sensitivity of sCysC to detect 
decreased GFR was only 22% compared to 83% for sCr. For uCysC, 15/49 cats with CKD 
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had uCysC < LOD. Nevertheless tubulo-interstitial lesions are most commonly observed in 
cats with CKD, glomerular lesions could not be excluded. Additional studies with renal 
biopsy are warranted. This important study demonstrated that feline CysC measured with the 
available human assays is not a reliable marker for kidney function evaluation in cats. 
Therefore, we do not recommend to use this marker in cats. 
 
This thesis provided us new insights in the use of CysC for the detection of feline 
CKD. In contrast to studies in dogs, we have validated feline CysC at analytical, biological 
and clinical level. We have shown that the human PENIA and PETIA are able to measure 
feline CysC, but PENIA is the preferred method. Cystatin C favored sCr at biological level, 
since sCysC was less influenced by breed, age, and sex. However, during this thesis, we 
observed that sCysC overlapped between healthy cats and cats with CKD, which was a major 
concern. Our suspicion was confirmed by comparing the correlation of GFR with sCysC and 
sCr and by comparing sCysC in cats with normal, borderline and low GFR. Therefore, we can 
conclude that sCysC measured with the human PENIA or PETIA is not a reliable GFR 
marker in cats. Urinary CysC should be evaluated more in-depth. 
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Chronische nierziekte (CNZ) is een vaak voorkomende irreversibele en progressieve  
aandoening bij katten. Een vroege diagnose is belangrijk om de ziekte af te remmen. De beste 
methode om de nierfunctie te evalueren, is schatting van de glomerulaire filtratiesnelheid 
(GFS). Deze methode is echter tijdrovend en arbeidsintensief, en wordt dus niet vaak 
gebruikt. Bijgevolg worden meestal de indirecte GFS-merkers, serum creatinine (sCr) en 
ureum gemeten, maar deze zijn niet gevoelig en niet specifiek. Daarom is er behoefte aan 
merkers die nierdysfunctie eenvoudig en snel kunnen detecteren in een vroeg stadium. Een 
mogelijke merker is cystatine C (CysC). Serum cystatine C (sCysC) bezit vele eigenschappen 
van ideale GFS-merker. Studies in de mens en hond hebben de superioriteit van CysC 
aangetoond boven Cr. Studies bij katten ontbreken echter nog. Bovendien kan urinair CysC 
(uCysC) gebruikt worden als merker voor schade in de proximale tubulus. 
 
In Hoofdstuk I werd de anatomie en fysiologie van de nieren uitgelegd, om beter de 
pathofysiologie van CNZ te begrijpen. In dit hoofdstuk werd een overzicht gegeven van de 
huidige kennis over CysC in de humane geneeskunde en diergeneeskunde, gevolgd door een 
kort overzicht van de principes van validatie. We concludeerden dat CysC veel potentieel had 
om een waardevolle renale merker te worden, maar dat verschillende studies vereist waren. 
Dit leidde tot de doelstellingen van deze thesis (Hoofdstuk II): de analytische, biologische en 
klinische validatie van felien CysC. 
 
Bij de start van dit onderzoek waren geen diergeneeskundige assays beschikbaar, en er 
waren geen rapporten beschikbaar over analytische validatie van felien CysC. In Hoofdstuk 
III werden de humane partikel-versterkte nefelometrische assay (PENIA) en turbidimetrische 
assay (PETIA) gevalideerd, gevolgd door een kleine pilootstudie waarbij CysC gemeten werd 
in serum en urine van zowel katten met CNZ als gezonde katten. Om na te gaan welke 
proportie felien CysC gedetecteerd kon worden met de humane assays, hadden we de intentie 
om felien recombinant CysC te produceren. Hiervoor werd het feliene CysC gen (CST3) in 
drie verschillende expressie-vectors gekloond: Escherichia coli, Pichia pastoris en HEK293T 
zoogdiercellen. Felien recombinant CysC kon echter niet geproduceerd worden. Daarom 
moeten we ervan uitgaan dat met de humane assays relatieve CysC concentraties gemeten 
worden. Zowel PENIA als PETIA zijn gebaseerd op antigen-antistof reactie. Bijgevolg was 
een Western blot analyse nodig om kruisreactiviteit aan te tonen tussen het feliene CysC in 
serum en urine, en de antistoffen van de assays. Er werden geen bandjes gezien ter hoogte van 
de verwachte 13 kDa MM, maar wel ter hoogte van 26 kDa en 52 kDa. De polymeervorming 
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kon veroorzaakt zijn door het gebruik van denaturerende agentia. De afwezigheid van een 
band in serum kon echter niet onmiddellijk verklaard worden. Onze hypothese was dat dit te 
wijten was aan een verschil in epitoopsequentie tussen het feliene en humane CysC. PETIA 
vertoonde een hogere detectielimiet, wat meting van uCysC zou kunnen bemoeilijken, en was 
ook iets minder accuraat dan de PENIA. Gebaseerd op de validatieresultaten, en uit praktische 
overwegingen, gebruikten we de PENIA voor de verdere analyses van felien CysC. Onze 
pilootstudie toonde aan dat katten met CNZ een significant hogere sCysC en uCysC/uCr ratio 
hadden vergeleken met de controlekatten. Er kon echter wel een overlap worden gezien in de 
sCysC concentratie. Aangezien er geen GFS gemeten was, kon de reden voor overlap op dit 
moment niet verklaard worden. 
 
In het tweede deel van deze thesis werd CysC biologisch gevalideerd. In Hoofdstuk 
IV, §4.1, evalueerden we hoe stalen bewaard kunnen worden en of het noodzakelijk was dat 
katten moesten vasten voor sCysC evaluatie en of er een diurnale variatie optrad. We toonden 
aan dat stalen bewaard kunnen worden op kamertemperatuur indien sCysC geanalyseerd 
wordt binnen de 24 u en op 4 °C gedurende 1 week. Als de stalen langer bewaard moeten 
worden, adviseren we bewaring op -20 °C of -72 °C tot 5 maanden. Langere bewaring raden 
we niet aan. Aandacht is vereist als pCysC vergeleken moet worden met sCysC, aangezien de 
pCysC concentraties significant lager waren. We evalueerden het effect van voeding en vasten 
zowel op sCysC als sCr in een crossover studie met 10 gezonde proefdierkatten. We 
observeerden geen verschil in sCysC en sCr tussen katten die nuchter waren en katten die 
gegeten hadden. Een significant verschil in sCysC werd geobserveerd tussen de ochtend- en 
avond stalen, maar de verschillen waren klein en niet klinisch relevant. Daarnaast werden 
grote verschillen tussen de individuele katten waargenomen. Gebaseerd op onze bevindingen, 
is het niet noodzakelijk om katten te laten vasten voor evaluatie van felien sCysC of sCr. 
 
Na de veelbelovende bevindingen in de pilootstudie van Hoofdstuk III, was het 
essentieel om een referentie interval (RI) te bepalen in een gezonde kattenpopulatie 
(Hoofdstuk IV, §4.2). Honderddertig katten van verschillende leeftijden, geslacht en ras 
werden geïncludeerd. Eerst evalueerden we of er een invloed was van deze fysiologische 
factoren, om na te gaan of verschillende RI nodig waren. De routine renale merkers, sCr, 
ureum, de systolische bloeddruk (SBP), het urinair soortelijk gewicht (USG) en de urinaire 
eiwit:creatinine ratio (UPC) werden ook geëvalueerd. We konden geen invloed van geslacht, 
leeftijd en ras op  felien sCysC observeren, in tegenstelling tot sCr. Er werden significant 
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hogere sCr concentraties gemeten bij de geriatrische katten, vergeleken met de jonge katten. 
De SBP was significant hoger in geriatrische katten vergeleken met katten van jonge en 
middelbare leeftijd; de UPC was significant hoger in mannelijke katten vergeleken met de 
vrouwelijk intacte en gesteriliseerde katten; en ureum was beïnvloed door leeftijd en geslacht. 
Er zouden echter longitudinale studies moeten worden uitgevoerd om deze bevindingen 
verder te onderzoeken. Aangezien geen aparte RI nodig waren, werd een RI van 0.58–1.95 
mg/L bepaald voor sCysC volgens de ASVCP richtlijnen. Het was echter wat zorgbarend dat 
de sCysC concentratie van de meeste CNZ katten uit voorgaande studies binnen ons RI viel. 
Dit moedigde bijkomende studies aan. Bovendien bepaalden we in deze studie ook een RI 
voor sCr, gemeten met de gemodificeerde Jaffe methode, van 64.5–161.8 µmol/L dat 
overeenkwam met eerder gepubliceerde RIs voor sCr bepaald met dezelfde methode.  
 
Publicaties uit de  humane geneeskunde toonden aan dat HIV en hyperthyroïdie een 
stijging van sCysC concentraties kunnen veroorzaken. In Hoofdstuk V, §5.1, onderzochten 
we de invloed van FIV en hyperthyroïdie op zowel sCysC als uCysC. Dit is belangrijke 
informatie voor gebruik in de praktijk. We bepaalden sCysC en uCysC in katten met FIV, 
katten met hyperthyroïdie en gezonde katten. Ook werden sCr, ureum, USG, UPC en totaal 
thyroxine bepaald. We verwachtten lage sCr en sCysC concentraties bij de hyperthyroïde 
katten, aangezien hyperthyroïdie een gestegen GFS veroorzaakt. We observeerden echter een 
significant hogere sCysC concentratie en uCysC/uCr ratio vergeleken met de gezonde katten. 
Serum Cr was significant lager, zoals verwacht. We observeerden ook een overlap in sCysC 
tussen de gezonde en hyperthyroïde katten en niet alle hyperthyroïde katten hadden 
detecteerbare uCysC. Onze bevindingen toonden aan dat sCysC geen goede GFS merker is bij 
hyperthyroïde katten, zoals ook eerder beschreven. Er zijn echter bijkomende studies nodig 
met nierbiopsie om uCysC te evalueren als tubulaire merker bij hyperthyroïde katten. In de 
FIV-positieve katten konden we geen significant hogere sCysC concentratie waarnemen en 
uCysC kon slechts bij 4/30 katten geobserveerd worden. Bovendien zouden deze resultaten 
beïnvloed kunnen zijn door een effect van niet-steroïdale anti-inflammatoire geneesmiddelen 
en antibiotica op de nierfunctie. In de drie groepen was er geen associatie tussen sCysC en 
sCr, wat betekent dat niet-renale factoren, milde nierdysfunctie onze resultaten beïnvloed kon 
hebben, of dat sCysC geen goede GFS-merker is. 
 
In de laatste studie van deze thesis (Hoofdstuk V, §5.2), hebben we nagegaan of CysC 
CNZ kan detecteren in katten, door sCysC en uCysC te vergelijken tussen katten met CNZ en 
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gezonde katten, door sCysC en sCr te correleren met GFS en de sensitiviteit en specificiteit 
van sCysC en sCr te berekenen om afgenomen GFS vast te stellen. De GFS werd geëvalueerd 
aan de hand van de gecombineerde plasma exogene creatinine-iohexol klaringstest (PEC-ICT) 
in 17 katten met CNZ en 15 gezonde katten. Er werd geen significant betere correlatie 
gevonden tussen sCysC en GFS vergeleken met sCr voor geen enkele van de drie geteste 
methoden (exogeen creatinine, endo- en exo-iohexol). Serum CysC was significant hoger bij 
katten met CNZ (n = 49) vergeleken met de gezonde katten (n = 41), maar een overlap kon 
geobserveerd worden. Gebaseerd op de resultaten van de plasma exo-iohexol klaringstest 
(PexICT), werden katten geclassificeerd met een lage, borderline of normale GFS. Serum 
CysC overlapte tussen deze groepen, in tegenstelling tot sCr.  De sensitiviteit van sCysC om 
gedaalde GFS te detecteren was slechts 22% vergeleken met 83% voor sCr. De uCysC 
concentratie lag beneden de detectielimiet in 15/49 katten met CNZ. Niettegenstaande katten 
met CNZ vooral tubulo-interstitiële letsels vertonen, konden glomerulaire letsels niet 
uitgesloten worden. Bijkomende studies met nierbiopsie zijn vereist. Deze belangrijke studie 
toonde aan dat felien sCysC geen betrouwbare merker is om de nierfunctie te evalueren bij de 
kat. Daarom raden het gebruik van deze merker af in de feliene geneeskunde. 
 
Deze thesis gaf ons nieuwe inzichten in het gebruik van CysC voor de detectie van 
CNZ bij katten. In tegenstelling tot studies bij de hond, hebben we een grondige validatie 
uitgevoerd van felien CysC op analytisch, biologisch en klinisch niveau. We hebben 
aangetoond dat de humane PENIA en PETIA felien CysC kunnen meten, maar de PENIA 
geniet de voorkeur. CysC was minder beïnvloed door biologische factoren dan sCr. Tijdens 
de verschillende studies bemerkten we echter een overlap in sCysC tussen de katten met CNZ 
en de gezonde katten. Onze waarnemingen werden bevestigd door de GFS te correleren met 
sCysC en sCr en door sCysC te vergelijken in katten met normale, borderline en lage GFS. 
Daarom kunnen we concluderen dat sCysC gemeten met de humane PENIA en PETIA geen 
betrouwbare merker is voor GFS bepaling bij de kat. Urinair CysC zou nog verder moeten 
onderzocht worden.  
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Hoewel deze thesis best wel omvangrijk geworden is, wil ik deze paar bladzijden er 
toch nog aan toevoegen. Het zijn zeker niet de minst belangrijke, omdat ik via deze weg toch 
heel wat mensen wil bedanken die me gesteund hebben in dit doctoraatavontuur. 
 
Mijn promotor: Prof. dr. Sylvie Daminet 
Sylvie, mijn eerste woord richt ik tot u. Ik wil u van harte bedanken om me de 
mogelijkheid te geven om te doctoreren. Ondanks uw superdrukke agenda was u toch altijd 
bereid om de talloze projecten van collega-bursalen na te lezen om te oefenen voor mijn IWT-
verdediging. Bedankt om me kritisch te leren zijn, en zelfstandig te laten werken, maar er toch 
te zijn als er problemen waren, om mijn artikels na te lezen, feedback te geven en me met de 
juiste personen in contact te brengen. Bedankt! 
 
Mijn co-promotor: Prof. dr. Dominique Paepe 
Domi, we weten beiden dat dit verhaal belange zo mooi niet geweest was zonder jouw 
immense input. Als pas afgestudeerd groentje was het niet eenvoudig om mijn weg te vinden. 
Maar jij hebt me gekneed, liet me rijzen en na die 5 jaar is er toch een ander broodje uit de 
oven gekomen dan wat er inging. Superbedankt om, ondanks je eigen onderzoek en 
kliniekactiviteiten, altijd klaar te staan met raad en daad, en voor de opbouwende 
commentaren die mijn artikels steeds weer naar een hoger niveau tilden. Veel succes met je 
nieuwe carrière. Ik ben ervan overtuigd dat je ZAP-aanstelling de kliniek en het 
diergeneeskundig onderzoek een immense boost zal geven. Ook de niet-werk gerelateerde 
babbels vond ik altijd erg fijn en ik denk nog regelmatig terug aan onze uitjes in Seattle. 
 
Prof. dr. Hervé Lefebvre 
   Dear Prof. Lefebvre, thank you very much for all the work you have performed for 
my PhD-thesis. Thank you for our brainstorm meetings, for the GFR estimations and the 
statistics of two studies. I am also very thankful for the effort from you and Brice Reynolds 
for collecting blood and urine samples from CKD cats in Toulouse. 
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Prof. dr. Joris Delanghe, dr. Astrid van Dongen, dr. Astrid Wehner, prof. dr. Evelyne 
Meyer and dr. Pascale Smets 
Dear members of my exam committee, thank you very much for reading my PhD so 
thoroughly. Your comments helped me to improve the content of my PhD thesis. 
Prof. dr. Joris Delanghe en de laboranten van het labo voor klinische biologie UZ 
Beste professor, hartelijk dank om ons de mogelijkheid te geven om de vele stalen te 
laten analyseren. Elke en co, bedankt om steeds tijd te maken om mijn grote hoeveelheden 
stalen te analyseren, hoewel het bij jullie altijd gezellig druk was. 
 
Prof. dr. Evelyne Meyer en de collega’s van de Biochemie 
Beste Evelyne, hoewel ik nooit een Western Blot expert zal zijn, wil ik jou en Kristel 
superhard bedanken om me deze wondere wereld te leren kennen en altijd tijd voor mij te 
maken. Ook Jella, Donna, Jorien, Heidi, Koen, Bert en Dieter wil ik bedanken. Het was altijd 
erg fijn om wat PhD-gossip te kunnen delen. 
 
Prof. dr. Siska Croubels, Sigrid en Jelle 
Professor Croubels, ik wil u van harte bedanken voor de goede samenwerking voor de 
iohexol-analyses en het nalezen van mijn abstract en artikel. Bedankt Sigrid en Jelle om de 
analyses steeds in te plannen in jullie drukke agenda. 
 
Prof. dr. Luc Duchateau 
Beste professor, hartelijk dank voor uw statistische analyses. Bedankt om me te helpen 
met mijn studiedesign, en om antwoorden te formuleren op statistische vragen van de 
reviewers, op elk moment van de dag, en soms zelfs van ergens op een luchthaven in 
Ethiopië.  
 
Prof. dr. Myriam Hesta en de collega’s van op diervoeding 
Beste professor, hartelijk dank om uw katten te mogen “gebruiken” voor mijn 
voedingsstudie. Bedankt Veerle om de voeding te berekenen. Ook een dikke merci aan Amy 
en Liesbeth om me zo goed te helpen bij deze zware studie.  
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Alle katten en hun eigenaars 
Jullie verdienen een belangrijke plaats in mijn dankwoord. Zonder jullie was dit 
doctoraat niet mogelijk geweest. Bedankt aan alle collega’s, studenten, vrienden,….die hun 
kat voor even met plezier afstonden aan de wetenschap in ruil voor een aaike of een knuffel. 
 
The girls from ultrasound 
Thank you Elke, Laure, Caroline, Els, Anaïs, Yseult, Veerle and Olga for all the 
ultrasound guided cystocentheses! 
 
Dr. Eva Vandermeulen 
Beste Eva, hartelijk dank voor je bijdrage aan mijn doctoraat. De maandagen met de 
hyperthyroïde katjes vond ik altijd erg leuk. Bedankt voor je hulp met de revisie en hoewel ik 
mij vaak heb moeten haasten om op tijd in de crèche te zijn als ik je rond 17u30 tegenkwam, 
was een babbel met jou altijd erg deugddoend. Ik zal het missen! 
 
Bieke en Saar 
Een speciaal woordje van dank voor onze kattenfluisteraars. Jullie maakten van een 
GFR voor zowel de poezels als voor mij, een aangename gebeurtenis. Een extra dikke merci 
aan Bieke. Denk dat het niet veel mensen gegeven is om bij 5 katten 3 cc bloed te nemen in 
10 minuten. Zonder jou had ik de voedingsproef nooit tot een goed einde gebracht, en het 
verdient een extra “dankjewel” om ’s avonds voor mijn laatste staal om 21u30 nog eens door 
weer en wind terug te keren naar de faculteit.  
 
Mijn bureaucollega’s 
Bart, Isabel, dr. Capiau, Katrien, Pascale, Elien en Pieter. Bedankt voor de gezellige 
sfeer in ons bureau. Hoewel ik best wel beter kon doorwerken als er geen talloze telefoons 
naar eigenaars waren, had ik voor geen geld ter wereld jullie kliniekavonturen willen missen. 
Ik mis nu al de plagerijen tussen Bart en Elien, maar we spreken binnenkort nog wel af ;). 
Merci Katrien voor uw “mama-tips”. Ze komen zeker van pas! Julie en Noor hebben dezelfde 
leeftijd, dus geen excuus om elkaar hierna niet meer te zien. 
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Filip Clompen 
Beste Filip, bedankt voor de vele hulp bij het bewerken van mijn figuren. Dankzij jou 
heb ik ook mijn eerste stapjes gezet in de wondere Photoshop-wereld. Bedankt! 
 
Mensen die mee geholpen hebben aan mijn boekje 
Bedankt Leslie Bosseler voor de foto’s van de schrompelnieren. Bedankt Bart De 
Pauw, om de plastinaten van de kattennieren zo mooi vast te leggen. En heel erg bedankt Luc 
Gevaert om mij (opnieuw) een prachtige foto van Nestor, de kat van jouw collega te 
bezorgen.  
 
De collega’s kleine huisdieren en MBV 
Iedereen van de vakgroep kleine huisdieren en MBV wil ik bedanken. Van het regelen 
van betalingen van facturen, tot een gezellige babbel tijdens de middagpauze. Bedankt 
Nathalie, Sophie en Valentine. Onze babbels waren steeds weer een duwtje in de rug. Aan 
iedereen, dikke dikke merci! 
 
Elien 
We kennen elkaar al een goeie 10 jaar, van lid van ons olijk groepje van 6, bus-
compagnon en carpoolmaatje tijdens onze studies, tot collega en hartsvriendin. Computers 
hebben geen geheimen voor je, en ik kon steeds op je rekenen als er figuurkes, grafiekskes of 
tabellen hun eigen leven begonnen te leiden. Ik heb je gemist, die laatste maanden op de 
bureau, maar heb gezien hoe je openbloeit in je nieuwe job en wens je een fantastische 
carrière toe. Je hebt wat in je mars en dat doctoraat komt er ook, daar ben ik zeker van! Niet 
alleen professioneel, maar ook persoonlijk heb ik je meer en meer leren appreciëren. Samen 
hebben we al wat vijvertjes doorzwommen. Steeds kon ik bij je terecht, zeker de laatste jaren. 
Onze zorgen en bekommernissen kunnen we met elkaar delen, maar ook alles "what makes 
life fun". Het deed je erg veel pijn dat je er vandaag niet bij kon zijn, maar vrijdag maken we 
dat goed! Ik denk dat ik je enkele maanden terug wel duidelijk gemaakt heb hoeveel je voor 
me betekent. Laat onze vriendschap niet verwateren...."Patatjes forever!"  
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Mijn vrienden 
Anja, Katrien VdB, Vliennie en Neleke. Anja, we kennen elkaar al lang, maar hebben 
elkaar de laatste jaren wat minder gezien. Ik hoop dat daar snel verandering in komt, we 
hebben veel bij te praten! Katrien, van collega-schermweduwe, tot vriendin. Ik mis onze 
dinsdagafspraakjes, maar hoop de draad weer op te pikken als enkel "Deinze" ons nog 
scheidt. Vliennie, zotte doos. Op het moment dat ik dit dankwoord schrijf, ben je al 
hoogzwanger, en zul je net wel of niet bevallen zijn op het moment van mijn verdediging. 
Telkens opnieuw slaag je erin om mensen te amuseren. Uw stijl, onnavolgbaar!  Onze piepkes 
zullen ongeveer even groot zijn, dus laat ze maar veel samenspelen! Ik wens je het allerbeste 
met Thomas, je dochtertje en je praktijk. Neleke, de laatste jaren hebben we elkaar beter leren 
kennen. Wat kijk ik telkens weer uit naar onze maandelijkse culinaire afspraakjes! Dat er nog 
veel mogen volgen! 
 
De schermfamilie 
Ja, dat zijn jullie, familie. Zo lang heb ik niet geschermd, maar jullie hebben me met 
open armen ontvangen en nu nog steeds vind ik het fijn om deel te nemen aan 
schermgerelateerde activiteiten. Seppe, Servaas, Harry, Pedro, Lexie, Vinnie, Hanne, 
MarYann, Linde, Jules-Emile, Elise DL, Elise V, Barbara, Fredje, Kathleen....Bedankt voor 
de gezellige sfeer die alleen heerst bij de "sabreurs". Ik voel me altijd direct op mijn gemak 
met jullie in de buurt. Ook bedankt aan Kathleen en Xavier. Ik hoop dat "El Celler de Can 
Roca" binnenkort eens lukt. Het is fijn onze culinaire passie samen met jullie te kunnen delen.  
 
Jochem 
"Mens sana in corpore sano" is een spreuk die wel erg toepasselijk is voor mij, en waar 
jij je wel degelijk van bewust bent. Bedankt voor de vele work-outs, niet alleen fysiek, maar 
ook mentaal. Mijn batterijen waren soms leeg, maar na de training weer volledig opgeladen. 
Merci!!  
 
Mijn schoonfamilie 
Mutti, pappie, tatie, de bonnie en Stéphanie. Bedankt om me als jonge student in Gent 
deel te laten uitmaken van jullie gezin. We zijn het misschien niet altijd eens, maar besef maar 
al te goed hoeveel jullie voor ons doen. Een dikke, welgemeende "dankjewel" voor alles. 
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Mijn papa en mijn zus 
Lieve papa, bedankt voor alle kansen die je me gegeven hebt. Ik denk dat de tuincentra 
in Merelbeke een ferme duit verdiend hebben aan die opleiding van mij. De uren die je er 
doorbracht om me te brengen en te halen naar een examen zijn talloos. Altijd sta je klaar om 
te helpen als we een probleem hebben. Ik zeg het misschien niet genoeg, maar "dank u papa"!  
 
Griet, enkele maanden terug was het aan jou. Wie had dat gedacht, dat we kort na 
elkaar nog maar eens zouden "afstuderen". Bedankt om, ondanks je drukke leven als arts, toch 
te proberen om tijd te maken voor mij en mijn gezinnetje.  
 
Mama 
Het doet pijn, om je er, net als op andere speciale dagen, ook vandaag niet bij te 
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